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General introduction
Chapter 1

Chapter 1.1
Clinical presentation and prognosis
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1Diagnosis and symptoms
Uveal melanoma (UM) is the most common intraocular malignancy in the Western 
World in adults.1 UM derive from the melanocytes in the uveal tract of the eye, in 
which the choroid is the most frequent location for UM (70-80%), followed by the 
ciliary body (10-20%) and the iris as the least frequent location (5-10%).2 Diagnosis is 
made by an ophthalmologist using fundoscopy in which a mass can be observed in the 
eye (Figure 1). Additional techniques to confirm or make the diagnosis more likely are 
ultrasonography (US), indocyanine green chorioangiography (ICG), optical coherence 
tomography (OCT) and fluorescence angiography (FAG).3-5 
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Figure 1. Cross section of an eye containing a posterior choroidal melanoma. On the right a schematic overview 
with the anatomical structures.
UM patients usually present with common ophthalmic symptoms such as decreased 
sight, visual field defect, floaters and/or flashes.4,6 In up to 21% of the patients, the UM 
is missed or misdiagnosed during first examination.4,7,8 Besides the common ophthal-
mic symptoms, a large part of UM patients (13-45%) are asymptomatic at the time of 
diagnosis. These tumors tend to be found during routine ophthalmic examinations 
co-incidental with other ocular disorders.4,6,8  
14 
Ocular nevi are benign lesion which occur in approximately 0.2 to 30 % in the Western 
World.9,10 Although the prevalence is high, the annual risk for malignant transforma-
tion is around 1 in 4300-9000.9,10 To discriminate between small malignant melanoma 
and benign nevi, Shields developed the mnemonic ‘To Find Small Ocular Melanoma 
Using Helpful Hints Daily (Figure 2)’.11,12 The 5-year risk for malignant transformation 
of a melanocytic lesion with three or more risk factors is more than 50% and thus urges 
early treatment in these cases.11,12
Figure 2. Clinical presentation  of a patient with a  choroidal nevus. Listed on the left are the risk factors for 
malignant transformation (TFSOMUHHD mnemonic from Shields et al. indicated with a ‘+’ if present).12 
(A) Fundus photo revealed a pigmented lesion with larger and smaller drusen on top of the tumor with a halo 
surrounding the tumor. The pigmented tumor is located only one disk size (~1.5mm) from the optic disc. (B) 
Ultrasonography showed hollowness and a tumor thickness of 2.5 mm. (C) OCT scan of the macula showed 
subretinal fluid, which was the reason for the newly developed blurry vision. All these risk factors combined 
give a high-risk for malignant transformation.
 
Incidence and risk factors
The incidence of UM ranges from 4.0 to 10.0 in a million in the Western World, with the 
highest incidence in Scandinavian countries.1,13 As described before, people with ocular 
nevi are at risk for the malignant transformation.9-11 Other predisposing factors for the 
development of UM are Nevi of Ota which have a 1 in 400 lifetime risk of developing 
UM.14,15 Cutaneous nevi and freckles are described in the literature as associated with 
increased risk for UM.16 Besides the oculodermal lesions mentioned above, UMs are 
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1also more common among people with a Caucasian ethnicity and light-colored eyes.17 
It is hypothesized that due to the lack of melanin, the melanocytes are more at risk of 
a malignant turnover caused by damaging UV-light.17,18 However, despite these risk 
factors, the role of UV-light in UM remains unclear.18 Unlike cutaneous melanoma, in 
which UV-light is proven to be a risk factor, the incidence of UM has not increased 
in the last several decades, indicating that UV-light does not play a major role in the 
development of UM.1,18
 
Treatment primary tumor
Treatment of the primary UM depends largely on tumor size. Other factors that play a 
role are; tumor localization, periorbital growth, general patient condition and patient 
choice.19 The treatment options can be divided in tumor irradiation or tumor removal. 
The main goal of tumor irradiation is primarily to preserve the eye and secondarily 
the sight. The most commonly used irradiation techniques for small-to-medium sized 
tumors are proton-beam therapy, stereotactic radiotherapy and episcleral plaque radi-
ation therapy, for which Iodine 125 and Ruthenium 106 are the most used isotopes.6,20-25 
For all irradiation treatment options the success rate of primary tumor control is more 
than 90%.20-22,25,26 However, tumors located juxtapapillary are more prone to tumor 
recurrence and metastatic spread since these tumors are more often radioresistant.27 
Thus for patients with large tumors and tumors located near the optic disc or macula, 
an enucleation is preferred. For both treatment options, either irradiation or removal, 
the risk for metastatic disease is similar when corrected for tumor size and location.4,24 
 
 
Prognosis
Despite successful primary tumor treatment, patients still develop metastases in 
approximately half of the cases (Figure 3A), with a peak at 4 years after diagnosis.1,28-30 
Moreover these metastases have preference for the liver, which is affected in more 
than 90% of the cases.31 Since metastasis occurs even after complete removal of the 
primary tumor with enucleation, it is suggested that micrometastases are present at 
time of treatment.28 These micrometastases can grow out to a clinically detectable 
size even more than 10 years after primary treatment.28. Overall survival for patients 
with metastasis is very poor and most patients die within one year (Figure 3B).32,33 
16 
Currently, treatment of metastatic disease in UM patients is limited and in general 
unsuccessful. These metastases seem to be resistant to traditional chemotherapy.32,34,35 
Some patients with single (or limited) solitary liver metastasis may benefit from partial 
liver resection, however also for these patients the success rate is very low.36,37 Several 
clinical trials are conducted in which specific oncogenic pathways are targeted such as 
the MEK or RAS-ERK kinase pathways. Unfortunately, also for these trials the success 
rates are very low.38 
Early diagnoses and thus metastasis treatment could be obtained by more intensive 
monitoring of high-risk patients. Therefore, it is very important to stratify patients for 
high-risk and low-risk to develop metastatic disease. For patients with UM, several 
prognostic markers are already known. These prognostic markers can be divided in 
clinical, histopathological and genetic markers.  
Figure 3. (A) Kaplan Meijer curve showing the metastasis-free survival in all uveal melanoma patients (n = 
709) in the Rotterdam Ocular Melanoma Study group cohort. (B) Kaplan Meijer curve showing the survival 
in patients with uveal melanoma metastasis (n = 180). The arrows indicate the survival probability at the 
given times. 


Chapter 1.2
Clinical and histopathological 
prognostic markers
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1Patient-related prognostic markers
To adequately inform patients about the risk for systemic spread of UM, prognostica-
tion is essential. Several patients and tumor characteristics have been associated with 
metastatic disease in UM patients. 
Males and females are affected equally, however the risk for metastasis remains debat-
able. The Collaborative Ocular Melanoma Study (COMS) group conducted a  on more 
than 8,000 patients and found no difference in survival between men and women.39 In 
contrast to the COMS report, Zloto and colleagues were able to observe a difference in 
survival in 723 UM patients and Rietschel and colleagues in 119 UM patients, in which 
men were more at risk for metastasis and developed metastasis faster than females.40,41 
Besides gender, also age at diagnosis is associated with survival. Patient diagnosed 
at a higher age tend to have a worse prognosis.39 Moreover, patients diagnosed at a 
higher age usually also present with larger tumors.42 Caucasian people are more at 
risk for developing UM, however according to a recent study which involved 8100 
participants, ethnicity is not associated with the prognosis of UM.43 Thus, although 
Caucasians are more at risk for developing UM, the risk for metastasis is not increased. 
On the other hand, patients with ocular melanosis have an increased risk for UM 
development and also a two-fold increased risk for developing metastasis.44,45 
 
Tumor-related prognostic markers
Besides patient characteristics, also several tumor characteristics have been correlated 
to patient prognosis. The metastasis-rate varies for tumor location. Patients with iris 
melanoma have a five to ten-fold decreased risk of metastasis when compared to 
choroidal and ciliary body melanomas.46,47 Patients with ciliary body melanoma or 
choroidal melanoma with ciliary body involvement (CBI) have the highest risk for 
metastasis when compared to posterior melanoma and iris melanoma.46,47 Besides 
location, is has been shown that tumor diameter and thickness are both independently 
associated with survival, in which larger tumors associate with increased risk of metas-
tasis.29,47 Risk assessment for metastasis showed an increase in risk of 8% per millimeter 
extra in tumor diameter.29 Local invasion which may occur via aqueous channels, cil-
iary arteries or nerves, vortex veins or the optic nerve may associate with prognosis.48 
Extraocular extension (EXE) can be identified using ultrasonography.49 An increase in 
the size of the extension is associated with shorter survival.42,50   
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Tumor Node Metastasis (TNM) Classification
The tumor (T), node (N) and metastases (M) classification is a universally used clas-
sification based on primary tumor size and regional and systemic dissemination of 
the malignancy at the time of diagnosis, to prognosticate patients in risk groups. The 
first classification for uveal melanoma was described in the 7th edition of the American 
Joint Committee on Cancer (AJCC) Cancer Staging Manual in 2009.51 For tumor stage (T) 
it includes tumor diameter, tumor thickness (prominence), ciliary body involvement 
(CBI) and extraocular extensions (EXE). Based on tumor size the UM are categorized in 
T1 – T4 (larger tumors have higher T categories) and subcategorized in (a) – (d) based 
on CBI and EXE. With the tumor category (T) in combination with the metastasis status 
(M), UM patients can be divided in four stages with an increasing risk of metastasis 
with increasing stage.42,51,52 Patients with Stage IV are patients with confirmed diagno-
ses of metastasized disease at the time of diagnose. In contrast to histopathological and 
genetic prognostic markers, the TNM Staging classification lends the possibility for 
risk assessment without the need for tumor material, since tumor size and local infil-
tration (in the ciliary body or sclera) can be determined using ultrasonography.42,51,52
 
Histopathological prognostic markers
Whenever tumor material is available, UM can be investigated for several histopatho-
logical features. UM can be divided based on two cell types, which are spindle cells 
and epithelioid cells (Figure 4A and 4B). The presence of epithelioid cells in the UM 
are associated with a worse prognosis for the patient.53,54 Also high mitotic activity, 
the presence of closed vascular loops (Figure 4C), inflammatory inflammation, tumor 
necrosis (Figure 4D) and degree of pigmentation are associated with metastasis.53,54 
However, a study of 1,527 enucleated eyes conducted by the COMS group revealed 
that these histopathological characteristics are not independent but associated with 
each other.53 Tumors located in the peripheral choroid of the eye are in general larger, 
contain more epithelioid cells and contain more tumor necrosis. Moreover, epitheli-
oid cells in UMs are associated with a higher degree of tumor necrosis, pigmentation 
and inflammation and large tumor size.53 Based on the statistics it is hard to deter-
mine which feature precedes the other. It is most likely that tumors located more 
anterior might be diagnosed later since these tumors tend to cause less symptoms. 
Growing tumors without proper vascularization develop necrosis, which recruits 
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1inflammatory cells. The hypoxia-induced necrosis can also recruit vascularization 
and epithelial-to-mesenchymal transition (EMT) factors that promote proliferation 
and local invasion.55 This results in a higher metastatic risk.
With the increasing knowledge on genetics and the development of Next Generation 
Sequencing tools to explore tumor specimen, a shift towards genetic determinants of 
tumorigenesis and risk for metastasis was feasible.
 
Figure 4. (A) Heamatoxylin and eosin (HE) staining of a uveal melanoma sample (EOM-0921) with spindle 
cell type (200x). (B) HE staining of a sample with epithelioid cell type (200x). (C) Periodic acid–Schiff (PAS) 
staining showing closed vascular loops (400x). (D) HE staining showing tumor necrosis (25x).

Chapter 1.3
Genetic prognostic markers 
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1Chromosomes
Somatic cells in humans are diploid with 46 chromosomes, containing two parental 
copies of the 22 autosomale chromosomes (2 x 22) and two sex chromosomes which 
are either XX in women or XY in men. Cancer is a malignancy of human somatic cells 
that in general contain chromosomal aberrations either as the initiation of cancer or 
consequence of cancer. These chromosomal aberrations can be numerical (loss or gain 
of entire chromosomes) or structural e.g. translocations of chromosome parts to other 
chromosomes. Uveal melanoma is a malignancy  characterized by several non-ran-
dom recurring chromosomal aberrations.56-58 ‘Non-random recurring’ means that the 
tumors in a proportion of the patients contain similar chromosomal aberrations. As 
every chromosome has two copies, chromosomal aberrations are also named copy 
number variations (CNVs). 
Chromosome 3
Among these non-random recurring CNVs, the loss of the entire chromosome 3 was 
observed several decades ago in tumor material of UM patients. Loss of chromosome 3 
(monosomy 3) is observed in nearly half of the UM, and is to date still the most strongly 
associated CNV with metastases.56-58 In UM with monosomy 3, different regions of 
the tumor were analyzed for chromosome 3 to determine intra-tumor heterogeneity. 
This revealed that monosomy 3 UMs show loss of chromosome 3 in the entire tumor 
suggesting that UM with monosomy 3 are quite homogenous.59 Besides monosomy 
3, another chromosomal abnormality that can be observed is isodisomy 3.60 In these 
tumors there are two identical copies of chromosome 3, thus resulting in a loss of 
heterozygosity (LOH). LOH of chromosome 3 is even more predictive for metastasis 
than monosomy 3.60
Chromosome 8q
Another copy number (CN) event is the gain of the long arm of chromosome 8. Gain 
of chromosome 8q is observed by either entire chromosome 8 gain, the formation of an 
isochromosome 8q or a partial amplification of the distal end of 8q.56,61 The formation 
of an isochromosome 8q is mainly observed mutually with the loss of chromosome 3 
(Figure 5),62,63 in which the combination of these CN events in the UM are associated 
with the most rapid systemic progression of the disease.64 Partial amplification of 
chromosome 8q, with the breakpoint at 8q21, is mainly observed in disomy 3 tumors.61
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Figure 5. A Single Nucleotide Polymorphism (SNP) array analyses of a uveal melanoma (EOM-0219). As 
observed in the upper picture (Log R ratio) this tumor has a loss of chromosome 3, loss of chromosome 8p 
and gain of chromosome 8q (indicative of isochromosome 8q)The lower picture represent the allelic imbalance 
displayed as the B-allele frequency.
Chromosome 6p
Chromosome 6p gain is present in almost half of the UMs and usually observed in 
tumor samples without chromosome 3 loss.56 Similar to chromosome 8q, chromosome 
6p gain is observed either by an entire gain of chromosome 6, via the formation of an 
isochromosome 6p or an amplification of the distal part of chromosome 6p.57,58,61,63,65 
Unlike chromosome 8q, the different types of gain have not been associated with other 
chromosomal aberrations. 
Other chromosomes
Other less frequent occurring chromosomal aberrations described in UM, are loss of 
chromosome 1p, 6q, 8p, and 16q.54,56-58,61-63,66-70 Chromosome 1p loss is usually observed 
together with monosomy 3, in which monosomy with loss of chromosome 1p has a 
worse prognosis than monosomy without chromosome 1p loss.67 Loss of chromosome 
8p has been correlated with worse outcome in the survival.71 However, these losses 
are frequently observed with isochromosomes 8q, thus making it likely that the loss 
of these chromosome arms are confounders to the isochromosome formation.61 Chro-
mosome 16q loss, observed mainly in tumors with loss of chromosome 3, has been 
proposed as a late event in tumorigenesis and is not associated with prognosis.66,70
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1Polyploidy
Besides aneuploidy, also polyploidy has been described in UM.72-74 Polyploidy is a 
state in which the genome has three or more copies of each chromosome instead of 
the usual diploid state.75,76 Polyploidy occurs in other malignancies as well, ranging 
from 11-54%.75 Polyploidization in a cell can occur through three mechanisms: cell 
fusion, problems during cytokinesis/metaphase/anaphase or by endoreduplication.75 
In general, polyploidy in malignancies has been associated with worse prognosis com-
pared to tumors with diploid cells.75,76 It is thought that polyploidy causes treatment 
resistance since these cells are very adaptive.76 Polyploidy in UM, measured with 
flowcytometry, has been described in 17-18% of the patients.72-74 In UM, this higher 
DNA content was also associated with an increased risk of metastasis.72,74
 
Genes
Besides presence of chromosomal aberrations, mutated genes are also a typical char-
acteristic of cancer. The type of mutation can be divided in germline and somatic 
mutations. Germline mutations are inherited from one or both of the parents. These 
mutations are present in all the cells of the affected individual and can give rise to 
cancer prone syndromes. An example is a BRCA1 germline mutation in hereditary 
breast cancers.77 Somatic mutations are acquired during the lifetime of an individual. 
Most somatic mutations are caused by environmental factors, such as smoking, alco-
hol and UV-light exposition. Cancer-associated genes can be divided in two major 
groups; oncogenes and tumor suppressor genes. Oncogenes are usually involved in 
cell growth. When mutated in cancer, these genes give a continuous activation of path-
ways promoting cell growth and thus have a gain-of-function effect in cancer.77 Tumor 
suppressor genes on the other hand are usually involved in apoptosis, cell division 
and DNA-repair, preventing cell growth and instability. Since human cells contain 
two copies of each gene, both copies of tumor suppressor genes must be affected to 
accomplish the loss-of-function effect in cancer. Besides these gain and loss-of-function 
mutations also other mutations have been described with an altered-function effect.77
Also UMs harbor mutations in genes that are in involved in tumorigenesis. Although 
most of these mutations are somatic, germline mutations giving rise to the BAP1-syn-
drome have been described which is typically associated with malignant mesothelioma 
and uveal melanoma development. In this Chapter we will only focus on somatic 
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mutations, since these germline mutated genes only represent in a very small amount 
of patients.78,79
GNAQ, GNA11, CYSLTR2 and PLCB4
Sequencing of 24 potential oncogenes involved in the RAF/MEK/ERK pathway led to 
the discovery of a hotspot mutation in GNAQ (Guanine nucleotide binden protein, 
subunit q; chromosome 9q21.2).80 This hotspot mutation targeting amino acid 209 
(Q209) was confirmed in UM by other groups.81,82 Within a year the hotspot Q209 
mutation in GNA11 (Gunanine nucleotide binding protein, subunit 11; chromosome 
19p13.3), the homologue of GNAQ, was identified.83 Besides mutation targeting Q209, 
recurring mutation targeting amino acid 183 (R183) were observed for both genes in 
UM.83 Mutations in either gene occuring in approximately 90% of the UM, were inde-
pendently or together not associated with survival.82,84
The majority of UM samples harbor GNAQ/GNA11 mutation, however there is a small 
percentage of UM samples that lack a mutation in one of these two oncogenes. In 
some of these cases recurring mutations in CYSLTR2 (Cysteinyl Leukotriene Receptor 
2; chromosome 13q14.2) were found, targeting amino acid L129 in all.85 CysLT2R is a 
G-protein Coupled Receptor (GPCR) upstream from Gαq. This recurring missense 
mutation causes activation of the same signaling pathways as GNAQ and GNA11.85 
Similar to GNAQ/GNA11 mutations, CYSLTR2 mutations were also found in blue 
nevi.86 Another mutated gene found in GNAQ/GNA11 wildtype UMs was PLCB4 
(Phospholipase C Beta 4; chromosome 20p12.3), targeting amino acid D630 in all 
described cases.87 Also this gene is part of the signaling cascade of GNAQ/GNA11, 
acting as a canonical downstream target.87 
Taken together with the occurrence of the same mutations in benign oculodermal lae-
sions, this suggests that activating mutations in these oncogenes are the initial steps 
in tumorigenesis of UM.
BAP1
Whole-exome sequencing (WES) of two samples with a loss of chromosome 3 led to the 
discovery of inactivating mutations in the tumor suppressor gene BAP1 (BRCA-associ-
ated protein 1; chromosome 3p21.1).88 Additional analyses of 45 samples revealed that 
BAP1 mutations occurred in ~40% of the patients and this was congruent with mono-
somy 3 status of the tumor.88 Since BAP1 usually harbors truncating mutations, the lack 
General introduction  |  31
1of BAP1 expression can be tested with immunohistochemical staining (IHC).89,90 Lack 
of BAP1 expression was almost congruent with BAP1 mutations, thus proving BAP1 
IHC to be a rapid and reliable alternative to sequencing all 17 coding exons of BAP1. 
Unlike GNAQ/GNA11 mutations, BAP1 status of the tumor was strongly correlated 
with survival.88,90,91
SF3B1
Additional WES of 18 primary UM, led to the discovery of an SF3B1 (Splicing factor 
3b, subunit 1; chromosome 2q33.1) missense mutation in exon 14 in two samples, 
targeting amino acid 625 (R625) in both.92 SF3B1 mutations also occurred in chronic 
lymphocytic leukemia (CLL) and myeolodysplastic syndrome (MDS) predominantly 
in exon 12 to 16, usually with other hotspot mutations.93,94 In approximately 20% of UM 
samples, an SF3B1 mutation was found targeting R625 in almost all cases, although 
rarely other mutations were also observed.92,95,96 SF3B1 mutations were strongly cor-
related to disomy 3 tumors.92,95 SF3B1-mutated tumors are also associated with a better 
disease-free survival when compared to SF3B1-wildtype within five years after treat-
ment,95 however another study with a prolonged follow-up of ten years was not able 
to see this difference.92 Moreover, when stratified for chromosome 3 status, we showed 
that UM with SF3B1 mutations were correlated to late-onset metastasis.97
EIF1AX
Another recurring mutated gene in UM discovered with WES is EIF1AX (Eukaryotic 
translation initiation factor 1A, X-linked; chromosome Xp22.12).96 Similar to SF3B1 
mutations, also EIF1AX mutations were strongly correlated with disomy 3 tumors.91,96 
EIF1AX mutations occur in approximately 20% of the UM cases, and were only found 
in the first 15 amino acid (exon 1 and partially exon 2).96  Also similar to the SF3B1 
mutations, the EIF1AX mutations are gain of function mutations result in an intact 
albeit altered protein. Tumors harboring an EIF1AX mutation are associated with a 
better survival compared to tumors without EIF1AX mutations.91,96,97 
 
Gene expression
Gene expression profiling (GEP) is commonly used in cancer research. The mRNA 
expression of several thousand genes are measured simultaneous to construct specific 
patterns that can be used to classify patients. Patients with UMs could be divided 
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in low-risk profiles (Class I) and high-risk profiles (Class II) based on RNA expres-
sion.98-102 In large multi-center studies, GEP proved to be more accurate in predicting 
metastasis at three years of follow-up when compared to the TNM classification and 
chromosome 3 status of the tumor.103,104 Although GEP proves to be an accurate pre-
dictor, Augsburger and colleagues described discordant GEP result in more than 10% 
of the cases in fine-needle aspiration biopsy (FNAB) extracted samples.105 Another 
report showed that also non-melanoma tumors can be categorized in Class I or II, 
falsely classifying non-melanoma tumors as uveal melanomas.106
Metastasis is most strongly correlated to class II UMs, however also a small propor-
tion of class I UMs eventually develops metastasis. Recently, PRAME (preferentially 
expressed antigen in melanoma) was identified as a marker for metastasis in class I 
UM, for which increased expression was associated with a high risk.107,108 
 
MicroRNA
New players in the field of oncology are microRNAs (miRNAs).  For several cancers 
it has already been shown that miRNAs can target  oncogenes and tumor suppressor 
genes.109 Compared to normal human cells, cancer cells generally have lower miRNA 
expression.110 
Unsupervised hierarchical clustering revealed that UMs can be divided into two clus-
ters based on miRNA expression, which overlapped with the GEP classes.111 Overall, 
Class II UMs (high-risk) expressed less miRNAs compared to Class I UMs (low-risk).111 
Similarly, another study showed that more miRNAs were downregulated in metasta-
sized UMs compared to non-metastasized UMs.112 
 
Methylation
Hypermethylation of promotor sites of tumor suppressor genes is also a way to epige-
netically silence gene expression.113,114 Also for UM, methylation has been investigated 
intensively. 
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1Several studies showed promotor methylation of RASSF1A (Ras Association Domain 
Family Member 1, chromosome 3p21.31) in 13-83% of UM cases and cell lines.115-118 Fur-
thermore, in vitro analyses revealed that ectopic RASSF1A expression in cell lines with 
promotor methylation of RASSF1A resulted in slower proliferation and more sensitiv-
ity to cisplatin.115,119 Also BAP1 was analyzed for methylation since it was hypothesized 
that this gene could also be silenced trough promotor methylation, however this was 
not the case.120

Chapter 1.4
Prognostic testing in patients 
with uveal melanoma
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1As described in this Chapter, we have seen that prognosis can be determined in many 
ways. The choice for different methods for prognostication depends largely on the 
available material and techniques.121 
Clinical variables, as described by the AJCC classification, are currently the only prog-
nostic classifiers when there is no tumor material available. However, many more 
options for prognostication are possible when tissue is available.
Several studies have been published in which the chromosome status, in particular 
chromosome 3 and 8q, minimizes the prognostic value of the AJCC classification.122 
Furthermore, the combination of AJCC classification and the chromosome status seem 
to be the most accurate predictor.122,123 An online tool, combining multiple prognostic 
factors, is the Liverpool Uveal Melanoma Prognosticator Online (LUMPO).124 This 
tool provides a patient specific risk for metastasis, taking into account the clinical and 
histopathological variables and chromosome 3 status, if available.124
Also for gene expression is has been shown that the GEP status together with tumor 
size are the most accurate prognostic predictors.104,125 Also when material was obtained 
by FNAB, GEP proved to be more superior in prognostic testing than cytogenetics.126 
For genetic analyses BAP1 status is shown to be the most accurate predictor for metas-
tasis, especially in combination with the EIF1AX mutation status.90,91
Future studies should be performed where all variables are included such as the 
clinical and histopathological variables, gene expression profiling, chromosome and 
mutational status. The Cancer Genome Atlas (TCGA) has recently made data available 
for 80 UMs including all of the before mentioned variables and more (available at 
https://cancergenome.nih.gov/). Studies using the TCGA data and other online-avail-
able data will hopefully provide more insight in the genetics of UM and also more 
insight in the prognostic value of all variables.

Chapter 1.5
Scope and outline of this thesis
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1With the development of novel techniques for genetic analyses, the genetic basis of 
uveal melanoma etiology has made a great progression.  Next-generation sequencing 
led to the discovery of recurrent mutated genes such as BAP1, SF3B1 and EIF1AX. 
The aim of this thesis was to investigate whether compared to AJCC classification or 
GEP analysis, these genetic changes would provide a better prognostic tool to classify 
patients with UM in high-risk and low-risk groups.
We set to analyze whether  different mutated genes have their own prognosis and 
chromosomal patterns. In Chapter 2.1 the prognostic value of SF3B1 mutation in UM 
was analyzed. Following this, Chapter 2.2 concerns the specific chromosomal aber-
rations and patterns associated with the recurrent mutated genes, BAP1, SF3B1 and 
EIF1AX. In this Chapter somatic mutational signatures in UMs, a novel technique to 
associate mutational spectrum with several clinical features and cellular pathways, 
are also analyzed. 
When metastasis occurs in UM patients, the metastases present themselves in a vari-
ety of ways. In Chapter 2.3, we set to analyze whether there is a clinical difference in 
metastasis presentation in patients with either BAP1 or SF3B1-mutated UMs.  For this 
purpose 100 scans of liver metastases of UM patients were collected and the genetic 
data of 68 UM patients. Furthermore, the prognostic value are described of polyploidy 
in UM and the association of polyploidy with the known mutated genes in UM (Chap-
ter 3.1) and the occurrence of chromothripsis, another chromosomal anomaly in UM 
(Chapter 3.2). Chapter 3.3 describes a case-report of lipomatous changes in an UM.
Finally, in Chapter 4 we discuss our results and the current literature on genetics in 
UM.
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Abstract
Objective: To investigate the prevalence and prognostic value of SF3B1 and EIF1AX 
mutations in uveal melanoma (UM) patients.
Design: Case series
Subjects: A cohort of 151 patients diagnosed and treated for UM.
Methods: SF3B1 and EIF1AX mutations in primary tumors were investigated using 
whole-exome sequencing (n = 25) and Sanger sequencing (n = 151). For the detection 
of BAP1 mutations a previously reported patient cohort of 90 patients was extended 
using BAP1 sequencing or immunohistochemistry.
Main outcome measures: Status of SF3B1, EIF1AX and BAP1 in tumors of patients 
were correlated to clinical, histopathological and genetic parameters. Survival anal-
yses were performed for patients whose tumors had SF3B1, EIF1AX and BAP1 
mutations. 
Results: Patients with tumors harboring EIF1AX mutations rarely developed metas-
tases (2 out of 28 patients) and had overall a longer disease-free survival (DFS 190.1 
versus 100.2 months, P < 0.001). Within the patient group with disomy 3 UM patients 
with an SF3B1 mutation had an increased metastatic risk compared to those without 
an SF3B1 mutation (DFS 132.8 versus 174.4 months, P = 0.008). Patients with such a 
mutation were more prone to develop late metastases (median 8.2 years, range 23-145 
months). Patients with UM and loss of BAP1 expression had a significantly decreased 
survival (DFS 69.0 versus 147.9 months, P < 0.001). Conclusion: According to our data, 
patients with UM can be classified into three groups of which EIF1AX mutated 
tumors and tumors without BAP1, SF3B1 and EIF1AX mutations associate with 
prolonged survival and low metastatic risk, SF3B1 mutated tumors associate with 
late metastasis, and tumors with an aberrant BAP1 in tumors associate with an early 
metastatic risk and rapid decline in patients’ disease free survival.
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Introduction
Uveal melanoma (UM) is the most frequent primary tumor in the eye, with an esti-
mated annual incidence between 4.3 and 8.6 cases per 1 million in the Western world.1,2 
This tumor is derived from melanocytes in the choroid, ciliary body or iris. Approxi-
mately 40% of patients demonstrate metastasis with a peak within 4 years after initial 
treatment, but metastatic disease has been observed even 15 years or longer after 
diagnosis. This suggests the presence of occult micrometastases at the time of primary 
treatment of the tumor since treatment of the primary UM is almost always successful 
without local recurrence.3,4 
In addition to clinical features, such as the age of the patient and the tumor size, molec-
ular and genetic markers are used to prognosticate UM patients with low- and high-risk 
profiles.5-7 Chromosomal aberrations have been associated with metastatic disease in 
UM patients, of which loss of chromosome 3 (monosomy 3) is the most prominent.7 
Monosomy 3 is present in approximately half of the tumors and is associated strongly 
with poor survival.7 In contrast, tumors with disomy 3 rarely metastasize within the 
first 3 years of follow-up.7 A gain of chromosome 8q is associated independently with 
decreased survival, and this is even more profound in combination with the loss of 
chromosome 3.8 In addition to chromosomal abnormalities, RNA expression also has 
been used to categorize UM patients in low-risk (class 1) and high-risk (class 2) cate-
gories with high accuracy.9 
DNA sequencing led to the identification of recurrent affected genes in UM. Activating 
GNAQ and GNA11 hotspot mutations were found in most cases of UM, but were 
not associated with prognosis.10-12 Hemizygous mutations in the BRCA-associated pro-
tein 1 (BAP1) were found in most monosomy 3 tumors, resulting in an inactivation 
of the protein and loss of BAP1 expression.6 Hence, BAP1 mutations or no detectable 
BAP1 expression are associated with metastatic disease in UM patients.13-15 
More recently, 2 other genes, SF3B1 (splicing factor 3 subunit B1) and EIF1AX 
(eukaryotic translation initiation factor 1A) were reported to be mutated in UM 
patients.13,16-19 SF3B1 mutations, almost exclusively in amino acid 625 (R625 located in 
exon 14) can be found in 10% to 21% of UM.16-18 Mutations in this gene have been associ-
ated with favorable prognostic features in UM patients, such as lower age at diagnosis 
and tumors with disomy 3, in contrast to patients with BAP1-mutated tumors.16,18 
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Survival analyses revealed that patients with SF3B1-mutated UM had a better sur-
vival compared to the SF3B1 wild-type patients.16 However, in another study with a 
longer follow-up, these survival differences between patients with SF3B1-mutant and 
SF3B1 wild-type tumors did not reach significance.18 In 16% to 19% of UM patients, 
EIF1AX mutations were observed mainly in disomy 3 tumors.13,17,19 The patients with 
EIF1AX mutations had a better survival than those with EIF1AX wild-type tumors 
at 48 months of follow-up.13 
The high prevalence of mutations in these genes and distinct survival patterns of UM 
patients urged us to investigate the prognostic value of these genes in a large cohort 
with long follow-up. We performed mutation analysis of SF3B1 and EIF1AX in 
tumor DNA of 151 patients. BAP1 mutation analysis and immunohistochemical 
detection of BAP1 loss in a subset of 74 tumors has been previously reported by our 
group,15 and additional immunohistochemistry and mutation data were added. We 
correlated the mutational status with clinical, histopathologic and genetic parameters.
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Methods
Study population
Tissue specimens were obtained from 151 UM patients. Patients with UM (n = 144) 
underwent primary enucleation between 1993 and 2013 at the Erasmus University 
Medical Centre or The Rotterdam Eye Hospital, the Netherlands. Seven patients pri-
marily underwent irradiation of the UM, of whom 6 patients underwent secondary 
enucleation (median, 15 months; range 3-55) and 1 patient underwent biopsy examina-
tion 26 months after irradiation. Patient survival data were updated from the patients’ 
charts. After enucleation, tumor material was obtained and partly snap frozen in liquid 
nitrogen, whereas the remaining tumor was embedded in paraffin. A histopathological 
diagnosis of melanoma was made by an experienced ophthalmic pathologist (R.M.V.) 
conforming to the Royal College of Pathologists guidelines (available at: www.rcpath.
org/resourceLibrary/dataset-for-the-histopathological-reporting-of-uveal-melano-
ma--3rd-edition-.html). Patients with iris melanoma were excluded. The local ethics 
committee approved this study, and informed consent was obtained before to the 
intervention. This study was performed according to the guidelines of the Declaration 
of Helsinki.
DNA extraction and copy number analysis
DNA was extracted directly from fresh tumor tissue or frozen sections using the 
QIAmp DNA-mini kit (Qiagen, Hilden, Germany) according to the manufacturer’s 
instructions. The tumors were processed for fluorescence in situ hybridization (FISH) 
and single nucleotide polymorphism(SNP) array analysis (HumanCytoSNP-12 v2.1 
BeadChip and Illumina 610Q BeadChip, Illumina, San Diego, CA), as described pre-
viously.15 Cutoff limits for deletion (>15% of the nuclei with 1 signal) or amplification 
(>10% of the nuclei with 3 or more signals) were adapted from the literature.20 Tumors 
were examined for ploidy status with fluorescence in situ hybridization using control 
probes on chromosome 5q (chromosome 5q is usually not altered in UM). Polyploid 
tumors were excluded from the analyses because chromosomal abnormalities in these 
tumors require much more detailed analyses.
Whole-Exome sequencing 
Uveal melanoma samples of 25 patients were subjected to whole-exome sequencing 
(WES). For 19 samples, SureSelect version 4 capture kit (Agilent Technologies, Santa 
Clara, CA) was used with 1 µg of genomic DNA, followed by sample preparation and 
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sequencing using the HiSeq 2000 system (Illumina). A CLC Cancer Research Work-
bench (QIAGEN, Redwood, CA) was used with default Burrows Wheeler aligner 
settings for the alignment against human reference genome build (hg19) to gener-
ate BAM files (*.bam). For the remaining 6 samples, the ACE Clinical Exome assay 
(Personalis Inc., Menlo Park, CA) was used on 1 to 3 µg genomic DNA. Sequencing 
(*.fastq) and alignment (*.bam) were generated and provided by Personlis, Inc. For 
all whole-exome sequencing samples, the BAM files were investigated manually for 
the regions of interest (BAP1, SF3B1, EIF1AX, GNAQ, and GNA11) using the 
Integrative Genomics Viewer version 2.3 (Broad Institute, Cambridge, MA). In general, 
all exons including the flanking regions (up to 25 base pairs) were covered at least 
10 times and for exons with insufficient coverage, additional Sanger sequencing was 
carried out. Found variants were validated using Sanger sequencing.
Sanger sequencing
We sequenced exon 14 of SF3B1 covering codon 625 (n = 151) with polymerase chain 
reaction (PCR). Additionally, we sequenced exon 12 to 16 of SF3B1 in 106 samples that 
proved to be wild-type for codon 625. For EIF1AX, we amplified the 5’UTR with exon 
1 and exon 2, including surrounding splice site sequences. The primers are shown in 
Supplementary Table 1. The PCR and Sanger sequencing protocols are available upon 
request. Sequences were aligned and compared with reference sequence hg19 from 
the Ensemble genome database (ENST00000335508 and ENST00000379607). De novo 
missense mutations found in the genes of interest were evaluated with PolyPhen-2 
(http://genetics.bwh.harvard.edu/pph2/index.shtml) and SIFT (http://sift.jcvi.org/) for 
predictions (using default settings) to determine the possible functional impact and 
pathogenicity of the amino acid change. Mutations analysis of GNAQ, GNA11 and 
BAP1 was carried out as reported previously.12,15 
cDNA sequencing
For cDNA sequencing, 5 samples were selected based on the mutation type in EIF1AX. 
As described previously,21 1 µg of RNA was extracted from fresh frozen tumor material 
and converted to cDNA with the iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories, 
Veenendaal, the Netherlands). This cDNA was amplified and sequenced using the 
primers shown in Supplementary Table 1. Sequences were aligned and compared with 
the same reference sequence used for genomic mutation analyses. 
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Immunohistochemical staining
Immunohistochemistry was performed with an automated immunohistochemistry 
staining system (BenchMark Ultra; Ventana Medical Systems Inc., Tucson, AZ), as 
described previously.15 For BAP1 staining, we used a mouse monoclonal antibody 
raised against amino acids 430 through 729 of human BAP1 (clone sc-28383, 1:50 dilu-
tion, Santa Cruz Biotechnology, Inc., Dallas, TX), for which liver, tonsil, breast tissue, 
and the retinal pigment epithelium were used as positive controls. All slides were cut 
at the time of staining. More details are provided in a previous paper.15 
Statistical methods 
Disease-free survival (DFS) was calculated from the date of enucleation to metastasis 
resulting from UM or last follow-up. Death resulting from another cause was censored. 
Survival curves were generated using the Kaplan-Meier method, and the difference 
between groups was compared with the log-rank test. The effect of continuous vari-
ables on DFS was assessed using the Cox proportional hazard analysis. Multivariate 
analysis was conducted with the Cox proportional hazard analysis using a forward 
stepwise method based on likelihood ratios. P values less than 0.05 were considered 
significant (SPSS software version 21.0; SPSS Inc., IBM, Armonk, NY). The Fisher exact 
and chi-square test were used to determine association between categorical variables. 
For continuous variables, we used the Mann-Whitney U test. To adjust for multiple 
testing with associations, a corrected P value less than 0.005 was considered signifi-
cant.
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Results 
FISH or SNP data and DNA were available for 151 tumors. Eighteen tumors had a poly-
ploid karyotype and therefore were excluded from further analysis. In the remaining 
cohort of 133 patient with a diploid tumor karyotype, FISH and SNP analysis revealed 
recurrent monosomy 3 (n = 57), loss of chromosome 1p (n = 36), and gain in chromo-
some 6p (n = 61) and chromosome 8q (n = 76; Table 1). In 7 cases of UM, a deletion of 
chromosome 3q was detected while the short arm of chromosome 3 showed 2 copies. 
The tumors were treated as disomy 3 tumors in further analysis based on published 
data.22,23 The demographic and histopathologic patient and tumor characteristics are 
shown in Table 1. At the time of diagnosis, the median age of the patients (72 men and 
61 women) was 61 years (range, 22–92 years). The mean largest tumor diameter and 
mean tumor height were 13.2 mm (range, 5–22 mm) and 7.9 mm (range, 1.5–22.0 mm), 
respectively. Mean follow-up time of the patients was 66.0 months (range, 0–209.1 
months). Of the 133 patients, 52 (39.1%) demonstrated metastasis and 50 subsequently 
died. Twenty-four patients died of causes other than metastatic disease.
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Figure 1. Schematic overview of the mutations (insertions and deletions) found in the SF3B1 and EIF1AX 
genes. Exons 12 to 16 of SF3B1 are shown (A). Exon 1 and 2 of the EIF1AX gene are shown (B). The missense 
mutations are depicted in blue, deletions in red and insertions in green. The red block with a green segment 
represents a triplet nucleotide deletion resulting in the deletion of two amino acids and replacement with a 
glycine (p.Gly9_Lys10delinsGlu). Both splice site mutations (shown in orange) led to an alternative splice 
site resulting in a loss of the first six nucleotides of exon 2.
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SF3B1, EIF1AX and BAP1 mutations
In total, 32 of the 133 tumor DNA samples (24.1%) harbored an SF3B1 mutation, and 
all but 1 were located at amino acid or codon 625. These missense mutations resulted in 
the amino acid changes p.R625C in 12 samples, p.R625H in 15 samples, and p.R625L in 
4 samples; all these amino acid changes were predicted to be probably damaging and 
deleterious by PholyPhen-2 and SIFT prediction software (Figure 1A; Supplementary 
Table 2). One UM (0.8%) had an SF3B1 mutation in exon 16 (p.G742D), which was 
predicted to be probably damaging by PolyPhen-2 and to be tolerated by SIFT. 
For EIF1AX, 28 of 133 tumors (21.1%) had a mutation in either exon 1 (n = 14) or exon 
2 (n = 14). Details are shown in Figure 1B and Supplementary Table 2. These mutations 
included missense mutations (n = 23), in-frame deletions (n = 2), an in-frame insertion 
(n = 1), and mutations located at a splice site of the exon (n = 2) (Figure 1B). cDNA 
sequencing confirmed that tumors that harbored a splice site mutation use alternative 
splicing by eliminating the first six nucleotides of exon 2, resulting in an in-frame 
deletion of two amino acids (Supplementary Figure 1). PholyPhen-2 (either benign or 
probably damaging) and SIFT (either tolerated or deleterious) software predictions 
were in all samples probably damaging and deleterious for missense mutation in 
exon 2 and predicted either benign (PolyPhen-2) or  tolerated (SIFT) if the missense 
mutation occurred in exon 1 (Supplementary Table 2). 
In total, BAP1 immunohistochemistry was available for 126 tumors, of which 48 had 
a loss of expression of BAP1 and 78 did express BAP1 (Figure 2). In seven tumors, the 
BAP1 immunohistochemistry could not be performed because of the absence of tumor 
tissue. Mutation analyses data was obtained from a previous publication for 47 samples, 
of which 17 tumors harbored a mutation in BAP1 and 28 were wild-type.15 Additionally, 
we sequenced BAP1 in 12 samples of which nine harbored a mutation in BAP1 and 
three were wild-type for the coding exons. Of those 12 samples, we observed discrep-
ancies between immunohistochemistry and mutational analyses in 6 tumors. One of 
these samples had no expression of BAP1, whereas the mutation analyses of the coding 
exons did not reveal a mutation. Five tumors harboring a BAP1 mutation expressed 
BAP1 immunohistochemically, of which 4 were monosomy 3 tumors and in one case 
we observed 2 identical copies (isodisomy) of chromosome 3 (Figure 2). In 3 cases, the 
mutations were missense mutations (p.S10N, p.C91Y and p.A92V) and the 2 remaining 
cases contained nonsense mutations (p.Q36* and p.E406*). All three missense mutations 
were predicted probably damaging by PolyPhen-2 and deleterious by SIFT.
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Table 1.  Correlations between SF3B1, EIF1AX and BAP1 and other clinic-histopathological and 
genetic features.
n=133 Associations
mean (range) SF3B1 EIF1AX BAP1
Variables n (%) Mutated Wild type P-value Mutated Wild type P-value No expression Expression P-value
Age, years (range) 61.0 (22-92) 54.1 64.0 <0.001a 61.7 61.6 0.895a 67.5 58.3 0.001a
Largest tumor diameter, mm (range) 13.2 (5 – 22) 13.8 13.1 0.219a 12.6 13.4 0.314a 14.0 13.0 0.101a
Tumor height, mm (range) 7.9 (1.5 – 22.0) 7.9 7.8 0.508a 8.9 7.6 0.187a 8.1 7.9 0.644a
Sex
     Male, n (%) 72 (54.1) 18 54 0.783b 16 56 0.719b 22 47 0.114b
     Female, n (%) 61 (45.9) 14 47 12 49 26 31
Involvement ciliary body, n (%)
     Present, n (%) 34 (25.6) 8 26 0.933b 4 30 0.124b 18 16 0.037b
     Not present, n (%) 99 (74.4) 24 75 24 75 30 62
Cell type, n (%)
     Spindle, n (%) 62 (46.6) 21 32 0.001b 12 41 0.714b 7 42 <0.001b
     Epithelioid/mixed, n (%) 71 (53.4) 11 69 16 64 41 36
Extracellular matrix patterns
     Present, n (%) 58 (44.3) 5 53 <0.001b 7 51 0.031b 34 24 <0.001b
     Not present, n (%) 73 (54.9) 26 47 20 53 13 53
Chromosome 3 d
     Loss, n (%) 57 (42.9) 0 57 <0.001b 4 53 0.001b 45 9 <0.001b
     Normal, n (%) 76 (57.1) 32 44 24 52 3 69
Chromosome 8q
     Normal, n (%) 57 (42.9) 15 42 0.598b 24 33 <0.001b 6 47 <0.001b
     Gain, n (%) 76 (57.1) 17 59 4 72 42 31
BAP1 mutation
     Mutated, n (%) 26 (45.6) 0 26 <0.001b 1 25 0.016c 16 10 <0.001b
     Wild type, n (%) 31 (54.4) 17 14 9 22 2 29
GNAQ mutation
     Mutated, n (%) 65 (49.2) 20 45 0.052b 17 48 0.171b 20 40 0.263b
     Wild type, n (%) 67 (50.8) 11 56 11 56 28 37
GNA11 mutation
     Mutated, n (%) 44 (44.7) 11 48 0.238 b 11 48 0.516b 26 32 0.16 b
     Wild type, n (%) 73 (55.3) 20 53 17 56 22 45
P-values for the associations with continuous data were obtained by Mann-Whitney test (indicated 
with a), and for the categorical data by χ2-test (indicated with b) or Fisher’s exact test (indicated 
with c). A P-value ≤ 0.005 was considered significant (shown in bold). Seven UM with partial de-
letion of chromosome 3q were included in the disomy 3 group (indicated with d). 
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Figure 2. Schematic overview of the uveal melanoma target genes. A doughnut chart was constructed for 
all samples (n = 133) regarding the mutation or expression status of uveal melanoma target genes EIF1AX, 
SF3B1 and BAP1 (A). The doughnut charts of disomy 3 and monosomy 3 tumors with the corresponding 
disease-free survival (DFS) with the survival status and presence of metastasis (B).
Associations of SF3B1, EIF1AX and BAP1 mutations
The occurrence of SF3B1 and EIF1AX mutations was not mutually exclusive (P 
= 0.173), and 4 tumors (3.0%) harbored a mutation in both genes. BAP1 mutations 
were mutually exclusive from SF3B1 mutations and EIF1AX mutations (P < 0.001 
and P < 0.001, respectively). Patients with an SF3B1 mutation in the tumor were 
diagnosed at a younger age compared with SF3B1 wild-type patients (mean age, 
54.1 vs. 64.0 years; P < 0.001). SF3B1 mutations were associated significantly with 
spindle-cell type (P = 0.001) and were associated inversely with extracellular matrix 
patterns (P < 0.001) and monosomy 3 (P < 0.001; Table 1). EIF1AX mutations were 
associated significantly with disomy 3 and disomy 8q in the overall cohort (P = 0.001 
and P < 0.001, respectively; Table 1). Patients with no expression of BAP1 in the tumor 
were significantly older at diagnosis (P < 0.001). Lack of BAP1 expression also was 
associated significantly with the presence of epithelioid cells (P < 0.001), the presence 
of extracellular matrix patterns (P < 0.001), monosomy 3 (P < 0.001), and gain of chro-
mosome 8q (P < 0.001; Table 1).
We divided the patients into groups based on the mutation status of the tumor. Patients 
with exclusive mutations in SF3B1 or EIF1AX or no BAP1 expression in the tumor 
and tumors that do not harbor any of these mutations were considered separate groups. 
Twenty-two patients (16.5%) could not be categorized because of either an absence of 
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BAP1 status (n = 4), a lack of BAP1 expression with a co-occurring EIF1AX muta-
tion (n = 4), co-occurrence of SF3B1 and EIF1AX mutations (n = 4), or tumors with 
BAP1 mutation however with the presence of BAP1 protein (n = 10) in the tumors.13 
Differences in age at diagnoses between the separate groups showed that patients 
without BAP1 expression in the tumor were diagnosed at the oldest age (mean, 66.9 
years), and patients with an SF3B1 mutation at the youngest age (mean, 54.5 years; 
P < 0.001). Epithelioid cells were present most frequently in tumors without BAP1 
expression (86%), less frequently in tumors with an EIF1AX mutation (60%), and 
least frequently in SF3B1 mutated tumors and tumors without mutations in these 
3 genes (36% and 32%, respectively; P < 0.001). Extracellular matrix patterns were 
observed most frequently in tumors without BAP1 expression (70%), followed by 
tumors without BAP1, SF3B1 or EIF1AX mutations (42%), and least frequently in 
tumors with SF3B1 or EIF1AX mutations (both 15%; P < 0.001). Chromosome 3 loss 
was observed in almost all tumors without BAP1 expression and present sporadically 
in EIF1AX-mutated tumors and tumors without these mutations. Chromosome 3 
loss was completely absent in the SF3B1-mutated tumors (Figure 2). Chromosome 8q 
gain was present in almost all tumors without BAP1 expression (95%), more than half 
of the SF3B1-mutated tumors (54%) and was present less frequently in EIF1AX-mu-
tated tumors and tumors without BAP1, SF3B1 or EIF1AX mutations (10% and 
21%, respectively; P < 0.001). Tumors had the largest diameter in patients without 
BAP1 expression in the tumor (mean, 14.1 mm) and in patients with SF3B1-mu-
tated tumors (mean, 13.8 mm) when compared to patients with EIF1AX-mutated 
tumors or without a mutation (mean for both, 12.3 mm); however this did not reach 
significance (P = 0.0.72). Also, no difference was observed for tumor height, gender, 
involvement of the ciliary body, GNAQ and GNA11 mutations between the patients 
in the separate groups (Table 2).
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Table 2.  Correlations between the BAP1, SF3B1, EIF1AX and no mutation groups and other 
clinic-histopathological and genetic features.
Associations
BAP1 SF3B1 EIF1AX No 
mutation
Variables n=111 No ex-
pression Mutated Mutated
P-value
Age, years (range) 61.1 (22-92) 66.9 54.5 61.3 57.3 0.001
Largest tumor diameter, mm 
(range)
13.4 (5 – 22) 14.1 13.8 12.3 12.3 0.072
Tumor height, mm (range) 7.7 (1.5 – 
22.0)
8.0 7.6 8.5 6.5
0.234
Sex
     Male, n (%) 59 (53.2) 20 (45%) 16 (57%) 12 (60%) 8 (42%) 0.621
     Female, n (%) 52 (46.8) 24 (55%) 12 (43%) 8 (40%) 11 (58%)
Involvement ciliary body
     Present, n (%) 32 (28.8) 18 (41%) 7 (25%) 3 (15%) 4 (21%) 0.124
     Not present, n (%) 79 (71.2) 26 (59%) 21 (75%) 17 (85%) 15 (79%)
Cell type
     Spindle, n (%) 45 (40.5) 6 (14%) 18 (64%) 8 (40%) 13 (68%) <0.001
     Epithelioid/mixed, n (%) 66 (59.8) 38 (86%) 10 (36%) 12 (60%) 6 (32%)
Extracellular matrix patterns
     Present, n (%) 46 (41.4) 31 (70%) 4 (15%) 3 (15%) 8 (42%) <0.001
     Not present, n (%) 64 (57.7) 13 (30%) 23 (85%) 17 (85%) 11 (58%)
Chromosome 3 d
     Loss, n (%) 44 (39.6) 42 (95%) 0 (0%) 1 (5%) 1 (6%) <0.001
     Normal, n (%) 67 (60.4) 2 (5%) 28 (100%) 19 (95%) 18 (94%)
Chromosome 8q
     Normal, n (%) 48 (43.2) 2 (5%) 13 (46%) 18 (90%) 15 (79%) <0.001
     Gain, n (%) 63 (56.8) 42 (95%) 15 (54%) 2 (10%) 4 (21%)
GNAQ mutation
     Mutated, n (%) 52 (47.3) 18 (41%) 16 (59%) 11 (55%) 7 (37%) 0.311
     Wild type, n (%) 58 (52.7) 26 (59%) 11 (41%) 9 (45%) 12 (63%)
GNA11 mutation
     Mutated, n (%) 52 (47.3) 24 (55%) 11 (41%) 9 (45%) 8 (42%) 0.650
     Wild type, n (%) 58 (52.7) 20 (45%) 16 (59%) 11 (55%) 11 (58%)
P-values for the associations with continuous data were obtained by One-way ANOVA test (indicated 
with a), and for the categorical data by χ2-test (indicated with b). A P-value ≤ 0.005 was considered 
significant (shown in bold). Seven UM with partial deletion of chromosome 3q were included in the 
disomy 3 group (indicated with d).
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Survival analysis
Tumors harboring EIF1AX mutations were associated significantly with a better 
metastatic-free survival (DFS, 190.5 [mutant] vs. 100.2 [wild type] months; P < 0.001; 
Figure 3A), whereas SF3B1 mutations were not (DFS, 132.8 [mutant] vs. 120.9 [wild 
type] months;  P = 0.252; Figure 3B; Table 3). Tumors with no BAP1 expression were 
associated with a worse survival (DFS, 69.0 [no expression] vs. 147.9 [with expression] 
months; P < 0.001). Univariate analyses of other single prognostic factors showed sig-
nificant lower DFS for patients with larger tumor diameter (P = 0.019), the presence of 
epithelioid cells (P = 0.007), the presence of extracellular matrix patterns (P = 0.001), 
the loss of chromosome 3 (P < 0.001) and gain of chromosome 8q (P < 0.001) in the 
tumor compared with those without these features. Because SF3B1 and EIF1AX 
mutations are associated with disomy 3,13,16-19 we stratified for chromosome 3 status 
in the survival analysis to eliminate the impact of monosomy 3 on survival. In tumors 
with disomy 3 (n = 76), the presence of an SF3B1 mutation (n = 32) was associated 
with a significantly worse prognosis and the development of late metastasis (DFS, 
132.8 [mutant] versus 174.4 [wild type] months; P=0.008; Figure 3B; Table 3), whereas 
an EIF1AX mutation (n = 24) was associated with a better DFS survival (P = 0.031; 
Figure 3A; Table 3). Univariate analyses of other single prognostic factors showed a 
significantly lower DFS for patients with chromosome 8q gain (P = 0.035). No signif-
icant associations were observed for the other clinical parameters. 
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Figure 3. Kaplan-Meier curves showing disease-free survival (DFS) for EIF1AX, SF3B1 and BAP1 status. 
In the overall group, the prognosis was better among uveal melanoma patients with an EIF1AX mutation (P 
< 0.001) (A). No difference in prognosis could be detected in patients with an SF3B1 mutation in the overall 
group (P = 0.252), however in the disomy 3 group, SF3B1 mutations were associated with worse survival (P 
= 0.008) (B). Tumors without BAP1 expression had a worse survival in the overall group (P < 0.001) (C). 
Survival curve for clustered based mutation status showed distinct survival patterns for each group (P < 
0.001) (D).
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Table 3. Univariate and multivariate analysis of the uveal melanoma parameters in relation to 
patient survival
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
Mean Mean95% CI P-value HR 95% CI P-value 95% CI P-value HR 95% CI P-value
Total group (n = 133) Disomy 3 (n = 76)
Largest tumor diameter (mean) 13.24 1.016-1.195a 0.019c - - 0.057c Largest tumor diameter (mean) 13.02 0.904-1.212a 0.541c - - -
Tumor height (mean) 7.85 0.995-1.117a 0.425c - - - Tumor height (mean) 7.70 0.760-1.102a 0.349c - - -
Cell type Cell type
    Spindle  (n = 53) 139.2 117-161b 0.007d - - 0.703c     Spindle (n = 45) 150.3 128.8-171.8b 0.671d - - -
    Mixed/epithelioid (n = 80) 108.5 87-130b     Mixed/epithelioid (n = 31) 158.8 132.5-185.1b
Closed vascular loops Closed vascular loops
    Present (n = 58) 96.3 71.9-120.7b 0.001d - - 0.172c     Present (n = 17) 148.5 112.8-184.1b 0.808d - - -
    Absent (n = 73) 136.5 117.4-155.6b     Absent (n = 57) 155.0 135.6-174.6b
Chromosome 3
    Loss (n = 57) 73.4 52.0-94.8b <0.001d 12.6 2.89-54.9 0.001c   - - - - - -
    Normal (n = 76) 155.1 138.2-172.1b   - - -
Chromosome 8q Chromosome 8q
    Normal (n = 57) 173.6 153.6-193.7b <0.001d 2.61 1.02-6.66 0.045c     Normal (n = 49) 168.0 149.9-186.0b 0.035d - - 0.126c
    Gain (n = 76) 82.8 64.4-101.1b     Gain (n = 27) 131.1 100.1-162.1b
BAP1 expression 
    Yes (n = 68) 147.9 130.6-165.3b <0.001d - - 0.849c  - - - - - - -
    No (n = 58) 69.0 45.8-92.3b  - - - -
SF3B1 SF3B1 
    Wild type (n = 101) 120.9 101.2-140.7b 0.252d 5.28 1.13-24.6 0.034c     Wild type (n = 44) 174.4 155.9-193.0b 0.008d 4.764 1.325-17.12a 0.017c
    Mutated (n = 32) 132.8 107.4-158.2b    Mutated (n = 32) 132.8 107.4-158.2b
EIF1AX EIF1AX 
    Wild type (n = 105) 100.2 83.7-116.7b <0.001d 0.125 0.016-0.979a 0.048c     Wild type (n = 52) 142.8 121.3-164.3b 0.031d - - 0.131c
    Mutated (n = 28) 190.5 166.2-214.8b     Mutated (n = 24) 174.8 155.3-194.3b
CI: confidence interval; HR: hazard ratio. The 95% CI were calculated either for HR (indicated by 
a) or for survival in months (indicated by b). P-values for the univariate analyses were obtained by 
Log-rank test (indicated with c) and for the multivariate analysis by Cox regression analysis (indi-
cated with d). A P-value ≤ 0.05 was considered significant (shown in bold). BAP1 mutations were left 
out of the disomy 3 multivariate analyses due to the low number of tumors with a BAP1 mutation.
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A survival curve based on the groups (no BAP1 expression; SF3B1 mutation; 
EIF1AX mutation; and no BAP1, SF3B1 or EIF1AX mutation) revealed signifi-
cantly different survival patterns between the groups (P < 0.001; Figure 3D). Five years 
after diagnosis (dotted vertical line in Figure 3D), patients without BAP1 expression 
in the tumor were at risk of developing metastases, whereas the other groups were 
not. However, after a longer survival period, the patients with an SF3B1 mutation 
also demonstrated metastases. Patients with an EIF1AX mutation or no mutations 
in the target genes were at minimal risk of metastases developing. 
Multivariate Cox regression analysis was performed for those variables that were 
associated significantly with survival in the univariate analyses to determine which 
of these parameters were independent prognostic factors for DFS. SF3B1 was also 
included in the multivariate analyses because SF3B1 also was predictive when cor-
rected for chromosome 3. For the overall group, loss of chromosome 3 (hazard ratio 
[HR], 12.6; P = 0.001), SF3B1 mutations (HR, 5.28; P = 0.034), chromosome 8q gain 
(HR, 2.61; P = 0.045) and EIF1AX mutations (HR, 0.125; P = 0.,048) were shown to 
be independent predictors for metastatic disease in UM patients (Table 3). In disomy 
3 tumors, only SF3B1 mutations (HR, 4.8; P = 0.017) were an independent predictor 
for metastases. In this subgroup, EIF1AX mutation status and chromosome 8q gain 
did not reach significance.
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Discussion 
Uveal melanoma is a rare ocular tumor with a high mortality. Currently, UM prognosis 
is based on dichotomous classifications, either by gene expression (class 1 vs. class 2),9 
chromosome status (monosomy 3 vs. disomy 3),7,8 or protein expression (presence vs. 
absence of BAP1 expression),13-15 in which a group of patients tends to be misclassified. 
In this study, we found evidence that UM patients have different risks for metasta-
ses based on the mutational status of BAP1, SF3B1 and EIF1AX. As described 
by others, BAP1 mutations in the tumor are associated with rapid metastasis and 
EIF1AX mutations with prolonged metastatic-free survival.13-15,17 SF3B1 m u t a -
tions have an intermediate risk and are associated with late metastasis. 
In the multivariate analyses we observed that chromosome 3 loss, SF3B1 mutation, 
chromosome 8q gain and EIF1AX wild-type status were associated independently 
with metastatic disease. Contrary to previous work by our group and others, we did 
not find BAP1 immunohistochemistry results to be the strongest predictor of metastases 
of all variables.6,13-15 However, this can be explained by the discrepancies between BAP1 
staining and BAP1 mutation analyses in the entire cohort. Ten tumors stained positive 
for BAP1, whereas mutation analyses did reveal a mutation in the tumors. Among these 
10 patients, metastases developed in 8, as illustrated in Figure 2. Within a cohort of 133 
patients, the impact on survival of these patients with metastasis is very high, and there-
fore can explain why BAP1 immunohistochemistry is not an independent prognostic 
predictor. However this does not mean that BAP1 immunohistochemistry is irrelevant. 
In fact, if we cluster BAP1-mutated tumors with tumors lacking BAP1 expression 
together, we observe that BAP1 status is the strongest predictor for metastases of all 
variables (statistics not shown). Furthermore, in 40 of the 52 patients with metastatic 
disease, we detected a BAP1 mutation or, with immunohistochemistry, loss of BAP1 
expression. Moreover, we found that 90% of these patients in whom metastases devel-
oped demonstrated this within 5 years after diagnosis. BAP1 is a tumor suppressor 
gene that is involved in various cancers.24 Functionally, BAP1 is involved repair of DNA 
damage, most notably double-strand breaks, through deubiquitination and chromatin 
remodeling.25 DNA-damage repair insufficiency leads to genomic instability, and thus 
enhancement of the cancer pathogenicity.26 Patients with tumors with BAP1 muta-
tions account for the majority of metastasizing UM in our cohort; nevertheless, there 
remains a subgroup of patients who demonstrate metastasis, mainly beyond 5 years 
after primary treatment, who do not harbor BAP1 mutations. 
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Previous studies demonstrated that SF3B1 mutation in UM associated with good 
prognostic features and that UM tumors with these mutations rarely metastasize.16-18 In 
this study, we confirmed the association of SF3B1 with known favorable prognostic 
features in the overall cohort. Ewens et al.13 reported a series of 63 UM patients with 
metastasis (cases) and 53 patients without metastasis (controls) in which SF3B1 muta-
tions did not influence the metastatic behavior of UM. In that study, the cutoff point 
for follow-up was set at 48 months. In the Kaplan-Meier survival curve of the overall 
group in our study, we also observed a better survival for patients with SF3B1-mu-
tated tumors versus wild-type during the first years after diagnosis (Figure 3B). 
However, when the follow-up is longer, as shown in Figure 3B, the decline in survival 
for UM patients with SF3B1 mutations in their tumors began at a later stage. A sim-
ilar survival curve was created by Harbour et al,18 whose study showed that SF3B1 
mutations seem to predispose for favorable outcome, but this did not reach signifi-
cance with a follow-up of 10 years. The most likely explanation is that, as in the series 
of Ewens et al, some of the nonmetastatic patients with an SF3B1 mutation in their 
tumor will demonstrate metastasis when the follow-up is prolonged. In our cohort, 
we demonstrated that in patients with an SF3B1 mutation, metastasis occurred in 
general (in 64%) more than 5 years after diagnosis, with a median of approximately 
8.2 years (range, 23-145 months). This emphasizes the importance of a long follow-up 
time in prognostic UM studies. 
To eliminate the impact of monosomy 3 tumors, we stratified for chromosome 3 status 
in the survival analysis. In this subset of 76 disomy 3 tumors from the present study 
we demonstrated that patients with disomy 3 tumors and SF3B1 mutations have a 
5-fold increased risk of metastatic disease occurring at a longer follow-up time, thus 
contradicting the current literature on the prognostic value of SF3B1 in UM.13,16-18 This 
highlights the fact that patients with an SF3B1 mutation are a distinct subclass among 
UM patients with an increased risk of metastatic disease. Fourteen disomy 3 patients 
demonstrated metastasis, of whom 11 harbored an SF3B1 mutation in the tumor, 
explaining 79% (11/14) of metastatic cases of disomy 3 patients. Two other disomy 3 
patients who demonstrated metastases harbored BAP1 mutations. Although these 
tumors stained positively for BAP1 using immuhistochemistry, we detected a homo-
zygous BAP1 missense mutation (p.A92V) in 1 patient and 2 N-terminal missense 
mutations (p.Y173C & p.P88del) in the other patient, indicating that these 2 patients 
belong to the BAP1-mutated subgroup. These 2 metastases were diagnosed at 34 
and 44 months after initial treatment, which fits in the metastatic rate of monosomy 
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3 patients with BAP1 mutations and seems earlier compared with metastases from 
patients with SF3B1 mutations. However, we need to validate the effect of these 
missense mutations with functional assays before we can draw absolute conclusions. 
SF3B1 mutations are described in other malignancies such as chronic lymphocytic 
leukemia and myelodysplastic syndrome.27,28 SF3B1 is essential in pre-mRNA splic-
ing,29 and is hypothesized to be involved in cancer through alternative splicing of 
target genes, which may play a role in tumorigenesis.16 More recently, SF3B1 has been 
described to be involved in DNA-damage repair as well,30,31 which may explain the 
unfavorable prognosis through a potential role in pathways similar to BAP1. 
EIF1AX mutations are also associated with favorable prognostic features and are 
correlated with prolonged survival,13,17,19 which we confirm in this study. Even when 
stratified for chromosome 3 status, patients with EIF1AX mutations have a signifi-
cantly better DFS than patients without EIF1AX mutations (Figure 3A). One can 
debate whether an EIF1AX mutation on its own is correlated with better survival or 
whether the lack of BAP1 and SF3B1 mutations is the reason for a better survival; 
first, most missense mutations in EIF1AX are predicted by the PolyPhen-2 and SIFT 
software to be either benign or tolerated. Secondly, similar survival has been observed 
between patients who do not harbor mutations in BAP1, SF3B1 and EIF1AX in the 
tumor (wild-type) versus patients with only EIF1AX mutations in the tumor (Figure 
3D). EIF1AX is involved in mRNA translation through its essential role in start codon 
recognition of the target mRNA.32 Overexpression of EIF1AX has been described to 
promote protein synthesis and cell proliferation, which may explain its role in cancer.33 
As observed in the overall survival curves, the impact of the large proportion of 
BAP1-mutated tumors has an enormous effect on survival (Figure 3) and can cause 
erroneous interpretations for the disomy 3 patients. After eliminating that group, we 
observed that patients with SF3B1 mutations are also at risk for metastasis, in par-
ticular late-onset metastasis. 
All but 1 of the investigated tumors were obtained after enucleation, an intervention 
that is performed mainly in patients with large tumors. None of the mutations were 
associated significantly with tumor size (Table 2). Whether an enlarged tumor size 
increases the risk for metastases is unclear; it has been reported that by calculating 
tumor doubling time, tumors can disseminate up to 5 years before treatment.4 The 
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mutational spectrum for smaller tumors may differ from larger tumors, although we 
cannot draw any conclusions based on our data. In a previous study, monosomy 3 
was described in half of the patients who underwent secondary enucleation after frac-
tionated stereotactic radiotherapy as a treatment of the primary UM (which was small 
to medium-sized).34 In our current cohort, we also observed monosomy 3 in approx-
imately half of the patients, suggesting a similar spectrum of genetic abnormalities 
between medium sized and large tumors. 
The discrepancies between the BAP1 staining and the BAP1 mutation status, as men-
tioned before in this discussion, also must be addressed. BAP1 staining is a rapidly 
applicable technique to determine BAP1 inactivation; however, we still observe tumors 
that express BAP1 immunohistochemically while harboring a mutation. We therefore 
suggest BAP1 mutation analyses in all tumors with loss of chromosome 3 (or isodi-
somy 3) in combination with BAP1 expression because alternative regulation of BAP1 
expression in these tumors still might contribute to metastasis. 
In conclusion, we showed that patients with aberrant BAP1 tumors correlate with a 
rapid decline in survival, patients with SF3B1 mutations with late-onset metastasis, 
and patients with EIF1AX mutations or no mutations in the BAP1, SF3B1 and 
EIF1AX genes have a prolonged survival. These results suggest that there are more 
than 2 classes in UM; however, validation of our findings using an independent data 
set is needed to confirm this new classification. 
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Abstract
Purpose: Classification of structural and numerical  chromosomal changes to eluci-
date the observed metastatic risk difference in uveal melanoma (UM) patients with 
mutually exclusive BAP1, SF3B1 and EIF1AX mutations.
Design: Case series.
Participants: 280 UM patients from the Rotterdam Ocular Melanoma Study (ROMS) 
cohort.
Methods: Unsupervised hierarchical clustering of genome-wide single nucleotide 
polymorphism (SNP) array data was used to identify molecular subclasses with dis-
tinct chromosomal patterns. Conventional karyograms were analyzed for the number 
and type of copy number variations (CNVs) and correlated with the different muta-
tional statuses of UM. Results were validated using data from The Cancer Genome 
Atlas (TCGA). 
Main Outcome Measures:  Identification of specific chromosomal profiles correspond-
ing to the mutational status of UM patients. To determine whether specific anomalies 
such as isochromosomes or structural variants are associated to the different molecular 
subclasses. 
Results: Unsupervised clustering identified five clusters with distinct copy number 
aberrations patterns, each of them was mainly comprised of UMs with a specific 
mutated gene. BAP1, SF3B1 or EIF1AX-mutated UMs contained distinctive and spe-
cific chromosomal patterns. We show that BAP1 negative UMs have the largest CNVs 
in size and SF3B1-mutated UMs harbored the most CNV events. Whereas EIF1AX-mu-
tated UMs were characterized by the lack of CNVs. Isochromosomes occurred almost 
exclusively in BAP1 negative UMs. Somatic mutation signature analyses generated dif-
ferent signatures for the clusters harboring mutations in either BAP1, SF3B1 or EIF1AX.
Conclusion: UMs harboring mutations in BAP1, SF3B1 or EIF1AX have distinct 
chromosomal aberration patterns that mainly differ by the affected chromosomes, 
the absolute number of  CNVs and the type of CNVs. Mutations in these genes are 
strongly associated with distinct molecular subclasses. This highlights and reflects the 
biological difference between UMs on a genetic level.
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Introduction
Uveal melanoma (UM) is a rare malignancy, characterized by non-random chromo-
somal aberrations and recurrent mutated genes. Despite successful treatment of the 
primary tumor, half of the patients develop clinically detectable metastases within 
five years after diagnosis.1
Copy number variations (CNVs) and chromosomal changes have been investigated 
extensively in tumors of UM patients. Classification using a combination of chromo-
some 3 and chromosome 8q CNVs indicated that UM patients can be categorized 
into at least four groups with each a different metastatic risk.2-4 Loss of chromosome 
3 (monosomy 3), observed in half of the patients, is strongly associated with early 
metastatic disease.5 Monosomy 3 is often observed in combination with gain of chro-
mosome 8q and this combination gives the worst prognosis for UM patients compared 
to solely monosomy 3 or chromosome 8q gain. 2-4, 6 Disomy 3 is usually a favorable 
feature in UM patients, with a low metastatic disease risk.3-6 However, disomy 3 with 
chromosome 8q gain is an indicator for intermediate risk of metastatic disease. Gain 
of chromosome 6p was found to correlate with a favorable prognosis in UM patients 
and is almost exclusively observed in patients with disomy 3 UM.3, 4, 7
Besides these chromosomal changes, recurrent mutations in tumor suppressor and 
oncogenes have been described. GNAQ and GNA11 encode for guanine nucleo-
tide-binding protein G subunit alpha (Gα) and the activating mutations of codons 
p.R183 and p.Q209 occur in over 90% of the UM.8-11 Tumors without GNAQ/GNA11 
mutations often contain activating hotspot mutations in PLCB4 (phospholipase C, 
beta 4) or CYSLTR2 (cysteinyl leukotriene receptor 2).12, 13 PLCB4 is a downstream 
effector of Gα whereas CysLT2R is located upstream in the Gα pathway.
12, 13 Since Gα 
mutations were not associated with survival it was hypothesized that these mutations 
are an initial step in tumorigenesis.9
Half of the UMs display monosomy 3 in which the remaining allelic copy of the BAP1 
(BRCA-associated protein 1) gene, situated at chromosome 3, is inactivated leading to 
early metastatic disease.14-16 Somatic mutations in SF3B1 (splicing factor 3, subunit 1) 
and EIF1AX (eukaryotic initiation factor 1A, X-linked) are almost exclusively observed 
in disomy 3 tumors.17, 18 The N-terminal part of EIF1AX is changed by an in frame 
mutation of the first 15-20 amino acids of this protein in 20 % of UM patients, and 
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these patients seldom develop metastases.18, 19 SF3B1 mutations are seen in 20-25% of 
UM patients and target mostly codon p.R625.8, 17, 19, 20 Although UM patients harboring 
somatic SF3B1 mutations appear to have a favorable prognosis compared to patients 
with BAP1 mutations,20 a longer follow-up study showed that also SF3B1-mutated 
UM patients will eventually developed metastases.19 Mutations in BAP1, SF3B1 and 
EIF1AX occur almost mutually exclusive, and associate with distinct survival patterns 
suggesting that these somatic changes appear to mark different tumor subtypes within 
UM patients.19, 21 
BAP1 and SF3B1 are both involved in DNA damage repair pathways.22, 23 It is therefore 
likely that mutations in these genes will give rise to chromosomal aberrations. The 
aim of this study was to integrate the chromosomal and mutational characteristics of 
UMs. We demonstrate that CNV patterns in UM correlate with these different mutated 
subtypes of UM. Using data from genome-wide profiling and traditional karyotyping 
we show that the type and combination of chromosomal aberrations are distinct for 
BAP1, SF3B1 and EIF1AX-mutated UM. This highlights the genetic diversity of UMs 
and is a further step towards the elucidation of affected cellular pathways determining 
the prognosis of UM patients.
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Methods
Study population
Patients were selected from the Rotterdam Ocular Melanoma Study group (ROMS) 
database based on the availability of whole-genome single nucleotide polymorphism 
(SNP) array analysis and karyotyping. Patients with iris melanoma or patients who 
underwent primary tumor irradiation were excluded. In total, 280 patients were 
included in this study. All patients underwent primary enucleation (n = 278) or received 
a biopsy (n = 2) between 1993 and 2015 at the Erasmus University Medical Center or 
the Rotterdam Eye Hospital, the Netherlands. SNP array data of the primary UM was 
available for 217 patients and karyotyping of the tumor was available for 119 patients. 
For 56 patients, SNP array data as well as cytogenetic data was available. An overview 
of patient and tumor characteristics is provided in Table 1. Patient’s follow-up data 
was updated until March 2016. Informed consent was obtained from all patients. This 
study was approved by the local ethics committee and performed according to the 
guidelines of the Declaration of Helsinki.
Mutational status
After enucleation or biopsy, the tumor was divided in three parts and either snap-fro-
zen in liquid nitrogen, embedded in paraffin or used for culturing and DNA extraction. 
DNA was extracted from fresh or frozen tumor tissue using the QIAmp DNA-mini kit 
(Qiagen, Hilden, Germany) according to the manufacturer’s instructions as described 
previously.19 
Mutation analyses of GNAQ, GNA11, BAP1, SF3B1 and EIF1AX were performed using 
Sanger sequencing and targeted sequencing on the ION Torrent Personal Genome 
Machine (Life Technologies, Carlsbad, CA, USA) as described before.19, 24 BAP1 protein 
expression was analyzed in most cases using immunohistochemistry (IHC), and in 
101 cases also Sanger sequencing was used to confirm mutations in the coding exons 
of BAP1.16, 24 We sequenced exon 14 of SF3B1 and exon 1 and 2 with flanking regions 
up to 25 base pairs into the intron of EIF1AX. Based on the presence of mutations, 
the subgroups were defined into four major groups namely (1) BAP1neg: patients with 
BAP1 negative tumors (thus no BAP1 protein expression using IHC or a hemizygous 
BAP1 mutation), (2) SF3B1mut: SF3B1-mutated tumors and (3) EIF1AXmut : EIF1AX-mu-
tated tumors. Tumors which stained BAP1 positive and contained no SF3B1 or EIF1AX 
mutations were grouped together and were called the (4) No Recurrent Mutations 
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(NRM) group. This group was further split into NRMLOH+ and NRMLOH- subgroups 
based on the loss of heterozygosity (LOH) status of BAP1. We postulated that UMs 
with LOH of BAP1 (allelic imbalance) might still harbor BAP1 mutations despite the 
detection of BAP1 protein expression.
Table 1. Clinical information of the ROMS cohort. 
Variable (n = 277) n / median / mean
Gender
Female 133
Male 144
Age at diagnosis Median; range 62.4 years (22 – 95 years)
Largest tumor diameter Mean; 95% CI 13.0 mm (12.5 – 13.4 mm)
Tumor thickness Mean; 95% CI 7.4 mm (7.0 – 7.9)
TNM category
1 41
2 79
3 127
4 22
Cell type
Spindle 115
Mixed 113
Epithelioid 44
Ciliary body involvement 
No 201
Yes 71
Extracellular matrix patterns
Absent 142
Present 125
Extraocular extensions
Absent 200
Present 34
SNP array analyses
Two hundred nanograms of DNA input was used for whole-genome copy number 
analyses by SNP arrays. Three patients were excluded during SNP data processing 
since these samples only mapped approximately 65 % of the SNPs, whereas the thresh-
old for adequate analyses was set at >90 % mapped SNPs. For the entire set, four types 
of Illumina Human SNP array platforms were used according to the manufacturers 
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guidelines: 18 UMs were analyzed using the CytoSNP-12 v2.0 BeadChip; 58 UMs were 
analyzed using theCytoSNP-12 v2.1; 46 UMs were analyzed using OmniExpress-12 v1 
and 92 UMs were analyzed using CytoSNP-850K BeadChips (Bead Studio Illumina, 
San Diego, CA, USA). Nexus Copy Number 8.0 (BioDiscovery, Inc., El Segundo, CA, 
USA) was used to calculate the total percentage aneuploidy of the entire genome, the 
total copy number (CN) events and for visualization of the whole-genome SNP array 
data. For these calculations, the chromosomal aberrations of the sex chromosomes 
were left out of the analysis to prevent gender-based bias. Pairwise Wilcoxon test was 
used to compare the medians between the different groups. Holm’s correction was 
used to correct for multiple testing. The statistical analyses was conducted using the 
R statistical package version 3.3.0.
Unsupervised hierarchal clustering
As mentioned earlier, data were generated on four different platforms, each has differ-
ent number of SNPs. To combine samples across the four platforms, we only retained 
the 215,138 overlapped SNPs (Supplementary Figure 1). Thus, the dataset used for 
downstream analysis is of size 214 (samples) x 215,138 (features). To remove germ-
line specific aberrations, tumor profiles in each platform underwent correction using 
the data from ten normal samples tented in that platform. The R-package NoWaves 
was used for this end.25 Segmentation analysis was performed on the corrected data, 
which subsequently used to calculate the called data using R-package CGHcall.26 The 
segmented and called data were combined to generate the regioned data, which has 
far more less features than the former two. Finally, hierarchical clustering analysis was 
performed using the dedicated R-package WECCA on the regioned data.27 All analyses 
have been performed using the R statistical environment, version 3.3.1.
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Figure 1. (A) Heatmap for the copy number variations (CNVs) constructed with unsupervised 
hierarchical clustering.(B) Chromosomal patterns for the five clusters constructed by unsupervised 
hierarchical clustering.(C) Doughnut charts for every cluster showing the distribution of the muta-
tion status.
Karyotyping
For cytogenetic analyses, metaphases were obtained after short term tissue culture as 
described previously and were carried out according to the ISCN guidelines.28, 29 In five 
cases, besides conventional karyotyping, spectral karyotyping (SKY) was performed to 
define the affected regions more accurately. These five cases were described in detail 
previously.29, 30 Cytogenetic data from conventional karyotyping was available for 119 
cases. The superiority of conventional cytogenetic analyses over SNP arrays is illustrated 
by the possibility to observe the origin and complexity of the chromosomal anomaly in a 
single cell, and the identity of the structural variants. Each sample was analyzed for the 
presence of isochromosomes and the amount of structural variants (translocations and 
subchromosomal CNVs). The mutational status was known in 70 patients (discovery 
set). Statistical analyses to determine differences between the groups was performed 
using the pairwise Fisher’s exact test. Holm’s correction was used to correct for multi-
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ple testing. Of the 70 UMs, six cases revealed completely normal karyotypes, whereas 
the SNP array and direct FISH data showed chromosomal aberrations indicating that 
after short-term culture only normal cells were analyzed. These six cases were therefore 
excluded from the analyses. The 49 cases with an unknown mutational status were used 
as a validation cohort for the karyotype analyses.
The Cancer Genome Atlas (TCGA) database
For the SNP array analyses, a validation cohort of UM data (n = 80) was obtained from 
the National Institute of Health TCGA server. Level 3 SNP array data (normalized 
segmented copy number data), Level 2 Whole Exome Sequencing derived data (Broad 
Institute curated somatic mutation calling) and Level 3 RNA-seq V2 data (normalized 
expression) were used for analyses. We screened whole-exome data for mutations 
in the UM genes. The segmented SNP array data was visualized using Nexus Copy 
Number 8.0. The percentage of aneuploidy was calculated the same as for the SNP 
arrays in the ROMS cohort. 
Signatures of Somatic Mutations Analysis
Mutation Annotation Format (MAF) files of UM Whole Exome Sequencing( WES) 
data generated by The Cancer Genome Atlas (TCGA) consortium was downloaded 
from the National Cancer Institute GDC portal (https://gdc-portal.nci.nih.gov/). For 
each somatic variant, its trinucleotide context was derived using the human reference 
genome (build hg19) and enumerated into a mutational spectrum matrix Mij (i = 96; 
number of trinucleotide contexts ;j = number of samples or groups of samples) using 
the SomaticSignatures R packages version 2.8.4 from Bioconductor version 3.3.31, 32 
The consensus mutational signatures, established by Alexandrov et. al, (matrix Sij; i = 
96; number of trinucleotide motifs ;j = number of signatures) were downloaded from 
COSMIC (http://cancer.sanger.ac.uk/cancergenome/assets/signatures_probabilities.
txt).33 Per group, a constrained linear combination of the 21 validated mutational sig-
natures from Alexandrov et al. was constructed which reconstructs the group-specific 
mutational spectrum, using non-negative least squares regression implemented in 
the  R package pracma version 1.9.3 (retrieved from https://cran.r-project.org/pack-
age=pracma). Samples were grouped based on mutually exclusive BAP1, SF3B1 and 
EIF1AX mutations (n =48). Relative contributions of Alexandrov’s validated signatures 
per group are depicted in Figure 5. Signatures with less than one percent average 
contribution over all groups were combined as “others”. The statistical analyses was 
conducted using the R statistical package version 3.3.0.
86 
Results
Association of the clusters with mutational status 
From the ROMS cohort, we selected patients for which SNP array data was available. 
Unsupervised hierarchical clustering (HC) was performed to examine whether the 
SNP array data could predict the mutational status. For this, the SNP arrays of 214 
UM patients were analyzed using HC. For 209 patients the mutational status (BAP1 
IHC and mutations in BAP1, SF3B1 or EIF1AX) of the UM was known.
HC analyses unraveled five clusters, which are mainly driven by CNVs on chromo-
somes 1, 3, 6 and 8 (Figure 1A). The first major branching of the HC tree (cluster 1 
versus cluster 2) divided disomy 3 and monosomy 3 UMs (Supplementary Figure 2A). 
For Cluster 1 and 2, also chromosome 8q CNV had a high importance score in dis-
criminating between Cluster 1 and 2. Strikingly, the centromeric part of chromosome 
8q had a higher importance score than the distal part of chromosome 8q. Within the 
two major clusters, we defined five sub-clusters.
The most discriminating CNV in the three sub-clusters in the left branch of the HC tree 
are characterized by CNVs in chromosome 6q (Supplementary Figure 2B and Figure 
1C). Samples in Cluster 1a have no CNVs on chromosome 6q, whereas Cluster 1b was 
characterized by chromosome 6q gain and Cluster 1c is composed of patients with 
chromosome 6q loss in the UM. Chromosome 6q was also the most discriminating 
CNV between Cluster 2a and 2b (Supplementary Figure 2D). 
Cluster 1a contained samples with only small CNVs or no CNVs at all (Figure 1B). 
Two-third of the samples in this cluster were EIF1AXmut UMs or belonged to the NRM 
group (Figure 1C). Fourteen UMs had a partial chromosome 8q gain, of which none 
were EIF1AXmut but 12 of the 14 cluster 1a UMs with partial chromosome 8q gain har-
bored an SF3B1-mutation. Interestingly, also four BAP1neg UM cases clustered in this 
group, probably because these tumors lacked typical aberrations such as monosomy 
3 and chromosome 8q gain.
Cluster 1b was characterized by a gain of an entire chromosome 6, which was solely 
observed in EIF1AXmut and NRM UMs (Figure 1C). Only two UMs in another cluster 
(Cluster 2b) harbored an entire chromosome 6 gain. Moreover, these two UMs dis-
played a polyploid genome with many CNVs stretching entire chromosomes. This 
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suggests that chromosome 6 gain without polyploidy is predictive of EIF1AX-mutated 
tumors or UM without a recurrent mutation.
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Figure 2. Summary CNV plots for the mutations specific  groups of uveal melanomas (UMs) in the 
Rotterdam Ocular Melanoma Study (ROMS) (A) and The Cancer Genome Atlas (TCGA) (B) cohort. 
The chromosomes are depicted on the x-axis. The Y-axis shows the cumulative percentage of copy 
number variation per group. Dark blue indicates gain of chromosome and red indicated loss of 
chromosome. The sex-chromosomes are excluded.
Cluster 1c was characterized by gains in chromosome 6p and 8q, loss in chromosome 
6q (Figure 1B) and enriched for SF3B1mut (77 %; Figure 1C).
As displayed in Figure 1C, Clusters 2a and 2b were enriched for BAP1neg UMs (70 
%). Other samples in Cluster 2 consisted of five SF3B1mut and seven NRM UMs (10%) 
that could be explained by polyploidy. As described previously, polyploid UM are 
highly aneuploid and contain a relative loss of chromosome 3 in all cases, which may 
cause the clustering in Cluster 2.24 Eight other UMs in cluster 2 had a disomy 3. These 
cases have chromosome 1p loss without chromosome 6q loss. The remaining sixteen 
cases consisted of three SF3B1mut, two EIF1AXmut and eleven NRM UMs with LOH of 
BAP1. As these UMs displayed similar chromosomal patterns as BAP1 deficient UMs, 
it is likely that these tumors might harbor cryptic BAP1 mutations or have epigenetic 
silencing of the BAP1 We observed that the clusters are indicative of the samples’ 
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mutation status. BAP1neg UMs mainly clustered based on monosomy 3. UMs with 
EIF1AX mutations or no detectable recurrent mutations tightly clustered together by 
either a very limited number of CNVs or the presence of chromosome 6 gain. SF3B1mut 
UMs cluster together based on recurring CNVs of chromosome 6p, 6q and 8q. These 
analyses indicate that the UM tumor cells that are BAP1neg, SF3B1mut or EIF1AXmut do 
have distinct chromosomal patterns. 
Mutation-specific chromosomal changes 
To validate this hypothesis, we performed supervised clustering. Cases were grouped 
based on the mutation status and analyzed for mutation-specific recurring CNVs (n = 
209). Cases with double mutations - BAP1 & EIF1AX (n = 4) or SF3B1 & EIF1AX (n = 
4) - were analyzed separately. To validate our findings in an independent cohort, we 
analyzed the publicly available UM data from TCGA (n = 80). A flowchart of the cases 
in both cohorts are illustrated in Supplementary Figures 3A and 3B.
BAP1neg tumors (n = 85) were characterized by loss of chromosome 3 (95 %) and gain 
of the entire long (q)-arm of chromosome 8 (85 %) as illustrated in Figure 2A. Gain of 
chromosome 8q was often accompanied by loss of chromosome 8p (31 % of the cases). 
Loss of chromosome 1p, 6q and 16q was also observed frequently (25 %, 20 % and 20 % 
of the cases, respectively). BAP1-mutated UM (n = 24) in the TCGA dataset had similar 
results with loss of chromosome 1p (25 %), chromosome 3 (100 %), chromosome 6q 
(42 %), chromosome 8p (50 %) and chromosome 16q (29 %). Gain of chromosome 8q 
was observed in 96 % of the cases.
SF3B1mut tumors (n = 42) were characterized by gain of chromosome 6p (86 %) and 8q 
(74 %), and loss of chromosome 6q (55 %) and 11q (48 %) (Figure 2A). In addition, loss 
of chromosome 1p (36 %) and gain of chromosome 9q (24 %) were present in SF3B1mut 
tumors. Compared to BAP1neg tumors, structural variants (SVs) within SF3B1mut tumors 
were observed more frequently. BAP1neg tumors harbored a gain of the entire chro-
mosome 8q whereas SF3B1mut UM were characterized by either a gain of chromosome 
8q23qter or chromosome 8q13qter. Other SVs with gain or deletion of the distal ends 
of chromosomes were chromosome 6p12.3pter gain, chromosome 6q16.1qter loss, and 
chromosome 11q22qter loss. Although chromosome 1p loss occurred by deletion of 
the distal part of chromosome 1p, no clear recurring breakpoint could be observed. 
SF3B1mut UM (n = 15) in the TCGA dataset also showed gain of chromosome 6p (86 
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%) with the breakpoint in chromosome band 6p12.3 and gain of chromosome 8q (86 
%) at breakpoint 8q13.3 and 8q23.2. Chromosome 1p loss was observed in 43 % and 
chromosome 6q in 58 % usually with a breakpoint at chromosome band 6q16.1. The 
SVs with the recurring breakpoints in our set and that of TCGA were similar. There was 
only a clear difference observed for chromosome 11q deletions, which were practically 
absent in SF3B1mut UM in the TCGA dataset.
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Figure 3. Statistical comparisons of the percentage of aneuploidy between the major groups (A) and 
the total number of copy number (CN) events (B) in the Rotterdam Ocular Melanoma Study (ROMS) 
cohort. (C) Comparison of the percentage of aneuploidy in The Cancer Genome Atlas (TCGA) cohort 
between the major groups. (D) Comparison of the number of structural variants obtained from 
cytogenetic data of the ROMS cohort between the major groups. The continuous lines between the 
groups are statistically significant differences (P < 0.05) between the groups. The dashed line depicts 
no significant difference between the groups. 
For EIF1AXmut tumors (n = 26) only gain of chromosome 6 or 6p was recurrent (65 %). 
Mostly a gain of chromosome 6p21.33pter was observed, which is a more distal region 
on chromosome 6 compared to that of SF3B1mut tumors. Likewise, in the TCGA dataset, 
we observed a breakpoint mainly at chromosome band 6p21.1 in EIF1AXmut UM with 
chromosome 6/chromosome 6p gain (89 %).
Tumors that were SF3B1 and EIF1AX wildtype and stained BAP1 positive (NRM; n = 
48) were subdivided based on LOH of BAP1, to prevent falsely NRM classified UMs. 
Nineteen UMs harbored LOH of BAP1 (NRMLOH+). The remaining 29 UMs were het-
erozygous for BAP1 (NRMLOH-). 
NRMLOH- tumors were enriched for gain of chromosome 6p (52 %) and 8q (31 %), and 
loss of chromosome 6q (17 %). Moreover, ten of the 29 patients with NRMLOH- UMs 
lacked any large CNV (>1Mb) in the tumor. In the TCGA dataset no mutation in BAP1, 
SF3B1 and EIF1AX were reported in 29 UMs. Fourteen of these UMs were classified 
as NRMLOH+ and fifteen as NRMLOH-. The NRMLOH- UMs - similar to the ROMS data - 
were characterized by partial chromosome 6p (80%) and chromosome 8 gain (33%).
As for the NRMLOH+ UMs, these cases were enriched for monosomy 3 and chromosome 
8q gain with 8p loss and also chromosome 6p gain with 6q loss, very similar to BAP1neg 
UMs in our cohort. For most cases in our cohort with LOH of BAP1, the coding exons 
were sequenced. In ten of the sixteen UMs, a mutation was observed despite the pres-
ence of protein expression. This positive BAP1 expression can largely be explained by 
the fact that four of the mutations were missense mutations and three were frameshift 
mutations at the C-terminus. For the remaining three mutations, which consisted of 
one nonsense mutation and two splice site mutations, Western blotting should be per-
formed to explain the positive BAP1 IHC. Six UMs were wildtype for BAP1, however, 
four of these samples were polyploid and contained an isodisomic chromosome 3 pair, 
which explains the LOH of BAP1.24 Similarly, UMs in the TCGA dataset that were 
wildtype for BAP1, SF3B1 and EIF1AX, but with LOH of BAP1, harbored the same 
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chromosomal aberrations as BAP1-mutated UMs suggesting that UMs with LOH of 
BAP1, still might harbor mutations which are not detected by WES. 
Minor groups were defined by co-occurring mutations in BAP1, SF3B1 and EIF1AX. 
Our cohort lacked any BAP1 negative UMs with SF3B1 mutations, whereas the TCGA 
dataset did not contain BAP1 and EIF1AX co-mutations. Since the numbers per minor 
groups were too small, we could not draw conclusions based on recurring CNVs 
(Supplementary Figure 4). 
All together, these analyses revealed that BAP1, SF3B1 and EIF1AX-mutated UMs 
harbor specific chromosomal patterns. A similar association of specific mutations with 
chromosomal anomalies was seen in the independent cohort. More specific BAP1 defi-
cient UMs harbored entire chromosome or chromosome arm CNVs, whereas SF3B1mut 
UMs harbored partial chromosome arm CNVs.
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Figure 4. Cytogenetic data (reverse banded karyograms) illustrating the distinct chromosomal 
changes in the BAP1 or SF3B1-mutated uveal melanoma (UM). A: Karyogram of a typical BAP1 
negative UM (Case 98)  shows monosomy 3 with 2x isochromosome 8q. B: Karyogram of an atypical 
BAP1 negative UM (Case 75) with monosomy 3, an isochromosome 6p and gain of chromosome 8. 
C: Karyogram of a typical SF3B1-mutated UM (Case 48) displaying multiple structural anomalies29. 
Arrow indicates isochromosomes. Asterisk indicates structural chromosomal changes. 
Aneuploidy in BAP1, SF3B1 and EIF1AX-mutated UM
Since we observed that BAP1neg UMs contain entire chromosome or chromosome arm 
CNVs, and SF3B1mut UMs smaller partial chromosome CNVs, we hypothesized that 
BAP1neg UMs contain more aneuploidy. The total amount of aneuploidy of the genome 
(percentage) per tumor and the total number of CN events per tumor were calculated. 
Sex chromosomes were excluded to prevent gender-bias. Also, polyploid UMs were 
excluded to prevent biases since polyploid UMs are known to have multiple CNVs.24
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The median percentage of aneuploidy in BAP1neg tumors was 11.8 % of the genome and 
the median CN event was 11 events as measured by Nexus Copy Number software 
(Figure 3A and 3B). The median percentage of aneuploidy in SF3B1mut tumors was 
9.3 % of the genome and the median CN events was 14.5 events. BAP1neg tumors are 
more aneuploidy  than SF3B1mut tumors (P = 0.024) however had less CN events than 
SF3B1mut tumors (P = 0.074), although the latter did not reach significance.
The median percentage of aneuploidy in EIF1AXmut tumors was 1.7 % of the genome 
and the median CN events was 5 events. EIF1AXmut tumors had significantly less CN 
variations of the genome than BAP1neg tumors and SF3B1mut (P < 0.001 for both) and 
also less CN events (P < 0.001 for both). The median percentage of aneuploidy in 
NRMLOH- tumors was 4.3 % of the genome and the median CN events was 7 events. 
Aneuploidy of the genome was lower than in BAP1neg and SF3B1mut UM (P < 0.001 and 
P = 0.001, respectively) but not significantly different from EIF1AXmut UM (P = 0.846). 
BAP1neg and SF3B1mut UM had more CN events than NRMLOH- UM (P = 0.011 and P = 
0.001, respectively). 
To validate these findings, the TCGA data was also analyzed for aneuploidy. Compar-
ison between the numbers of CN events could not be performed as the curated TCGA 
SNP-array data contained segmented data, in which one CN event was annotated as 
several fragments. In the TCGA dataset, the median percentage aneuploidy of the 
entire genome was 17.2 % in BAP1mut UM; 10.6 % in SF3B1mut UM; 2.1 % in EIF1AXmut 
UM; and 9.8 % in NRMLOH- UM as illustrated in Figure 3C. BAP1mut UMs had more 
aneuploidy than SF3B1mut and EIF1AXmut UMs (P = 0.002 and P < 0.001, respectively), 
whereas EIF1AXmut UMs had less aneuploidy compared to the other groups (P = 0.001 
for SF3B1mut and P = 0.052 for NRMLOH-). Although the percentages aneuploidy were 
higher in the TCGA dataset, the results were still comparable to our cohort. BAP1mut 
UM harbored the largest CNVs, followed by SF3B1mut UM and NRMLOH-. EIF1AXmut 
UM were characterized by lack of CNVs. 
These findings show that BAP1mut UMs contain larger CNVs of entire chromosome and 
chromosome arms, whereas SF3B1mut UMs are characterized by a greater frequency 
of smaller CNVs events. EIF1AXmut UMs on the other hand are characterized by the 
lack of CNVs.
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Conventional karyotyping shows different type of chromosomal anomalies
To investigate whether the type of aneuploidy differs between the distinct groups, 
isochromosome formation and chromosomal structural variants (CSVs) were analyzed 
in UM cases for which karyotyping and mutation status were available. The discovery 
set consisted of 64 karyotypes. The cases in which the mutation status was not known, 
were used as a validation cohort (validation set; n = 49).
Isochromosomes were observed in 74 % of the BAP1neg tumors (n = 25/34), of which 19 
had an isochromosome 8q. Two tumors also harbored an isochromosome 6p besides 
8q, and one tumor harbored an isochromosome 1q and 8q. Two tumors only had an 
isochromosome 6p and one harbored an isochromosome 2q. In the SF3B1mut (n = 12) 
and EIF1AXmut (n = 6) UMs, no isochromosomes were observed. One sample harbored 
an SF3B1 and an EIF1AX mutation. This tumor also did not have any isochromo-
somes. In the tumors that were classified NRM (n = 11), four had an isochromosome. 
For these four UMs, the coding exons of BAP1 were analyzed for the presence of any 
mutations. Two tumors had a mutation in BAP1, whereas the other two did not contain 
any mutations in the coding exons of BAP1. Moreover, the latter two also displayed 
a polyploid genome.
Of all cases with isochromosomes 93% were BAP1 negative tumors and the rest were 
polyploid NRM UMs. Isochromosomes were completely absent in UMs harboring 
SF3B1 and/or EIF1AX mutations (Chi-square; P < 0.001).
Besides isochromosomes, we also investigated CSVs. Translocations or partial chro-
mosome arm CNVs were categorized as CSVs. The mean number of CSVs was 1.06 
variants per tumor in BAP1neg UM, 4.67 in SF3B1mut UM and 1.5 in EIF1AXmut UM. The 
median CSVs in the NRM tumors was also 1.5 variants per tumor. Although cases 
were limited, SF3B1mut UMs associated strongly with more than three CSVs per tumor 
compared to BAP1neg (P = 0.002; Figure 3D). Moreover, 70% of the UMs with more than 
3 CSVs harbored SF3B1 mutations.
To validate the hypothesis that isochromosomes mainly occur in the tumors with a 
BAP1 deficiency, and that multiple CSVs (more than three) occur mainly in SF3B1mut 
tumors we selected cases from the cytogenetic karyotyped cohort in which the muta-
tional status was not known (Supplementary Table 1). Since isochromosome 8q with 
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monosomy 3 strongly associated with BAP1neg UMs, we only selected those cases 
with isochromosome formation of other chromosomes besides chromosome 8q. To 
analyze whether isochromosome formation in general is associated with deficient 
BAP1 these cases were tested for BAP1 expression with IHC. Tumors that had more 
than three CSVs were additionally stained for BAP1 and tested for the presence of 
SF3B1 mutations. 
In the validation set, nine UMs had an isochromosome other than or besides isochro-
mosome 8q (Supplementary Table 1). From these nine UMs, two samples were not 
available for BAP1 IHC. Five of the remaining seven tumors were negative for BAP1, 
whereas two did express BAP1. One tumor was sequenced for BAP1 since BAP1 IHC 
could not be performed in this sample. This tumor harbored a nonsense mutation at 
p.Q253. Interestingly, the samples from the discovery set and validation set which con-
tained isochromosomes with BAP1 expression but without BAP1 mutations suggests 
that similar pathways are involved that give rise to this specific type of aneuploidy. 
For the validation of multiple CSVs, seven UMs displayed more than three CSVs. For 
two cases, no material was available for mutational analyses. Of the remaining five 
tumors, four harbored a hotspot p.R625 SF3B1 mutation. 
These analyses showed that the majority of UMs with isochromosomes besides 
chromosome 8q are BAP1 deficient and that UMs with multiple CSVs are mainly 
SF3B1-mutated (Figure 4). Strikingly, the same chromosomes are affected in BAP1 
deficient UMs and SF3B1-mutated UMs by either isochromosome formation or CSVs. 
This highlights a biological difference between these UMs, suggesting that different 
pathways might be involved that give rise to the same CNV event.
Mutational signatures 
To get insight into the biological processes that generate the mutations in UM, we com-
pared the somatic mutational signatures in UM with somatic mutational signatures as 
described by Alexandrov et al.33 In this landmark study, they constructed 21 validated 
signatures based on single nucleotide mutations and its trinucleotide context. These 
signatures can be directly connected to the DNA damage and repair pathways among 
other processes and risk factors in cancer.33, 34 We constructed somatic mutational spec-
tra using the TCGA WES dataset, as our ROMS cohort did not contain tumor-normal 
matched WES data. The total number of somatic single nucleotide mutations detected 
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in the WES data ranged from 8 to 28 mutations per patient, with one outlier that 
harbored 578 mutations. Since the numbers of mutations per sample are limited we 
grouped the samples according to their mutational status of BAP1, SF3B1 and EIF1AX 
and estimated the contribution of each signature to the three mutational spectra. 
In general, all three groups displayed similar mutational  spectra due to enrichment 
of specific somatic mutations  in their trinucleotide context (Supplementary Figure 5). 
These specific  mutations can be explained by the recurrent UM mutations that code 
for amino acid changes in the UM recurrent genes. BAP1-mutated were enriched for 
CTG>CAG mutations, which were mainly GNA11 p.Q209L amino acid changes. When 
compared to the other groups, BAP1neg IHC and GNA11 p.Q209L amino acid changes 
co-occurred more often. Similarly SF3B1mut tumors harbored more often GNAQ 
p.Q209P amino acid changes. SF3B1mut UMs were also enriched for ACG>ATG and 
CCG>CTG mutations, which could be explained by the recurring hotspot mutations 
in SF3B1. UMs with solely SF3B1mut harbored in 87 % (13/15) a p.R625H or p.R625C 
amino acids changes in SF3B1. EIF1AXmut UMs had more often ACC>ATC mutations 
which could be explained by the recurring p.G6D, p.G9D and p.G15D amino acid 
changes in EIF1AX. 
The relative contribution of the mutational signatures were identified for the groups 
with BAP1, SF3B1 and EIF1AX mutations, respectively (Figure 5). Both Signature 1 
and 5 are clock-like signatures and reflect the high median age when the enucleation 
of the primary UM tumor is commonly conducted.33 Notably, in SF3B1mut UMs Sig-
nature 5 was not detected and as reported before, patients with SF3B1mut UMs are in 
general younger than patients with BAP1-mutated UMs.19 Signature 16 contributed 
only to the signature of the BAP1-mutated UMs. Although the etiology is unknown, 
Signature 16 has been found in liver cancer, the organ that is affected in almost all 
metastasized patients with BAP1 mutations. More than in the other groups, Signature 
3 was found in SF3B1mut UMs. Strikingly, Signature 3 has been strongly associated to 
BRCA1 and BRCA2 mutations. Therefore, the proposed etiology is defective DNA 
double-strand break-repair by homologous recombination. This might explain the 
multiple CSVs found in SF3B1mut UMs. A large proportion of BAP1 mutations and 
to a lesser extent the SF3B1mut  were explained by Signature 6 and 15. Both signatures 
are usually observed together and are associated with DNA mismatch repair. In the 
EIF1AXmut UMs only, both Signature 15 and the clock-like Signature 5, contributed 
substantially to their mutational phenotype. Moreover, a small number of mutations 
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are explained by Signature 4 , a mutational signature that is associated with smoking. 
However, Signature 7 that is associated with UV damage and is prominent in cutane-
ous melanoma was not detected in these samples.
The somatic signatures analysis revealed that different pathways may be involved in 
the initiation and progression of UMs, which is  reflected by different single nucleotide 
mutations within their trinucleotide context. All UMs groups contained signatures 
involved in DNA mismatch repair, whereas defective homologous repair was most 
prominent in SF3B1mut UMs and was not detected in EIF1AXmut UMs. Validation could 
not be performed since other independent cohorts with mutational signature analyses 
did not contain samples from each mutational group.13, 20
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Figure 5. Relative contribution of mutational signatures detected in Whole Exome Sequencing data 
from TCGA uveal melanoma cohort. The signatures33 are stratified by recurrent mutated genes 
BAP1, SF3B1 and EIF1AX in uveal melanoma indicated with number of cases and number of total 
somatic single nucleotide mutations (n).
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Discussion
Uveal melanoma is a malignancy characterized by non-random recurring chromo-
somal aberrations and recurrent mutated genes. Previous studies have shown that 
patients with either BAP1, SF3B1 or EIF1AX mutations in their tumor have a diverse 
risk of metastatic disease.19, 21 In this study, we show that UMs with different mutated 
genes also have a distinct chromosomal patterns with different types of chromosomal 
aberrations. 
By unsupervised hierarchical clustering, UMs with the same mutated gene clustered 
predominantly together (Figure 1). The two major clusters were separated based on 
monosomy 3 and disomy 3 together with chromosome 8q. Disomy 3 was observed 
with partial chromosome 8q gain whereas monosomy 3 was more frequently observed 
with gain of entire chromosome 8q. Trolet et al. also described this difference in chro-
mosome 8q gain based on chromosome 3.4 Similar to our analyses, Trolet et al. found 
two major clusters based on chromosome 3. Within their disomy 3 cluster, one of 
the two sub-clusters was characterized by chromosome 6p gain, as our cluster 1a. 
The other disomy 3 cluster was characterized by 6p gain with 6q loss and 8q gain as 
observed in our cluster 1c. The breakpoint of chromosome 8q in disomy 3 UMs was 
at chromosome band 8q21, also comparable to our findings (Figure 2).4 In contrast 
to others, the sub-clustering in monosomy 3 UMs was based on chromosome 6q and 
not chromosome 8q.4, 35 In the hierarchical clustering chromosome 6q was represented 
more often (Figure 1A), and this weighed more than chromosome 8q gain. Although 
this sub-clustering based on chromosome 6q seems to be technical rather than biologi-
cal, it still provided clusters which were homogenous and correlated to the mutational 
status of the UM. Polyploidy was the major cause of misplacement in other clusters, 
and should therefore always be checked in case of UM prognosticating based on the 
chromosomal aberrations. 
Since the unsupervised hierarchal clustering showed clear correlations between chro-
mosomal patterns and mutational status, we performed supervised clustering with 
the known mutational status. In this current study, different techniques were used 
to analyze the BAP1 status. In our ROMS cohort, we used predominantly BAP1 IHC 
whereas in the TCGA cohort, BAP1 was analyzed by WES. This should not make a 
difference in comparing both groups, as we and others have shown a strong associ-
ation between the lack of BAP1 IHC staining and the presence of BAP1 mutations.16, 
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36 When comparing both groups all affected chromosomes were the same, however 
the absolute numbers CNVs of these chromosomes were more frequent in the TCGA 
set. As shown in Figure 1A and 1B, some BAP1neg UMs harbored no CNVs in the 
entire genome, which can explain the decreased cumulative frequency of CNVs in the 
ROMS cohort. BAP1neg tumors are associated with the loss of chromosome 3 and gain 
of chromosome 8q, which has been described by our group and others.14-16, 36-38 Also 
chromosome 1p loss, 6q gain, 8p loss and 16q occurred frequently. These CNVs have 
been correlated to monosomy 3 UMs before. 3-6, 35, 39, 40 Surprisingly, also chromosome 
6p gain was observed in both datasets, as chromosome 6p gain is inversely associated 
to monosomy 3.5, 7, 39, 41 Moreover, when investigated with cytogenetic data, these chro-
mosome 6p gains were due to isochromosome 6p formation.
SF3B1 mutations, on the other hand, have been associated to chromosome 6p gain.17-19 
In the clustered overview, other CNVs were also observed such as chromosome 1p 
loss, 6q loss, 8p loss, 8q gain and 11q loss. In general, CNV frequencies were similar 
in those in the TCGA cohort, except for chromosome 11q loss which was almost com-
pletely absent in the TCGA data. Unfortunately, the unprocessed TCGA SNP array 
data was not available to be processed exactly as our SNP arrays. Thus, we cannot 
exclude that perhaps e.g. different threshold settings for segmentation or the content 
of the SNP array could explain this difference for chromosome 11q CNVs. Strikingly, 
in case of SF3B1mut UMs, recurrent chromosome breakpoints were observed, in contrast 
to BAP1neg UMs, which almost exclusively had entire chromosomes or chromosome 
arm CNVs. Translocations with recurring breakpoints in combination with disomy 3 
are described more often,42, 43 however, never associated with SF3B1 mutations. 
For EIF1AXmut UM, the characteristic feature of the CNVs was the overall lack of CNVs 
or only partial chromosome 6p or entire chromosome 6 gain. Similar to EIF1AXmut 
UMs, also NRMLOH- UMs harbored these CNVs. This suggests that these type of UMs 
are relatively stable, which could be a protective factor in the metastatic process. 
UMs that were BAP1 positive and wildtype for SF3B1 and EIF1AX were treated as a 
heterogeneous group. Moreover, NRM UMs with LOH of BAP1 harbored the same 
CNVs as BAP1neg UMs, and NRM UMs without LOH of BAP1 were more similar to 
EIF1AXmut UMs. As expected subsequential analyses of BAP1 for the NRMLOH+ UMs 
revealed mutations in most of them. Also for the TCGA data, cases without BAP1 
mutations with LOH were excluded. RNA expression was analyzed in these samples, 
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and this showed a low RNA expression similar to UMs with BAP1 mutations (data 
not shown). We expect that these UMs might harbor BAP1 mutations which are not 
easily detected by Whole Exome Sequencing.36 
Besides the chromosomal patterns, also the aneuploidy and number of CN events per 
tumor were analyzed for each group. This revealed that BAP1 deficient UMs harbored 
the largest CNVs, whereas SF3B1mut UMs harbored the highest number of CN events, 
suggesting that different pathways are involved causing these genome rearrange-
ments.
This was confirmed by analyzing conventional cytogenetic data. Monosomy 3 has 
been correlated to isochromosome 8q before, and we confirmed this in our study.6, 39, 
41 Besides isochromosome 8q, we also observed other isochromosomes in BAP1 defi-
cient UMs. This finding warrants future studies to investigate whether BAP1neg UM 
cells have a deficiency in pathways involving the separation of chromosomes during 
metaphase.
By analyzing the cytogenetic data, we confirmed that SF3B1mut UMs have in absolute 
numbers the most CN events. These CN events consisted of CNVs such as translo-
cations and partial chromosome losses. SF3B1 and BAP1 are both involved in DNA 
double-strand break damage response.22, 23 Since, the non-homologous end-joining 
repair pathways play a large role in chromosomal translocation,44 it is likely that SF3B-
1mut UMs make use of these pathways. This would be of interest in the treatment of 
metastasized UMs, since deficiencies in DNA double-strand break repair can serve as 
a targetable therapy in malignancies.45
Somatic mutational signatures in other malignancies showed to be strongly associated 
with several cellular pathways and risk factors in cancer.33 In  WES data  of UMs  only 
a limited number of mutations were observed.13, 20 Since single UMs did not contain 
more than 30 somatic mutations, we therefore analyzed UMs with the same mutated 
gene (BAP1, SF3B1 and EIF1AX) as a cumulative group. Using the Whole Genome 
Sequencing (WGS) data would have been more appropriate . Unfortunately, WGS 
performed by Furney et al. and Johansson et al. did not contain enough SF3B1mut 
UMs to compare the BAP1-mutated and EIF1AXmut UMs. With the somatic mutational 
signature analyses of the WES data we showed that Signature 3 - which is associated 
with a homologous recombination deficiency - was more prominent in the signature 
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of SF3B1mut UMs. Comparison between the signatures as constructed by Johansson 
et al. showed overlap for Signature 1, 3, 5 and 16 for BAP1-mutated UMs. Somatic 
mutational signatures can be studied more robustly in a larger cohort of patients with 
UMs and with using WGS data.
In conclusion, we show that patients with UM can be divided in molecular subclasses 
based on chromosomal patterns, and above all these groups correspond to the BAP1, 
SF3B1 and EIF1AX mutational status. More importantly, we previously reported that 
the survival in patients with UM can be stratified based on mutation status. Here we 
have shown that each group is characterized by recurring CNVs. Also, these three 
subtypes of UMs harbor different type of chromosomal aberrations indicating that 
different pathways are involved in the etiology of UM development and progres-
sion towards metastatic disease. The exact nature of these pathways and the genes 
involved, remain elusive but will be important to develop the most optimal targeted 
therapy solution for the individual UM patients.
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Supplementary Figure 1. Overview of the single nucleotide polymorphism (SNP) array analyses 
used for hierarchical clustering. (1) The distribution of the four SNP array types which were used 
in the analyses. (2) Venn-diagram depicting the overlap in SNPs. (3) The distribution of all samples 
clustered by the array type measured in entropy count. (3) The distribution of entropy after nor-
malization of the data.
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Supplementary Figure 2. Graphs depicting discriminating copy number (CN) variations between 
clusters. A higher importance score corresponds to a higher discriminating value of copy number 
variations (CNV) between clusters. (A-D) Graphs for the several cluster comparisons.
106 
209
BAP1 negative/mutation
0 5
85 42
26
SF3B1 mutation
EIF1AX mutation 
BAP1 positive/wildtype and 
SF3B1 & EIF1AX wildtype (NRM)
48
BAP1 LOH 
(n = 19) 
no BAP1 LOH 
(n = 29) 
80
24 9
15
29
BAP1 LOH
(n = 14)
no BAP1 LOH 
(n = 15)
NRM 
SNP-array available (n = 214)
Mutation status known (n = 209)
ROMS cohort
SNP arrays
ROMS cohort
Karyotyping
4 4 2 1
NRM 
(A) TCGA cohort
SNP arrays
(B)
64145 49
34 12
6
11
BAP1 LOH (n = 6) 
no BAP1 LOH (n = 5) 
0 1
Karyogrom available (n = 119)
(C)
Discovery set
Validation set
LOH+
LOH- NRM 
NRM LOH+
LOH-
NRM 
NRM LOH+
LOH-
Supplementary Figure 3. Venn-diagrams depicting the distribution of several mutational groups 
used in the different analyses. A: ROMS Uveal Melanoma (UM) cohort samples stratified for the 
presence of specific mutations used for SNP array clustering. B: idem for the Cancer Genome Atlas 
(TCGA) samples. C: ROMS UM samples used for cytogenetic stratification.
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Supplementary Figure 5. Specific somatic mutations in their trinucleotide context obtained from 
Whole Exome Sequencing (WES) in BAP1-mutated (n=24), SF3B1-mutated (n=15)and EIF1AX-mu-
tated (n=9) uveal melanomas (UMs) in the TCGA dataset.
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Supplementary Table 1. Mutation analysis of samples from the validation set. UM cases with  iso-
chromosomes (top rows) or multiple chromosomal structural variants (CSVs) were tested.
Case # Isochromosome(s) BAP1 IHC BAP1 SF3B1 EIF1AX
Cases with isochromosome(s)
14 1q positive wildtype wildtype wildtype
20 6p, 8q n.a. p.Q253* wildtype wildtype
107 6p negative n.a. n.a. n.a.
110 6p, 8q n.a. n.a. n.a. n.a.
111 1q, 4q negative n.a. n.a. n.a.
124 5q, 6p, 22q positive wildtype wildtype wildtype
131 6p negative n.a. n.a. n.a.
132 6p, 8q negative n.a. n.a. n.a.
142 1q, 8q negative n.a. n.a. n.a.
Cases with more than three SVs
92 none positive wildtype p.R625H wildtype
93 none positive n.a. wildtype wildtype
112 none positive n.a. n.a. n.a.
125 none positive n.a. n.a. n.a.
138 none positive wildtype p.R625H wildtype
143 none positive wildtype p.R625H wildtype
148 none positive wildtype p.R625H wildtype
n.a. = not available
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Abstract
Purpose: This study reports the role played by the mutation status of the primary 
tumor in relation to hepatic tumor profiles found in metastasized uveal melanoma 
(UM). 
Methods and materials: From 1983 until 2017, metastatic UM samples and radiological 
images were obtained from 100 patients treated at the Erasmus Medical Center Rot-
terdam or the Rotterdam Eye Hospital. Radiological images were derived from either 
computed tomography or magnetic resonance imaging. Mutation status was deter-
mined using immunohistochemistry, Sanger sequencing or ION Torrent. Analyses 
were performed using Pearson’s chi-square test and Fischer’s exact test for correlations. 
Log-rank test (Kaplan-Meier) was used for survival analyses. 
Results: The mutation status of the primary tumor was not correlated with any hepatic 
tumor profiles (P = 0.296). Both the disease-free survival (DFS) and metastasized sur-
vival (MS) differed significantly from each of the tumor profiles (respectively, P = 0.032, 
P = 0.036). An overall trend was found for a shorter DFS and MS when livers harbored 
more lesions. However, only a significantly shorter DFS was found for the >10 lesion 
group compared to <10 lesions (P = 0.011). As well as a significantly different MS for 
the comparisons between: <5 lesions against  >5 lesions and <10 lesions against  >10 
lesions (respectively, P = 0.027, P = 0.045).  
Conclusion: Our study shows that there is an inverse correlation of the number of 
metastasis with the metastasized survival, indicating separate growth patterns. We 
also revealed that despite the lack of association between metastasis with the muta-
tion status, loss of chromosome 8p was observed more frequently in livers containing 
more lesions.
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Introduction
Uveal Melanoma (UM) is the most common intra-ocular malignancy in the Western 
World with an incidence of 5-6 per million per year.1,2 UM derive from the melano-
cytes in the uveal tract which consists of the choroid, ciliary body and iris.3 Treatment 
of the UM consists of radiotherapy, brachytherapy or enucleation. However in spite 
of excellent local tumor control, UM has a strong propensity to metastasize in up to 
50% of the patients within 15 years after diagnosis.4 Localization of these metastases 
can occur in the liver, pulmonary parenchyma, bone and skin. However, the liver is 
affected in more than 90% of the cases.4 
UM are characterized by nonrandom cytogenetic aberrations and recurrent mutated 
genes that are associated with the patients’ prognosis. The onset of metastatic UM is 
closely related to the presence of somatic mutations in the UM genes: BAP1, SF3B1 
and EIF1AX.5 BAP1-mutated UM being classified as high risk with early metastases, 
SF3B1-mutated UM as intermediate risk with late-onset metastases and EIF1AX-mu-
tated UM as low risk for metastases.5 As for chromosomal changes, loss of chromosome 
3 is most strongly correlated to metastatic disease together with the gain of chro-
mosome 8q.6,7 Other chromosomal aberrations that are associated with the worse 
prognosis include loss of chromosome 1p, 6q and 8p.6,7 Chromosome 6p gain is asso-
ciated with a favorable prognosis.6,7
The genetics of primary UM have been investigated intensively, however not much is 
known about the UM metastases (UMmeta). The liver is typically affected in metasta-
sized UM, thus biopsies are not taken regularly to confirm the diagnosis of metastasis 
since findings on Computed Tomography (CT) scans and Magnetic Resonance Imag-
ing (MRI) techniques suffice to make the diagnosis. Meir and colleagues investigated 
the expression of primary UM compared to matching metastases and showed that the 
expression of 193 genes differed between the primary and metastasized UM.8 More-
over, the expression of the liver metastasis resembled normal liver tissue, although 
it was histopathologically shown that the investigated metastasis material did not 
contain liver tissue.8 Looking at chromosomal aberrations in UMmeta, Trolet and col-
leagues showed that the majority of UMmeta harbor monosomy 3 with chromosome 8q 
gain.7 However a smaller proportion of these tumors are disomy 3 with a gain of the 
terminal end of chromosome 8q.7 As for the UM genes, loss of BAP1 expression and 
BAP1 mutations were also shown to be frequently present in the majority of UMme-
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ta.9-11SF3B1 mutations in UMmeta were described in 40% in one study (2/5 UMmeta) and 
4% in another study (1/26 UMmeta).9,10
Hepatic metastases can vary in size and pattern, from solitary lesions to a more dis-
seminated or miliary pattern.12 In this current study we set to analyze the difference in 
survival for the metastasis profiles and correlate these to clinical and genetic param-
eters of the primary UM.
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Methods
Patient inclusion
All UM patients who were diagnosed with UM between 1983 and 2017 at the Erasmus 
University Medical Center and the Rotterdam Eye Hospital (Rotterdam, The Nether-
lands) were reviewed for metastatic disease. Iris melanoma were not included due 
to their aberrant metastatic behavior and different genetic etiology.13 This study was 
performed retrospectively, in which we selected patients for whom CT or MRI images 
of the metastatic liver were available for analyses. This study was performed according 
to the tenets of the Declaration of Helsinki and after informed consent. The study was 
also approved by a local ethics committee.
Analyses of metastasis imaging
Classification of CT or MRI images were based on the total amount of hepatic metas-
tases, resulting in the following groups: single nodular lesion, between two and five 
lesions, between six and ten lesions and more than ten lesions. Sub-analyses were per-
formed on the group more than ten lesions, which we divided in more than ten large 
(>50 µm) lesions versus a miliary pattern (innumerable lesions of <50 µm). The first 
known and available CT or MRI images that confirmed hepatic metastases were used 
for analysis. Only CT and MRI images dating from 2003 and onwards were analyzed, 
because there were no digital images available before 2003. Also patients whom lacked 
available CT or MRI images, however still had well documented records of these 
images were included. Measurements of the CT or MRI images were taken manually 
with built-in measuring tools to determine the dimensions of hepatic metastases.
Material and mutation analyses
Whenever a patient was enucleated or a biopsy was taken, primary tumor material 
was available for genetic analyses. The mutation status of GNAQ, GNA11, BAP1, SF3B1 
and EIF1AX was determined using a combination of BAP1 immunohistochemistry 
(IHC), Sanger sequencing or sequencing using the ION Torrent Personal Genome 
Machine (Life Technologies, Carlsbad, CA, USA) as described before.14 Single nucle-
otide polymorphism (SNP) arrays (Illumina HumanCytoSNP-12 v2.1 BeadChip and 
Illumina 610Q BeadChip; Illumina, San Diego, CA, USA) were used for detection of 
chromosomal aberrations. Nexus Copy Number 8.0 (BioDiscovery, Inc., El Segundo, 
CA, USA) was used to visualize the chromosomal patterns.  
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Statistical analysis 
The disease-free survival (DFS) is defined as the first date of treatment till the devel-
opment of metastatic UM. Survival with metastatic disease was not computed due to 
the difference in patient treatment after diagnosis of metastasis. Deaths due to other 
causes were censored. The survival analysis was generated using the Kaplan-Meier 
method and made use of the Log-Rank test to find differences between the groups 
for categorical variables. Cox proportional analyses were used for survival analyses 
of continuous variables. Multivariate analyses were performed using the Cox propor-
tional regression analyses. Pearson’s chi-square test or Fisher’s exact test was used to 
test categorical groups with independent variables. Analysis of variance (ANOVA) 
was used to compare the means of multiple groups, while Fischer’s least significant 
difference was used for post hoc testing. P values of 0.05 or less were considered signif-
icant. SPSS (version 24.0, IBM, Armonk, NY, USA) was used for all statistical analyses.
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Results
A total of 197 patients with UMmeta were identified. The liver was affected in 191 
patients (97%) and extra-hepatic metastases were found in 74 patients (38%) including 
six patients without hepatic UM metastases. CT or MRI images of the liver metastases 
were available for 77 patients. Another 21 patients were included which lacked avail-
able CT or MRI images, however still had well documented records of these images 
(including the number of metastases). Two patients with existing radiological records 
were excluded from analysis due to a lack of details concerning the number of meta-
static lesions. The resulting 98 patients were included in the analyses.
From the included UM patients (n = 98; Table 1) a total of 64 underwent primary enu-
cleation and 33 received stereotactic radiation therapy (SRT) of which nine underwent 
secondary enucleation due to local complications. One patient did not receive primary 
treatment. This patient was diagnosed with metastasis at the time of diagnoses and 
wished not to receive treatment of the primary tumor. Clinical, histopathological and 
genetic characteristics of the study population are summarized in Table 1. The study 
population comprised of 48 males and 50 females with a median age of 64 years at 
diagnoses of the primary UM (range, 37 - 87 years). The median DFS was 26.5 months 
(range, 0 - 159.6 months) and median survival with metastatic disease was 6.1 months 
(range, 0 – 42.3 months). Mutation status was known for 68 patients; 58 with loss of BAP1 
expression, eight with an SF3B1 mutation and one patient with an EIF1AX mutation in 
the primary UM. One patient was classified as ‘No Recurrent Mutation’ (NRM) since the 
tumor did not harbor a mutation in BAP1, SF3B1, or BAP1. For 30 patients the mutation 
status was unknown, due to lack of material of the primary tumor. Patients treated with 
SRT amassed the greatest share with 24 of the 30 unknown mutations. Six patients did 
not have hepatic metastasis, and as such they were not included in the analyses. The 
UM of these six patients comprised of: two UM with BAP1 mutations and lack of BAP1 
expression, two UM with positive BAP1 staining with disomy 3 (SF3B1 and EIF1AX 
status unknown) and two patients with untested genetic status due to a lack of material.
Correlation with clinical and genetic features
Classification of CT or MRI images were based on the total amount of hepatic metas-
tases, this resulted in the following groups: single nodular lesion (Figure 1A), between 
two and five lesions (Figure 1B), between six and ten lesions (Figure 1C) and more 
than ten lesions (Figure 1D). 
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Figure 1. MRI images representing the classification based on the number of lesions found in met-
astatic UM in the liver, which have been contrasted by red markings. A, T1 weighted MRI with 
contrast showing a single nodular lesion in the liver. B, T2 weighted MRI with contrast showing 
four lesions. C, T2 weighted MRI sequence with contrast showing a total of seven lesions. Images 
from left to right correspond respectively from cranial to caudal localization. D, T2 weighted MRI 
sequence with contrast showing a total of twelve lesions. Images from left to right correspond 
respectively from cranial to caudal localization. E, T2 weighted MRI with contrast showing innu-
merable widespread small lesions throughout all liver segments. No red markings are present due 
to the number of lesions. 
The age at diagnoses was the eldest in patients who developed solitary hepatic metas-
tases, however a significant difference was not observed (P = 0.738). Mean largest basal 
diameter also did not differ between the metastases groups (P = 0728). A trend could be 
observed for tumor height of the primary UM, for which a larger tumor height of the 
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primary UM were to give more metastases, however no significance could be reached 
(P = 0.841). Also gender was equally divided between the groups (P = 0.776). BAP1 
IHC, SF3B1 and EIF1AX mutation status were not found to be significantly associated 
with any of the four different tumor profiles. (P = 0.976, P = 0.594 and P = 0.221, respec-
tively). Although not significant, in patients with solitary lesions none of the primary 
tumors harbored GNAQ mutation whereas five of the six harbored a GNA11 mutation. 
GNAQ and GNA11 were divided equally for the other metastasis profiles (Table 1). 
We also looked at whether the presence of extrahepatic lesions was correlated to the 
number of hepatic metastases, however this was not the case (P = 0.875). 
Table 1. Correlation between the number of metastatic lesions and Other Clinical, Histopathological, 
and Genetic Features
Metastasis profiles (number of metastases)
Variables 1 lesion 
(n = 14)
2-5 lesions
(n = 28)
6-10 lesions
(n = 15)
>10 lesions
(n = 41)
P-value
Mean age (95% CI), yrs 64.6 (59-70) 61.8 (57-66) 64.3 (58-71) 64.4 (61-68) 0.738  *
Mean largest basal diameter
(range), mm
10.0 (7-13) 10.3 (8-12) 8.1 (4-12) 9.4 (7-12) 0.728  *
Mean tumor height (range), mm 4.0 (2-6) 4.7 (3-6) 4.5 (2-7) 5.2 (3-7) 0.841  *
Gender, no. (%)
       Male 6 (12.5) 12 (25.0) 8 (14.0) 22 (45.8) 0.776 †
       Female 8 (16.0) 16 (32.0) 7 (16.7) 19 (38.0)
BAP1 IHC, no. (%)
       Negative 8 (14.5) 17 (30.9) 7 (12.7) 23 (41.8) 0.976 †
       Positive 2 (16.7) 4 (33.3) 1 (8.3) 5 (41.7)
SF3B1, no. (%)
       Wildtype 5 (20.0) 8 (32.0) 3 (12.0) 9 (36.0) 0.594 †
       Mutated 2 (20.0) 5 (50.0) 0 (0.0) 3 (30.0)
EIF1AX, no. (%)
       Wildtype 6 (16.7) 13 (36.1) 5 (13.9) 12 (33.3) 0.221 †
       Mutated 1 (100) 0 (0.0 0 (0.0) 0 (0.0)
GNAQ, no. (%)
       Wildtype 6 (26.1) 8 (34.8) 3 (13.0) 6 (26.1) 0.217 †
       Mutated 0 (0.0) 6 (42.9) 3 (21.4) 5 (35.7)
GNA11, no. (%)
       Wildtype 1 (5.9) 9 (52.9) 1 (5.9) 6 (35.3) 0.181 †
       Mutated 5 (27.8) 5 (27.8) 3 (16.7) 5 (27.8)
Extrahepatic lesions, no. 4/14 9/28 5/15 10/41 0.875 †
*One-way analysis of variance (ANOVA).
†Pearson’s chi-square test.
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We also analyzed the cumulative copy number variation (CNV) for each of the tumor 
profiles to look for potential differences (Figure 2). Majority of the known chromo-
somal aberrations were observed in each group, such as monosomy 3 and chromosome 
8q gain. However, loss of chromosome 8p did not occur in the single lesion group, 
while it occurred more frequently in livers harboring more than one lesion, especially 
more than five lesions (~50%).
Figure 2. Summary plot showing chromosomal patterns in the different tumor profiles of UM. Chro-
mosomes are depicted on the x-axis. The y-axis shows the cumulative percentage of copy number 
variation for each group. Blue indicates gain of chromosome and red indicates loss of chromosome. 
Sex chromosomes are excluded. Results are filtered to exclude gains and losses smaller than 1000 kB.
Survival analyses
Survival analyses were performed for time of diagnosis until metastasis (DFS). We 
observed a difference for DFS when comparing all groups (P = 0.032; Figure 3A). 
This showed a shorter DFS with increasing number of hepatic metastases. We also 
analyzed using thresholds rather than separate groups. These were set on one soli-
tary lesion versus more than one (1 vs. >1); five or less versus more than five (≤5 vs. 
>5); ten or less versus more than ten lesions (≤10 vs. >10). This was not significantly 
different for the former two comparisons (P = 0.093 and P = 0.076, respectively; Figure 
3B and Figure 3C), however did reach significance for ≤10 vs. >10 metastases (P = 
0.011) in favor of patients with ≤10 lesions. For the UMmeta with more than ten lesions 
we observed two patterns, namely livers containing more than ten large nodules (>50 
µm; Figure 3D) and a miliary pattern containing innumerable small lesions (<50 µm; 
Figure 3E). Comparing both groups did not show a significant difference in DFS (P 
= 0.922; Figure 3E).
We then analyzed whether a miliary metastatic pattern was of influence stratified for 
the mutation status. For patients without BAP1 expression in the primary UM, there 
was no difference in DFS between patients whom developed miliary metastases and 
those whom did not (P = 0.435). For SF3B1-mutated UM, although not significant (P = 
0.075), the two cases with miliary metastases both metastasized within five years after 
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diagnoses, whereas in those without miliary metastases only two of the six patients 
presented with metastatic disease within five years after diagnosis.
Figure 3. Kaplan-Meier curves showing the disease-free survival of the four classified tumor profiles 
as well as of multiple comparisons. A, The DFS differs significantly between the groups (P = 0.032). 
B, The DFS is trending in favor of the single lesions group, but it is not significantly different (P 
= 0.093). C, The DFS for the less than five lesions group is not significantly longer (P = 0.076). D, 
The more than ten lesions group has a significant shorter DFS compared to the less than ten lesion 
group (P = 0.011). E, Comparison of the more than ten lesions group and miliary pattern does not 
differ significantly (P = 0.992).
Since the metastatic patterns were predictive of DFS we also performed multi-variate 
analyses.  From the univariate analyses (Table 2) only the GNA11 mutation status (P 
= 0.041) and metastasis profiles (P = 0.032) were shown to associate with the DFS.  In 
the multi-variate analyses only GNA11 mutation in the primary UM was an indepen-
dent predictor of DFS in patients with metastasized UM with a hazard ratio of 2.05 
(P = 0.047).
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Table 2. Univariate and Multivariate Analyses for patient with Metastasized Uveal Melanoma
Univariate Multivariate
Covariate 95% CI P Value HR 95% CI P Value
Irradiation
  Yes 22.7-39.8 0.060*
  No 34.3-55.4
Gender
  Female 31.4-55.1 0.208*
  Male 26.9-45.8
Age at diagnosis 0.516†
Largest tumor diameter 0.471†
Tumor height 0.196
Extra-hepatic
  With 27.7-55.4 0.560*
  Without 30.0-48.3
BAP1 IHC
  Positive 46.7-100.1 0.065*
  Negative 27.5-46.9
GNAQ
  Wildtype 24.7-52.2 0.125*
  Mutated 28.4-81.5
GNA11
  Wildtype 36.3-80.7 0.041* 2.05 1.009-4.171 0.047†
  Mutated 19.8-50.5
Mutation status
  BAP1neg 27.6-46.2 0.096*
  SF3B1mut 40.6-114.1
  EIF1AXmut 120.6
  NRM 13.7
Metastasis profile
  1 lesion 39.1-84.0 0.032* - - 0.120†
  2-5 lesions 30.7-67.6
  6-10 lesions 22.5-36.6
  >10 lesions  20.8-38.9
*Log-Rank
 †Cox proportional regression analyses
Confidence interval (CI); 95% CI of survival (*) or hazard ratio (†)
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Discussion
UM is the most common intra-ocular malignancy of the adult eye with a strong pro-
pensity to metastasize to the liver. A great deal of progress has been made in finding 
prognostic genetic markers in UM, however less is known about the hepatic metas-
tasis in UM. Although a limited number of publications regarding this topic have 
appeared, none of them have focused specifically on the relation between the genetics 
of the primary UM and the pattern of metastases.  In this current study we found that 
regardless of the mutation status of the primary UM, the metastases in these patients 
display the same metastatic profile. However chromosome 8p loss was absent in UM 
which give single solitary metastasis and more frequently found in UMmeta with more 
lesions, especially more than five lesions. 
Interestingly enough, the DFS also differed between the groups. Although the sample 
size was not large enough to show a significant difference, the single nodular lesion 
group showed a trend towards a longer DFS compared to groups with more lesions. 
If the assumption was made that hepatic metastases grow in one linear fashion, single 
nodular UMmeta should have a shorter DFS than UMmeta with multiple lesions. However 
this was not the case, making it very likely that UMmeta with single nodular lesions 
have a slower growth and are distinct from UMmeta with multiple lesion. Histopatho-
logical findings showed that UMmeta indeed exhibit two types of growth patterns in 
the liver.15,16 An infiltrative growth pattern which usually presents as many small (size 
<50 µm) lesions, also named lobular or replacement pattern. Another growth pattern 
called the nodular growth, which contain less but larger lesions (> 50 µm).16 This 
nodular growth is also described as portal and pushing pattern. Both growth pat-
terns have distinct anatomical locations, and also mixtures of both growth patterns in 
one affected liver are described.17 Similar to our different metastatic patterns found 
with imaging, the difference in DFS is also shown for the histopathologically different 
growth patterns, in which the mean average doubling time of the infiltrative UMmeta is 
significantly less than that of the nodular UMmeta.18 
We hypothesized that the different types of lesions would correspond to the mutation 
status of the primary UM since we previously reported that BAP1mut UMs display 
rapid metastases and SF3B1mut UMs display mostly late-onset metastases.5 Strikingly 
this was not the case. It is thus very interesting that, irrespective of the mutation 
status, UMmeta with BAP1mut and SF3B1mut can show both growth patterns. However, 
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we did observe that the two patients with miliary metastases and an SF3B1mut in the 
primary UM, both had early-onset metastases. This difference was not that clear for 
BAP1mut UM. It remains debatable whether this metastatic spread is purely by change 
or whether there is a genetic predisposition of the primary UM. 
Similar to our findings, another study also reported a non-significant difference for chro-
mosome 8p CNVs in the primary tumor and the different growth patterns, in which loss 
of chromosome 8p was more present in UMs which have an infiltrative growth pattern.19 
We hypothesize that this could be the product of isochromosome 8q formation resulting 
in chromosome 8q gain with subsequent loss of chromosome 8p, but the precise etiol-
ogy remains uncertain. However, previous research suggests that metastatic growth 
properties are modulated by suppression of gene regions specific to chromosome 8p.20 
This not only underlines the importance of genes localized on chromosome 8p for the 
spread and development of hepatic metastasis in UM, but it is also indicative for the 
role played by the genetic landscape of the primary tumor in the homing of tumor cells.
Studying UMmeta is not only challenging due to the lack of material, but also due 
to the biases which is created by the methods used to obtain metastasis material. 
Material is usually available through metastectomy and this is only performed in 
patients who are suited for this therapy and not for patient with a miliary pattern. 
However, research into the genetics of metastases remains important especially since 
there are several reports which state the different metastatic patterns also react differ-
ently to therapy.17,19,21 It has been shown that patient with a nodular metastatic growth 
pattern whom receive hepatic arterial chemoembolization have a significant longer 
survival.19,21 One report even shows that in a patient with a mixture of infiltrative and 
nodular metastatic growth pattern, the nodular metastasis show reduction in size to 
hepatic radio-embolization whereas the infiltrative metastasis remain resistant and 
persist in growth.17 This highlights that targeted therapy and perhaps also combination 
therapy is the future in UMmeta therapy.
In conclusion, our study has shown that there is an inverse correlation of the number 
of metastasis with the metastasized survival, indicating separate growth patterns. We 
could not find an association of metastasis with the mutations status, however loss of 
chromosome 8p was observed more often in patients harboring more liver metastasis. 
Future endeavors could focus on discovering different genetic factors including chromo-
some 8p that influence the propagation and development of hepatic metastases in UM.
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Abstract
Purpose: Most of the uvea melanoma (UM) display a near-diploid (normal, ~2N) 
karyotype with only a few chromosomal changes. In contrast to these simple aberra-
tions 18% of the UM samples show a polyploid character (>2N) and this was associated 
with an unfavorable prognosis. This study attempts to gain insight in the prognostic 
value of polyploidy in UM. 
Methods: In 202 patients the ploidy status of the UM was determined using cytoge-
netic analysis, fluorescence-in-situ-hybridization (FISH), multiplex ligation dependent 
probe amplification (MLPA), and/or single nucleotide polymorphism (SNP) array 
analysis. Immunohistochemistry was used to determine the BAP1 expression and 
mutation analyses of BAP1 (coding regions) and the mutation hotspots for the SF3B1, 
EIF1AX, GNAQ, and GNA11 genes was carried out using Sanger sequencing or 
whole-exome sequencing. 
Result: Twenty-three patients had a polyploid UM karyotype (11.4%). Patients with a 
polyploid tumor had larger tumors (15.61 vs. 13.13 mm, P = 0.004), and more often loss 
of heterozygosity of chromosome 3 (P = 0.003). No difference in occurrence of muta-
tions between polyploid and diploid tumors was observed for BAP1, SF3B1, EIF1AX, 
GNAQ, and GNA11. Polyploidy did not affect survival (P = 0.143). BAP1 deficiency 
was the only significant independent prognostic predictor for patients with polyploid 
tumors, with a 16- fold increased hazard ratio (HR 15.90, P = 0.009).
Conclusion: The prevalence of mutations in the UM related genes is not different in 
polyploid UM compared with diploid UM. Moreover, similar to patients with dip-
loid UM, BAP1 mutation is the most significant prognostic predictor of metastasis in 
patients with polyploid UM.
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Introduction
Uveal melanoma (UM) is the most common primary intraocular malignancy in adults 
with an annual incidence of approximately 7 to 10 per million.1 In approximately one-
half of the patients UM metastasizes via the blood with a preference for the liver.1 The 
prognostic factors linked to metastatic disease include clinical variables (increased 
age, large tumor size), histopathologic findings (epithelioid cell type, closed vascular 
patterns), genetic, and chromosomal abnormalities (loss of chromosome 3, gain of 
chromosome 8q).2–5
For UM, the karyotype is usually near-normal (diploid) with only few nonrandom 
chromosomal changes, such as loss of chromosome 3 (monosomy 3) and gain of chro-
mosome 8q.6 Besides these near-diploid (~2N) tumors, UM with polyploidy (>2N) have 
also been described. Based on DNA content, a prevalence of 13% to 18% of polyploid 
UM has been observed.7–9 In addition to the prevalence, the prognostic value of the 
ploidy was also described, in which polyploidy was associated with an unfavorable 
prognosis.7,9 However, despite the impact on survival, polyploidy in UM is not men-
tioned in recent literature or investigated with the current knowledge of UM.
Nowadays in UM research, the focus is more on genetic variations. Monosomy 3 in 
combination with the loss of function of the tumor suppressor BAP1 (BRCA-associ-
ated protein 1) is strongly associated with metastases.10–13 In contrast, mutations in 
the SF3B1 (splicing factor 3 subunit B1) gene and the EIF1AX (eukaryotic translation 
factor 1A) gene are reported mainly in disomy 3 (no loss of chromosome3) tumors.14–16 
Therefore, mutations in SF3B1 or EIF1AX have been suggested as favorable prognostic 
factors in UM, with low risk of metastasis.10,14–17 Mutations in the oncogenes GNAQ 
(Guanine nucleotide-binding protein, q polypeptide) and GNA11 (Guanine nucleo-
tide-binding protein, subunit alpha-11) are present in the majority of UM and are not 
associated with patient prognosis.18–20 
This study attempts to describe the differences between polyploid and diploid UM 
regarding clinical variables, histopathologic findings, chromosomal abnormalities, and 
genetic mutations (BAP1, SF3B1, EIF1AX, GNAQ, and GNA11). We also aimed to inves-
tigate the prognostic value of polyploidy and prognostic factors within polyploid UM.
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Methods
Study Population
Tissue specimens were obtained from 324 patients with UM who were enucleated 
or had a biopsy between 1993 and 2014. Informed consent was given prior to enu-
cleation and the study was performed according to the guidelines of the Declaration 
of Helsinki. This study was approved by the local ethics committee. The clinical data 
from time of diagnosis until December 2014 were updated from the patients’ chart. All 
tumors were histopathologically confirmed. Tumor node metastasis (TNM) classifica-
tion of the UM was adapted from the AJCC Cancer Staging Manual.21 Iris melanomas 
were excluded from this study. 
DNA Extraction and Copy Number Analysis
DNA was extracted directly from fresh tumor tissue or frozen tumor using the QIAmp 
DNA-mini kit (Qiagen, Hilden, Germany) according to the manufacturers’ instruc-
tions. Chromosome abnormalities were described following the recommendations 
for cytogenetic nomenclature.22 The tumors were processed for fluorescence in situ 
hybridization (FISH), multiplex ligation dependent probe amplification (MLPA), 
and/or single nucleotide polymorphism (SNP) array analysis (Illumina HumanCy-
toSNP-12 v2.1 BeadChip and Illumina 610Q BeadChip; Illumina, San Diego, CA, USA), 
as described previously.23 Cut-off limits for deletion detected by FISH (>15% of the 
nuclei with one signal) or amplification (>10% of the nuclei with 3 or more signals) 
were adapted from the available literature.23
Tumor Ploidy
For this study, 202 of 324 patients were included for whom the combination of several 
techniques was available to determine the ploidy status of the tumor. A threshold of 
greater than 20% polyploid cells was maintained for cytogenetic analyses. Based on 
cytogenetic or SNP array analyses, selected chromosomes, which were suspected to be 
3N or 4N, were analyzed with FISH to determine the ploidy fraction. A threshold of 
greater than 10% of the nuclei with three or more signals of these control chromosomes 
was used to classify a tumor as polyploid.23 Based on literature, we assumed baseline 
ploidy of polyploid UM as tetraploid (4N).24 Chromosomal copy number changes were 
calculated based on the ploidy baseline. For polyploid samples, chromosomes were 
treated as loss only in combination with loss of heterozygosity (LOH). For chromo-
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some gain, both quantitative gain (>2N) as well as relative gain (>4N) were included 
in the analyses of polyploid UM. 
Mutational Analyses
Mutation analyses using Sanger sequencing or obtained from whole-exome sequenc-
ing (WES) was available for 126 samples.25 Variants found in the WES data were 
validated by Sanger sequencing. BAP1, SF3B1, EIF1AX, GNAQ, and GNA11 muta-
tion analyses and BAP1 immunohistochemistry (IHC) were carried out as reported 
previously.13,18,25,26 For five polyploid samples no fresh or frozen tissue was available, 
therefore DNA was isolated from formalin-fixed, paraffin-embedded (FFPE) tissue. 
These DNAs were screened for mutations in the UM genes using the ION Torrent 
Personal Genome Machine (PGM) with the supplier’s materials and protocols (Life 
Technologies, Carlsbad, CA, USA). A custom primer panel was designed using the 
ION AmpliSeq Designer 3.2 (Thermo Fisher Scientific, Waltham, MA, USA). Reads 
were visualized with Integrative Genomics Viewer (v2.3; Broad Institute, Cambridge, 
MA, USA). Variants were validated with Sanger sequencing using primers (Supple-
mentary Table S1) and protocols for FFPE DNA. Protocols and designs regarding 
FFPE DNA sequencing are available upon request. De novo missense mutations were 
investigated with SIFT (in the public domain, http://sift.jcvi.org/) and PolyPhen-2 (in 
the public domain, http://genetics.bwh.harvard.edu/pph2/index.shtml) for predictions 
on possible functional impact and pathogenicity of the amino acid change. 
Statistical Analyses
Disease-free survival (DFS) was calculated as date of first initial treatment to date 
of clinically proven metastasis from UM. The Log-rank test was used for categorical 
variables, and Cox proportional hazard analysis for continuous variables. Statistical 
significant variables conducted from univariate analysis were analyzed using Cox 
proportional hazard multivariate analysis. P values of 0.05 or lower were considered 
significant for survival analyses. Chi-square or Fisher’s exact test was used for asso-
ciations with categorical data; Mann-Whitney U test was used for associations with 
continuous data. P values of 0.005 or lower were considered significant for correla-
tion analyses. All statistical analyses were performed with SPSS 21.0 Software (IBM, 
Armonk, NY, USA).
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Results
Patient and Tumor Characteristics
Polyploid UM was detected in 23 of 202 patients (11.4%). Nine patients were male 
and 14 were female with a mean age at diagnosis of 62.5 years. Mean tumor diameter 
was 15.6 mm with a mean tumor thickness of 8.9 mm. Histopathologically, 19 tumors 
contained epithelioid cells and 11 formed extracellular matrix patterns. All tumors (n 
= 23) showed a relative loss of chromosome 3 (<4N), resulting in LOH for chromosome 
3 in 20 tumors (Fig. 2), whereas three tumors (S28, S102, and S156) still contained two 
different alleles despite the relative loss (Figs. 1, 2). For chromosome 8q all polyploid 
UM had more than two copies, 19 tumors had a relative gain (>4N), all copies were 
present in three tumors (4N; S147, S156, and S161) and one tumor (S75) had three 
copies of chromosome 8q (Fig. 1). An overview of the clinical, histopathologic, and 
chromosomal variables are shown in Table 1.
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Figure 1. Overview of mutations and copy number variation in polyploid UM. The TNM classifica-
tion is represented on the first line. First row of blocks represent the GNAQ and GNA11 mutation 
status; dark gray, GNAQ mutation; light gray, GNA11 mutation; n.d. = not determined; All mutations 
were exclusive. Second row of blocks represent the BAP1, SF3B1, and EIF1AX mutation status; black, 
BAP1 mutation; striped, SF3B1 mutation; gray, EIF1AX mutation; and white, wild-type for the three 
genes. All mutations were exclusive. Third row of blocks represent the BAP1 expression; white, 
BAP1 expressed; black, BAP1 not expressed. Fifth row represent the alleles of chromosome 3; CNV 
¼ copy number variation (baseline is four copies); black, allele A; light gray, allele B; white, loss of 
chromosome. Sixth row represent the alleles of chromosome 8q; black, allele A; light gray, allele B; 
white, loss of chromosome; dark gray, gain chromosome(s). * In these samples the BAP1 mutation 
status could not be determined.
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Table 1. Patient and tumor characteristics of the study cohort, and associations between ploidy of 
the tumor with other clinical, histopathological and genetic variables. 
Ploidy status tumor
Variables (n = 202) Polyploid Diploid
(mean or n) (mean or n) p-value
Age at diagnoses 62.52 ± 2.67 61.17 ± 1.08 0.689 †
Gender
     Male 9 90 0.314 ‡
     Female 14 89
Localization
     Choroid 15 136 0.263 ‡
     Ciliary body 8 43
Largest tumor diameter 15.61 ± 0.76 13.13 ± 0.25 0.004 †
Tumor thickness 8.87 ± 0.75 7.68 ± 0.26 0.131 †
TNM classification
     Category 1 1 20 -
     Category 2 5 66
     Category 3 10 80
     Category 4 7 13
Cell type
     Spindle 4 59 0.129 ‡
     Epithelioid/mixed 19 120
Extracellular matrix patterns
     Absent 12 90 0.925 ‡
     Present 11 86
Chromosome 3 
     Relative loss (<4N*) 23 98 <0.001 ‡
     Normal (4N*) 0 81
Chromosome 3
     LOH 20 98 0.003 ‡
     No LOH 3 81
Chromosome 8q 
     Normal (2N) 0 69 <0.001 ‡
     Absolute gain (>2N) 23 110
Chromosome 8q
     Normal (4N*) 4 69 0.047 ‡
     Gain (>4N*) 19 110
BAP1
     Normal 8 69 0.223 ‡
     Deficient 14 68
SF3B1
     Wild type 19 83 0.546 ‡
     Mutated 4 25
EIF1AX
     Wild type 22 88 0.125 §
     Mutated 1 22
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Table 1. Continued. 
Ploidy status tumor
Variables (n = 202) Polyploid Diploid
GNAQ
     Wild type 11 52 0.946 ‡
     Mutated 12 55
GNA11
     Wild type 13 60 0.969 ‡
     Mutated 10 47
P-values≤ 0.005 was considered significant after correction for multiple testing. Mann-Whitney test 
† was used for associations with continuous data, Chi-square -test ‡ or Fisher’s exact test § was used 
for associations with categorical data. TNM classification was not compared since tumor diameter 
and thickness are analyzed separately. *: copy numbers for the polyploid UM.
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Figure 2. (A) Karyogram of S152 demonstrates a polyploid cell with three or four copies of most 
chromosomes and two copies of chromosome 3; the corresponding whole-genome SNP array (all 
chromosomes on the X-axis) demonstrates a relative loss of chromosome 3 as observed in the Log 
R ratio (negative values indicate a relative loss and positive values a relative gain). Loss of hetero-
zygosity of chromosome 3 can be deduced from the B-allele frequency (the B-allele frequency is 
either 1.0 or 0.0). (B) Karyogram of S28 demonstrates a polyploid cell with three or four copies of 
most chromosomes and two copies of chromosome 3; the corresponding whole-genome SNP array 
demonstrates a relative loss as observed in the Log R ratio; however, without the loss of heterozy-
gosity as demonstrated by the SNP’s (B-allele frequency of ~0.5).
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Genetic Analyses UM Genes
Within the patients with polyploid tumors 12 patients harbored a BAP1 mutation, 
which were hemi- or homozygous in all cases. In 13 of 22 patients, the tumors did 
not express BAP1 (examples provided in Fig. 3). In one case (S111) the lack of tumor 
material restricted us to investigate BAP1 both for mutations and expression. One 
patient (S76) could not be investigated for BAP1 mutations, but did reveal loss of BAP-
1expression. In one patient (S123), the tumor did not harbor a mutation in the coding 
exons, but had a loss of expression of BAP1 in the tumor. One patient (S121) harbored 
a missense mutation in the tumor, p.E30G, whereas the IHC did show expression of 
BAP1. This mutation was predicted as ‘Deleterious’ by SIFT software (J. Craig Venter 
Institute, Rockville, MD,USA) and ‘Probably damaging’ by PolyPhen-2 software(Har-
vard Medical School, Boston, MA, USA). All three patients (S76, S121, and S123) were 
treated as BAP1-deficient tumors in further analysis. SF3B1 was mutated in four sam-
ples targeting the hotspot p.R625 in three cases and p.V576del in one case. EIF1AX 
harbored a missense mutation, p.G15D, in one case, which was predicted as ‘Dele-
terious’ by SIFT software and ‘Probably damaging’ by PolyPhen-2 software. Twelve 
tumors harbored a GNAQ p.Q209 hotspot mutation, 10 harbored a GNA11 p.Q209 
hotspot mutation, and one tumor was wildtype for exon 4 and 5 of both genes. An 
overview of the mutations with the corresponding polyploid tumor is shown in Figure 
1. Mutations in BAP1, SF3B1, EIF1AX, GNAQ, and GNA11 in the patients with diploid 
UM were described previously.13,18,25 
Figure 3. Examples of BAP1 immunohistochemistry of two polyploid uveal melanoma cases. Left 
picture: BAP1 expression in the tumor cells of S28 (3400). Right picture: lack of BAP1 expression in 
the tumor cells of the case S162 (3400). Note the positive staining in the retinal pigment epithelium 
cells and macrophages.
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Statistical Analyses
Based on tumor ploidy, patients did not differ in age at diagnoses, sex, tumor localiza-
tion, tumor thickness, cell type, and presence of extracellular matrix patterns. Patients 
with a polyploid tumor had significantly larger tumors than patients with a diploid 
tumor (15.6 vs. 13.1 mm, P = 0.004; Table 1). For chromosomal abnormalities we clas-
sified the copy number changes for polyploid UM in two ways. For chromosome loss, 
we determined the relative loss from baseline and also loss with LOH. For chromo-
some gain, we determined absolute gain from disomy state and relative gain from 
baseline. Patients with polyploid UM showed more loss of chromosome 3 (P < 0.001), 
which was still significant after correcting for LOH (P = 0.003). For chromosome 8q, 
the polyploid UM contained more often absolute gain (>2N; P < 0.001). Relative gain 
of chromosome 8q was observed more often in polyploid UM (P = 0.047), and after 
correcting the P value for multiple testing to P less than or equal to 0.005 this was not 
considered significant. Mutational frequencies did not differ between polyploid and 
diploid UM for BAP1, SF3B1, EIF1AX, GNAQ, and GNA11. 
Survival Analyses
To test whether polyploidy in UM was associated with worse disease-free survival we 
performed survival analyses for the total group (n = 202). Ploidy was not associated 
with prognosis, because patients with polyploid tumors, as a group, did not differ 
from patients with diploid tumors based on the survival (Fig. 4A). Univariate analyses 
results are shown in Table 2. Also in the multivariate Cox-regression analyses, poly-
ploidy was not associated with disease-free survival. Larger basal tumor diameter (HR 
1.110; P = 0.015) and BAP1 deficiency (HR 5.132; P < 0.001) were the only independent 
significant predictors for disease-free survival in the total cohort (Table 2). Survival 
analysis was also performed for patients with polyploid UM to investigate prognostic 
predictors within this subset (n = 23). Loss of heterozygosity of chromosome 3 (P = 
0.050), BAP1 deficiency (P = 0.001), and SF3B1 wildtype mutation status (P = 0.035) 
were significantly associated with decreased disease-free survival. Other variables 
were not significantly associated with disease-free survival (Table 2). Chromosome 3, 
BAP1, and SF3B1 status, together with tumor diameter (because this was associated 
with polyploid UM) were included into the multivariate Cox analyses. This showed 
BAP1 deficiency as the only significant independent prognostic predictor for patients 
with polyploid tumors, with a 16-fold increased HR (HR 15.90, P = 0.009; Table 2).
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A Total cohort Total cohortB
Diploid
Polyploid
P = 0.143 P < 0.001
Diploid and normal BAP1
Polyploid and normal BAP1
Polyploid and decient BAP1
Diploid and decient BAP1
Figure 4. Kaplan-Meier survival analyses for; (A) polyploid UM compared to diploid UM (P = 0.143) 
and (B) survival analyses between polyploid and diploid UM stratified for BAP1 status (P < 0.001).
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Table 2. Univariate and multivariate analyses of the uveal melanoma parameters in relation to 
patient survival for the total cohort and patients with a polyploid tumor karyotype.
Covariate Univariate Multivariate Covariate Univariate Multivariate
Total cohort (n=202) 95% CI p-value HR 95% CI p-value Polyploid (n=23) 95% CI p-value HR 95% CI p-value
Age at diagnoses 1.006-1.036 0.004 0.683 Age at diagnoses 0.987-1.073 0.175 - - -
Largest tumor diameter 1.030-1.158 0.003 1.110 1.021-1.206 0.015 Largest tumor diameter 0.937-1.261 0.270 - - 0.156
Tumor height 0.997-1.113 0.065 - - - Tumor height 0.909-1.229 0.471 - - -
Cell type Cell type
     Spindle 121.7-160.9 <0.001 - - 0.912      Spindle 22.0-149.2 0.624 - - -
     Mixed/epithelioid 77.5-108.6      Mixed/epithelioid 
Closed vascular loops Closed vascular loops
     Present 59.4-94.3 <0.001 - - 0.072      Present 17.1-96.2 0.129 - - -
     Absent 117.1-149.6      Absent 52.5-128.6
Ploidy Ploidy 
     Diploid 99.6-128.0 0.143 - - 0.568      Diploid 
     Polyploid 49.2-117.9      Polyploid 
Chromosome 3 Chromosome 3
     Loss (with LOH) 50.6-80.1 <0.001 - - 0.549      Loss (with LOH) * 0.050 - - 0.357
     Normal 147.1-175.7      Normal 
Chromosome 8q Chromosome 8q
     Normal 155.1-190.7 <0.001 2.171 0.958-4.920 0.063      Normal 66.5-167.4 0.136 - - -
     Gain (relative) 60.7-87.9      Gain (relative) 35.0-107.0
BAP1 BAP1 
     Normal 141.2-172.5 <0.001 5.132 2.623-10.04 <0.001      Normal 123.7-211.5 0.001 15.90 1.97-128.3 0.009
     Deficient 44.4-75.5      Deficient 16.4-42.5
SF3B1 SF3B1 
     Wild type 84.3-121.3 0.028 - - 0.166      Wild type * 0.035 - - 0.294
    Mutated 114.9-165.5     Mutated 
EIF1AX EIF1AX 
     Wild type 75.9-106.8 <0.001 0.145 0.19-1.116 0.064      Wild type * 0.228 - - -
     Mutated 168.3-214.6      Mutated 
P-value of P≤0.05 was considered significant. Log-rank test and Cox regression analyses were used 
to obtain univariate analyses for categorical and continuous data respectively. Multivariate analyses 
was conducted with Cox regression analyses with variables significantly associated with survival in 
the univariate analyses. CI: confidence interval of survival (months/HR); HR: hazard ratio (expB). * 
No statistics could be computed because all cases were censored. 
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Table 2. Univariate and multivariate analyses of the uveal melanoma parameters in relation to 
patient survival for the total cohort and patients with a polyploid tumor karyotype.
Covariate Univariate Multivariate Covariate Univariate Multivariate
Total cohort (n=202) 95% CI p-value HR 95% CI p-value Polyploid (n=23) 95% CI p-value HR 95% CI p-value
Age at diagnoses 1.006-1.036 0.004 0.683 Age at diagnoses 0.987-1.073 0.175 - - -
Largest tumor diameter 1.030-1.158 0.003 1.110 1.021-1.206 0.015 Largest tumor diameter 0.937-1.261 0.270 - - 0.156
Tumor height 0.997-1.113 0.065 - - - Tumor height 0.909-1.229 0.471 - - -
Cell type Cell type
     Spindle 121.7-160.9 <0.001 - - 0.912      Spindle 22.0-149.2 0.624 - - -
     Mixed/epithelioid 77.5-108.6      Mixed/epithelioid 
Closed vascular loops Closed vascular loops
     Present 59.4-94.3 <0.001 - - 0.072      Present 17.1-96.2 0.129 - - -
     Absent 117.1-149.6      Absent 52.5-128.6
Ploidy Ploidy 
     Diploid 99.6-128.0 0.143 - - 0.568      Diploid 
     Polyploid 49.2-117.9      Polyploid 
Chromosome 3 Chromosome 3
     Loss (with LOH) 50.6-80.1 <0.001 - - 0.549      Loss (with LOH) * 0.050 - - 0.357
     Normal 147.1-175.7      Normal 
Chromosome 8q Chromosome 8q
     Normal 155.1-190.7 <0.001 2.171 0.958-4.920 0.063      Normal 66.5-167.4 0.136 - - -
     Gain (relative) 60.7-87.9      Gain (relative) 35.0-107.0
BAP1 BAP1 
     Normal 141.2-172.5 <0.001 5.132 2.623-10.04 <0.001      Normal 123.7-211.5 0.001 15.90 1.97-128.3 0.009
     Deficient 44.4-75.5      Deficient 16.4-42.5
SF3B1 SF3B1 
     Wild type 84.3-121.3 0.028 - - 0.166      Wild type * 0.035 - - 0.294
    Mutated 114.9-165.5     Mutated 
EIF1AX EIF1AX 
     Wild type 75.9-106.8 <0.001 0.145 0.19-1.116 0.064      Wild type * 0.228 - - -
     Mutated 168.3-214.6      Mutated 
P-value of P≤0.05 was considered significant. Log-rank test and Cox regression analyses were used 
to obtain univariate analyses for categorical and continuous data respectively. Multivariate analyses 
was conducted with Cox regression analyses with variables significantly associated with survival in 
the univariate analyses. CI: confidence interval of survival (months/HR); HR: hazard ratio (expB). * 
No statistics could be computed because all cases were censored. 
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Discussion
In our cohort polyploidy occurred in 11.4% of the patients with UM. Previously, we as 
well as other groups have reported ranges between 13% and 18%,8,9 and this difference 
in prevalence can be explained by the different methods which were used to determine 
the ploidy status and the DNA index (DI) thresholds which were adapted to classify 
a tumor as polyploid. Meecham et al.7 report polyploidy in 13% of the UM with flow 
cytometry measurements and a threshold of DI greater than 1.4 for polyploidy. Toti et 
al.9 report polyploidy in18% of the UM cases, while maintaining a threshold of DI greater 
than 1.3 for polyploidy, which would explain the higher prevalence of polyploidy. Mooy 
et al.8 reports tetraploidy (4N) in 17% of the cohort; however, this subset also contains 
preirradiated tumors, which they also correlate to a higher prevalence of aneuploidy. 
When compared with patients with diploid UM, we found larger tumor diameter in 
the polyploid patient group. Polyploid UM also contained more LOH of chromosome 
3. We could not confirm previous findings, which stated that polyploidy as a group is 
associated with worse patient survival.7,9 However, we did find that BAP1 deficiency 
was the most significant factor associated with survival in patients with a polyploid 
UM, similar to diploid UM. 
BAP1 expression has been shown as an independent prognostic marker in UM.10,12,13 
The gene is located on chromosome 3, and is mutated mainly in tumors with loss of 
chromosome 3,15 resulting in the loss of BAP1 expression.13 One sample harbored a 
missense mutation (p.E30G), whereas the staining did reveal BAP1 expression. This 
mutation was predicted ‘Deleterious’ and ‘Probably damaging’ by the prediction soft-
ware’s. Moreover, this mutation is located at the first b-sheet of the protein and also 
next to three amino acids (p.E31–p.Y33), which form a binding site for ubiquitin,27 
making it likely that the replacement of the negatively charged glutamic acid with the 
neutral glycine causes a structural malformation of the protein resulting in a deficiency 
of BAP1. The BAP1 expression can be explained, because the mutation is a missense 
mutation and does not lead to protein degradation. Also, the affected amino acid is 
located in the N terminal UCH domain, whereas the antibody used for the staining 
target the C-terminal end of the BAP1 protein.13 In this study, tumors with BAP1 
mutations and/or loss of BAP1 expression were categorized as deficient BAP1. In this 
way we observed that deficient BAP1 was the only independent prognostic marker in 
patients with polyploid UM. 
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For the other UM relevant genes we found GNAQ or GNA11 mutations in all but 
one polyploid UM as one would expect based on the occurrence described in diploid 
UM.19,20 SF3B1 mutations were observed in four of our polyploid tumors. Patients with 
SF3B1 mutation in the UM have been associated with the low-risk prognostic features; 
disomy 3, spindle-cell type, and low age at diagnoses.15,16 None of the patients in our 
polyploid group with SF3B1 mutations had developed metastatic disease and were 
alive at the end of the study (follow-up range, 1–192 months). Nevertheless, both to 
our own experience as well as by other groups patients can be identified with disomy 
3 tumors harboring an SF3B1 mutation that developedmetastasis.15,16,25,28 In our poly-
ploid cohort the numbers are too low and the follow-up for some tumors is too short in 
order to draw conclusions regarding the influence of SF3B1 mutations in the tumor on 
disease-free survival. EIF1AX mutations are mainly reported in disomy 3 tumors and 
are correlated with a good prognosis for these patients, and present in the tumor of one 
patient in our series of polyploid UM, who is metastasis-free and alive at a follow-up 
of 136 months.10,16,17,25 The missense mutation found in the tumor of this patient affects 
amino acid 15 (p.G15D), a missense mutation described in other UM samples as well 
(the COSMIC database; id=COSM3973544; in the public domain, http://cancer.sanger.
ac.uk/cosmic/). The first 18 amino acids at the N-terminus of the eiF1A protein are 
essential in the interaction with the 40S subunit,29 thus making it very likely that this 
mutation results in an altered function of the protein. In this current study, we have 
shown that the prevalence of mutations in the UM genes do not differ between tumors 
with diploid and polyploid karyotypes, indicating a similar behavior and progression 
toward metastatic disease, suggesting polyploid UM are not a subclass in UM.
Caution should be taken in the interpretation of chromosomal abnormalities and using 
one technique only this could possible lead to misclassifications. Uveal melanoma 
are characterized by nonrandom recurring chromosomal losses and gains.6 Loss of 
chromosome 3 has been correlated to metastasis,3–5 but in polyploid UM with loss of 
one or multiple copies of chromosome 3 this does not automatically result in LOH. 
This is shown in our polyploid tumors, which all contain a relative loss of chromo-
some 3, while three tumors do not display a LOH (Figs. 1, 2). These three patients 
without LOH are still alive with a median DFS of 11 years (range, 76–192 months), 
which is comparable to the survival of patients with disomy 3 tumors.3 Onken et al.30 
described that LOH of chromosome 3 is superior to quantitative loss of monosomy 3, 
and that is also the case in polyploid UM in our study. We emphasize the importance 
of SNP-array to investigate the zygosity of UM, to reduce false-negative (disomy 3 
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with LOH) and false-positive (relative monosomy 3 without LOH) prognostification. 
However, we cannot use the same reasoning for chromosome gain. Increase in copies 
of chromosome 8q is shown to be associated with shorter DFS.31 In polyploid UM, all 
tumors contain more than two copies of 8q, while four tumors do not have a relative 
gain based on the baseline of four copies. One of these four patients developed liver 
metastasis at 54 months and is still alive after a partial hepatectomy 20 months later, 
two died due to another cause at 38 and 149 months respectively, and one is alive and 
metastasis-free at 76 months. Because the survival of these patients is not homogenous 
we cannot draw conclusions regarding the pathogenicity of absolute gain without 
relative gain (tri- and tetrasomy) of chromosome 8q. 
In conclusion, here we show that polyploid UM do not differ from diploid UM based 
on prevalence of mutations in the UM genes, and that similar to patients with diploid 
UM, BAP1 is the most significant prognostic predictor of metastasis inpatients with 
polyploid UM (HR 15.90). Yet, the increased chromosome count and frequent losses in 
polyploid tumors can cause wrongful interpretations of chromosomal data and should 
therefore be analyzed for ploidy status.
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Abstract
Introduction
Uveal melanoma (UM) is the most common primary intraocular malignancy in the 
Western world. Recurrent mutations in GNAQ, GNA11, BAP1, EIF1AX and SF3B1 are 
described as well as non-random chromosomal aberrations. Chromothripsis is a rare 
event in which chromosomes are shattered and rearranged and has been reported in 
a variety of cancers including UM. 
Materials and methods
SNP-arrays of 249 UM from patients who underwent enucleation, biopsy or endore-
section were reviewed for the presence of chromothripsis. Chromothripsis was defined 
as ten or more breakpoints per chromosome involved. Genetic analysis of GNAQ, 
GNA11, BAP1, SF3B1 and EIF1AX was conducted using Sanger and next-generation 
sequencing. In addition, immunohistochemistry for BAP1 was performed. 
Results
Chromothripsis was detected in seven out of 249 tumors and the affected chromo-
somes were chromosomes 3, 5, 6, 8, and 12 and 13. The mean total of fragments per 
chromosome was 39.8 (range 12 – 116). In one UM, chromothripsis occurred simulta-
neously in two different chromosomes. A GNAQ or GNA11 mutation was present in 
five tumors. Five out of seven tumors harbored a BAP1 mutation and/or lacked BAP1 
protein expression in immunohistochemistry. Four of these tumors metastasized, from 
the fifth only short follow-up data is available. One tumor harbored an SF3B1 mutation 
and metastasized as well. No EIF1AX mutations were detected. 
Conclusion
Chromothripsis was observed in 2.8% of the UM with a mean of approximately fourty 
fragments per chromosome. Chromothripsis occurred concurrently in two different 
chromosomes in one UM. Five of the seven patients developed metastatic disease, four 
of these UM harbor a BAP1 mutation and one an SF3B1 mutation. Chromothripsis of 
chromosome 3 was detected in two UM, both having a BAP1 mutation. 
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Introduction
Uveal melanoma (UM) is a relative rare disease and has a high mortality rate due to 
metastasis in about half of all patients within 15 years after diagnosis.1-3 UM is the most 
common primary intra-ocular malignancy in adults in the Western world.4 Uveal mel-
anoma specific mutations in the alpha subunit genes GNAQ and GNA11 are described 
as well as mutations in BAP1, SF3B1 and EIF1AX.5-7 Mutations in the latter three genes 
are found in approximately 75% of all UM and useful for prognostication of patients.8-10 
BAP1 mutated UM give rise to early-onset metastasis whereas SF3B1-mutated UM 
give rise to late-onset metastasis and EIF1AX-mutated UM hardly metastasize.8
Copy number alterations in chromosomes 1, 3, 6 and 8 are correlated with prognosis of 
the UM patient.11, 12 UM with EIF1AX, SF3B1 and BAP1 mutations are associated with 
unique chromosomal patterns, suggesting distinct UM subclasses. BAP1 mutated UM 
harbor entire chromosome copy number variations (CNVs) and entire chromosome 
arm CNV anomalies (isochromosomes). UM with an SF3B1 mutation are characterized 
by many structural variants, often affecting the terminal ends of chromosomes and 
thus not entire chromosomes or chromosome arms.13 Besides these recurrent CNVs, 
also other chromosomal patterns are described such as polyploidy of the genome, 
which occurs in approximately 10-15% of all UM.14 Another chromosomal anomaly 
described in UM is chromothripsis.12 This is a phenomenon in which many genomic 
rearrangements occurs in a single chromosome or chromosome arm. In this case 
series we report on chromothripsis in seven UM. It has been described in congenital 
abnormalities, UM and a variety of other cancers such as bone cancer, lung cancer, 
myelodysplastic syndrome (MDS), colorectal cancer, mammacarcinoma and neuro-
blastoma.12, 15-19 Chromothripsis predicts a poor outcome in skin melanoma and occur 
in high risk neuroblastoma, mammacarcinoma and MDS.16, 18-20 A positive correlation 
between chromothripsis and progression free survival was observed in metastatic 
colorectal cancer.17 The clinical consequence of this phenomenon in uveal melanoma 
remains unclear.12 
The mechanism of chromothripsis remains elusive but several hypotheses are described 
such as the formation of micronuclei, premature chromosome compaction (PCC), TP53 
mutations and breakage-fusion bridge cycles or irradiation.21, 22 23 The formation of 
chromothripsis involving telomere regions and one chromosome arm is described and 
supports the hypothesis that events during the cell cycle are involved in the formation 
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of these chromosomal rearrangements.24 It is hypothesized that chromothripsis occurs 
through the formation of micronuclei that arise from lagging chromosomes or chro-
matid fragments during mitosis.15, 25-28 Moreover, these micronuclei are more prone 
to DNA damage, with subsequently DNA nuclease repair by non-homologous end 
joining (NHEJ), which could explain the chromosome reshuffling.15, 25, 28, 29 
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Materials and methods
Inclusion
Patients with UM that underwent enucleation, endoresection or tumor biopsy at the 
Erasmus University Medical Center (Rotterdam, The Netherlands) or The Rotterdam 
Eye Hospital (Rotterdam, The Netherlands) between 1992 and 2017 were selected. 
SNP (single nucleotide polymorphism) array data of the tumor was available from 
249 patients. Chromothripsis was defined as ten or more breakpoints per chromosome 
detected with SNP-array. This study was approved by the local ethics committee and 
followed the tenets of the Declaration of Helsinki. Informed consent was obtained 
prior to treatment. 
SNP-array
DNA was extracted from fresh tumor samples using the QIamp DNA-mini kit (Qiagen, 
Hilden, Germany) following the manufacturer’s instructions. SNP-array was per-
formed using 200ng of DNA as input for whole-genome analysis (Illumina 610Q 
BeadChip, Illumina, San Diego, CA, USA). The data was analyzed with Nexus Copy 
Number 9.0 software (BioDiscovery Incorporated, El Segundo, California, USA). The 
amount of copy number gains and losses were used to determine the number of frag-
ments. The total fragments were counted including copy number neutral fragments 
as separate fragments. 
Mutation detection
Mutation analysis for GNAQ, GNA11, EIF1AX, SF3B1 and BAP1 was performed with 
Sanger sequencing and Ion Torrent next-generation sequencing (NGS) (Thermo Fisher 
Scientific, Waltham, Massachusetts, USA sequencing) as described before.30 SeqScape 
Software 3 (Applied Biosystems, Foster City, CA, USA) and Integrative Genomics 
Viewer (IGV) Version 2.3.68 (97) (Broad Institute, Cambridge, Massachusetts, USA) 
was used to analyze the data. BAP1 immunohistochemistry (IHC) was performed as 
described previously.9 
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Results
Patient characteristics
In seven patients chromothripsis was detected in the UM. These seven patients com-
prised of five women and two men with a mean age at diagnosis of 57.4 years (range 
46.2 – 73.4 years). Six patients underwent enucleation as primary treatment. In one 
patient primary treatment was followed by external beam radiotherapy because of 
unclear surgical margins. One patient underwent brachytherapy as primary treatment, 
followed by enucleation almost three years later due to tumor recurrence. Metastasis 
developed in five patients after 31.9 to 78.7 months. The mean DFS was 51.5 months 
(range 15.5 – 99.0 months). In Table 1 an overview of patient characteristics is listed.
Tumor characteristics
Six tumors were located in the posterior choroid whereas one UM originated from the 
ciliary body. Mean largest tumor diameter was 13.5 mm (range 9.5-19 mm) and mean 
tumor thickness 7.5 mm (range 2 – 12 mm), Table 1. Three UM contained epithelioid 
cells and four were classified spindle cell type. Closed vascular loops were present in 
two of the seven UM and extra-ocular extensions were found in two cases. Correlations 
of chromothripsis with patient and tumor characteristics were not performed due to 
the limited number of cases. 
Table 1. 
Patient Sex Age DFS Metastasis
Tumor
diameter (mm)
Tumor 
thickness (mm)
Primary 
treatment
UM 1 F 46.3 42.7 Yes 14 10 Enucleation
UM 2 M 46.2 78.7 Yes 13 N.a. Enucleation
UM 3 F 57.4 47.4 Yes 9.5 2 Brachytherapy
UM 4 F 64.1 31.9 Yes 14 12 Enucleation
UM 5 M 55.8 99.0 No 12 4 Enucleation
UM 6 F 73.4 15.5 No 13 7.5 Enucleation
UM 7 F 58.6 45.4 Yes 19 9.5 Enucleation
F = female; M = male; age = age at diagnosis in years; DFS = disease free survival in months; n.a. = 
data not available.
BAP1 expression was present in three cases and absent in four cases. Mutation analysis 
was performed for all seven tumors (Figure 3). A mutation in GNAQ was detected in 
two tumors, a c.626A>C:p.(Gln209Pro) mutation. A GNA11 c.626A>T:p.(Gln209Leu) 
mutation was detected in the UM of three patients. One c.1873C>T:p.(Arg625Cys) 
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mutation in SF3B1 was found (UM 1) but all tumors were wildtype for EIF1AX. 
BAP1 mutations were detected in four patients, a c.89A>G:p.(Glu31Gly) (UM 2), a 
c.172_173del:p.(Ser58Profs*10) (UM 6), a c.206_207insA:p.(Thr69Asnfs*5) (UM 7) and 
a mutation two base pairs after exon 5 (c.375+2T>C)  (UM 4) resulting in alternative 
splicing with a premature stop before the next predicted splice site (prediction in 
Alamut Visual, Interactive Biosoftware, Rouen, France). Three of these four BAP1 
mutated UM had an absent BAP1 expression. In one tumor a BAP1 mutation was not 
detected with NGS, although IHC revealed lack of BAP1 expression. Moreover, this 
tumor was irradiated prior to the enucleation. Polyploidy occurred in two out of seven 
UM. See Figure 3 for an overview of mutation status and BAP1 IHC. 
Chromothripsis
In total eight chromosomes showed chromothripsis (Figure 1). One tumor harbored 
chromothripsis in two separate chromosomes (UM 5; Figure 2). UM 7 (chromothripsis 
of chromosome 13) showed eight fragments in chromosome 16  as well. However, since 
this did not meet our criteria of ten fragments, this chromosome was not included 
for further analysis. Chromosome 3 and 6 were affected in two UM. Regarding chro-
mosome 3, the breaking points were not present in the BAP1 gene. Other affected 
chromosomes were chromosome 5, 8, 12 and 13. The mean of the total fragments per 
chromosome was 39.8 (range 12-116, Figure 3). In four of the eight chromosomes the 
B-allele frequencies indicates more than two copy number states of the separate chro-
mosome fragments (Figure 1A and Figure 2). In five cases (UM 2, UM 3, UM 4, UM 5 
and UM 6) DNA from blood was available for germline analysis using SNP-array. No 
chromothripsis was observed in these samples.
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Figure 1. Two examples of chromothripsis. (A) UM 1 showing chromothripsis of chromosome 6q 
with an additional gain of the terminal short (p) arm of chromosome 6. Note the three different 
copy number states in the chromothriptic chromosome. (B) UM 4 showing chromothripsis of chro-
mosome 3.
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Figure 2. A case with two chromothriptic chromosomes. UM 5 showing chromothripsis of (A) chro-
mosome 6 and (B) chromosome 8. Note the three copy number states and a general gain of the 
entire chromosomes.
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Discussion
Recurrent chromosomal aberrations have been described in detail in UM, which are 
strongly correlated to the mutation status.13, 31, 32 In this paper, another chromosomal 
aberration, called chromothripsis, is described. Chromothripsis is characterized by ten 
to hundreds of chromosome fragments that are shattered and randomly rearranged.15 
This is described in numerable type of malignancies with a mean pan-cancer preva-
lence of 1-2%.12, 29, 33 Similar to other malignancies, chromothripsis is also rare in UM. 
In one study chromothripsis was observed in 2/25 UM.12 We detected chromothripsis 
in 2.8% of the UM which is in line with the low frequency rate as previously described. 
A relation between prognosis and chromothripsis has been reported in several studies 
on different malignancies. In high risk neuroblastoma, mammacarcinoma and MDS, 
chromothripsis is correlated with a poor outcome while in metastatic colorectal cancer 
a better progression free-survival has been described.15,17-19 In this report, metastatic 
disease was present in five out of seven patients. Four of the metastasizing tumors 
harbored a BAP1 mutation and or lacked BAP1 expression and in one tumor an SF3B1 
mutation was present. One of the two patients without metastatic disease did not 
harbor a BAP1 or SF3B1 mutation in the tumor and the IHC showed a positive BAP1 
expression while from the other patient (harbouring a BAP1 mutation in the tumor) 
only short follow-up data was available (16 months). The overall poor prognosis of 
this cohort could be explained by the mutations in BAP1 and SF3B1 since it is known 
that mutations in these genes are correlated with a high risk of metastasis.8, 10 
There are several risk factors known for chromothripsis such as irradiation.21 In one 
case, brachytherapy was followed by enucleation. Therefore, the chromothripsis in 
this UM could be an irradiation effect. Other factors correlated with chromothripsis 
formation are hyper- and polyploidization.34, 35 For a long time it was assumed that 
chromothriptic chromosomes only have two copy number states.15, 28, 29 However, an 
observation was made in a subtype of acute lymphoblastic leukemia, in which more 
copy number states were found in chromothriptic chromosomes.36 In this study two of 
the seven UM (29%) were polyploid. Polyploidy occurs in only 11% of all large UM14 
and chromothripsis is a rare event, this could explain the co-occurrence of polyploid 
UM with chromothripsis. In addition, in our cohort, seven out of eight chromothrip-
tic chromosomes harbored more than two chromosomes. This observation was also 
made in the only other study that described two cases of UM with chromothripsis.12 
This suggests that chromothripsis occurs in already duplicated chromosomes. Altered 
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chromosomes might even be more susceptible to chromosome lagging, as 50% of the 
chromosomes with chromothripsis in this study have more than two copy number 
states.36 Furthermore, chromothripsis can occur in more than one chromosome in the 
same tumor.15 In our cohort, more than one chromosome was affected in one tumor. It 
is noteworthy that the affected chromosomes in this study included chromosomes 3, 6 
and 8, since copy number variations in these chromosomes are correlated with muta-
tion status in UM.13 This is in line with other studies in which chromothripsis occur 
among known cancer driver genes.23, 37 Nevertheless, chromothripsis-like patterns 
across different tumor types showed a limited preference according to chromosome 
size. However, chromosome 17 was most frequently affected and to a lesser degree 
chromosomes 8,11 and 12 in another study.24 This could be explained by the fact that 
chromosome 17 also harbors TP53, an important cancer associated gene, which is 
correlated to chromothripsis as well.23 
To conclude, chromothripsis is a complex event that occurs in a variety of cancers.12, 16, 
18, 23, 24, 38 This study shows chromothripsis in almost 3% of UM affecting different chro-
mosomes. Limitation of this study was the small number of cases with chromothripsis. 
Although a large patient cohort was investigated, the rare occurrence of chromothrip-
sis prohibited performing proper statistical analyses. Further studies are needed to 
investigate the evolutionary advantage of this complex chromosomal aberration.
Figure 3. Overview of the affected genes in UM with chromothripsis. The first row of blocks rep-
resents the mutation status of GNAQ and GNA11. In the second row of blocks the mutation status 
of BAP1, SF3B1 and EIF1AX is given. The third row of blocks represents the BAP1 IHC staining. 
The fourth row indicates whether a patient developed metastasis. In the fifth row the chromosome 
with chromothripsis is given. The bottom row indicates the number of fragments per chromosome. 
* = Polyploid tumor 
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Abstract
Purpose: The aim of this study was to describe a case of lipomatous change in uveal 
melanoma. Procedures: The patient presented with a 2-year history of blurry vision. 
A full examination
of the right eye revealed a dome-shaped pigmented subretinal mass in the choroid 
with a thickness of 9 mm and a diameter of 15 mm. The eye was enucleated and pre-
pared for histopathologic, genetic and molecular investigation. 
Results: Histopathology revealed a small circumscribed area consisting of mature 
adipocytic appearing cells with abundant clear cytoplasm and small peripheral 
flattened nuclei within a spindle-cell melanoma of the uvea. The cytoplasm of the 
adipocytic cells stained negative for periodic acid- Schiff and Alcian blue and positive 
for Melan-A, HMB-45 and tyrosinase, confirming melanocytic lineage. Fluorescence 
in situ hybridization analysis confirmed trisomy of chromosome 6p22 and disomy of 
chromosome 3p13 in the nuclei of both the tumor spindle type B cells and in the nuclei 
of lipomatous tumor cells. 
Conclusions: Lipomatous change can be added to the many histopathologic faces of 
uveal melano-ma. To our knowledge, this is the first report of lipomatous change in 
uveal melanoma performed with cytogenetic investigations.
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Introduction
Malignant melanoma is well known for its protean morphologic appearance. Besides 
the common uveal melanoma types (epithelioid and spindle cell), other histopathologic 
variants have been reported. Clear cell change of the cytoplasm of uveal melanocytic 
cells can be observed as balloon cells, signet ring cells and clear cells.1-3 We describe 
lipomatous change in uveal melanoma.
 
Case Description
A 73-year-old male visited the outpatient department of ophthalmology because of 
a 2-year history of blurry vision, which could not be explained upon two prior visits 
to an ophthalmologist during these 2 years. At presentation, the best-corrected visual 
acuity was 20/50 OD and 20/16 OS. On dilated funduscopy (Figure 1A) and ultraso-
nographic examination of the right eye, a dome-shaped pigmented subretinal mass 
was seen with a thickness of 9 mm, a diameter of 15 mm and medium-to-low internal 
reflectivity. No atypical cutaneous pigmented lesions were observed. Systemic radio-
logic evaluation revealed no metastatic lesions. The patient opted for enucleation. After 
a follow-up of 12 months, there were no signs of metastases. 
Sections of the eye confirmed a dome-shaped tumor composed almost exclusively of 
spindle type B melanoma cells. A small circumscribed area consisted of mature adi-
pocytic appearing cells with abundant clear cytoplasm and small flattened nuclei at 
the periphery (Figure 1B). The cytoplasm stained negative for periodic acid-Schiff and 
Alcian blue stains, excluding glycogen or mucin. Mitotic figures were present at 4 × 
8 mm 2 (equivalent to 50 highpower fields). Intracytoplasmic brown pigment stained 
negative for Prussian Blue iron stain. No closed-loop extracellular matrix pattern was 
present. The tumor did not show extrascleral extension or invasion of the optic nerve. 
The lipomatous tumor cells stained positive for Melan-A, HMB-45 (Figure 1C) and 
tyrosinase, confirming melanocytic lineage. All tumor cell nuclei stained positive for 
BAP1. The lipomatous tumor cells stained negative for CD34. 
Single-nucleotide polymorphism array analysis (HumanCytoSNP-12 v2 BeadChip; 
Illumina, San Diego, CA, USA) showed gain of chromosome 6p and no loss or gain of 
chromosomes 3 and 8. Fluorescence in situ hybridization analysis confirmed trisomy 
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of chromosome 6p22 and disomy of chromosome 3p13 in the nuclei of both the tumor 
spindle type B cells and in the nuclei of lipomatous tumor cells (Figure 1D). Mutation 
analysis demonstrated a heterozygous GNA11 p.Gln209Leu mutation. GNAQ , SF3B1 
and EIF1AX were wild type.
Figure. 1. Fundoscopic, histologic, immunohistochemical and genetic appearance of the tumor. 
(A) Dilated fundoscopic photography of the tumor shows a dome-shaped subretinal mass in the 
posterior pole. (B) The tumor was mainly composed of spindle type B melanoma cells with a focus 
of lipomatous change (hematoxylin-eosin, original magnification ×100). (C) The cytoplasm stained 
positive for the melanocytic marker HMB-45 (original magnification ×400). (D) On fluorescent in 
situ hybridization, the nucleus of a representative lipomatous tumor cell (arrow) shows three red 
fluorescent signals for the 6p22 probe and two green fluorescent signals for the 3p13 probe (original 
magnification ×640).
 
Discussion
Primary uveal melanoma is classified as spindle cell, epithelioid cell or mixed cell 
type. The epithelioid cell type is associated with a significantly worse prognosis. 
Unusual cytomorphologic variants of uveal melanoma have been described, such as 
oncocytic, neuroendocrine, balloon cell, clear cell, signet ring cell and, as in our case, 
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lipomatous.1-5 Although the prognostic significance of these cytomorphologic variants 
is unknown, they should be recognized in order to avoid misdiagnosis with metastatic 
neoplasms. The divergent differentiation patterns of neoplastic uveal melanocytes may 
recapitulate the plasticity of neural crest stem cells. Individual cells from melanoma 
spheres (melanoma spheroid cells) derived from metastatic cutaneous melanoma can 
differentiate under appropriate conditions into multiple cell lineages such as melano-
cytic, adipocytic, osteocytic and chondrocytic lineages.6 The current case demonstrates 
that lipomatous change can also be observed in uveal melanoma. The fluorescence 
in situ hybridization results showed identical changes in the spindle type B mela-
noma cells and the lipomatous tumor cells. Immunohistochemistry confirmed the 
melanocytic lineage of the lipomatous change, whereas CD34 staining, commonly 
positive in adipocytes, was negative. The process of metaplasia implies full expres-
sion of the characteristics of the ‘new’ cell type. In our case, however, the neoplastic 
cells resembling mature adipocytes retained the immunohistochemical features of 
melanocytes and lacked specific immunohistochemical features of true adipocytes. 
Moreover, definite proof of the lipomatous character of the histomorphologic change 
would require fresh frozen tissue samples for lipid stainings that were not available 
in our case. We therefore prefer to refer to this phenomenon as lipomatous change. 
Other neuroectodermal tumors that may contain adipocytes include cutaneous mela-
nocytic nevi, schwannoma, neurofibroma, perineurioma, meningioma and adrenal 
adenoma.7-12 In most cases as well as in the current case, the cells retain at least some of 
the characteristics of their original lineage, which would argue against true metaplasia. 
Lipomatous change can also be observed in different cardiac pathologic processes, 
including ischemia, idiopathic dilated cardiomyopathy and arrhythmogenic right 
ventricular dysplasia.13 This phenomenon appears to be due to transdifferentiation of 
multipotential interstitial cells to adipocytes, which would be true metaplasia. Another 
hypothesis is that lipomatous metaplasia in cardiac muscle may be partially related to 
progressive myofibril degeneration and lipid accumulation within heart muscle cells, 
finally leading to phenotypical conversion, or lipomatous change, of cardiac myocytes 
into adipocyte-like cells.13 Speculation regarding the cause of lipomatous change in 
uveal melanoma might include degeneration and lipid accumulation within the mela-
nocytes due to senescence or to chronic injury such as ischemia or inflammation. To our 
knowledge, this is the first report of lipomatous change in uveal melanoma performed 
with cytogenetic investigations.
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Over the last years many advances have been made with prognostic testing in patient 
with UM. Most commonly used parameters are the AJCC classification, gene-expres-
sion profiles (GEP), chromosome status, BAP1 immunohistochemistry (IHC) and 
mutation status of the UM. In this thesis, I focus on chromosomal aberrations and 
mutation status of the primary tumor to gain insight in the genetics and to discuss the 
difficulties using these methods. We show in Chapter 2.1 the prognostic value of SF3B1 
mutations, which is correlated to an intermediate risk for metastasis. Next, we show in 
Chapter 2.2 that besides the different prognostic values, UMs with respectively BAP1, 
SF3B1 and EIF1AX mutations also harbor distinct chromosomal patterns and type of 
chromosomal aberrations.

Chapter 4.1
Prognostic values of UM 
specific mutations
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Besides the AJCC classification, most prognostic markers divide patients with UM 
dichotomously in either low-risk or high-risk categories, such as GEP Class 1 versus 
2 or disomy 3 versus monosomy 3.1-3 In this thesis I show that UMs consist of multiple 
subtypes rather than just two groups. UM patients can be divided in high  risk, interme-
diate risk and low risk for metastasis based on mutations in BAP1, SF3B1 and EIF1AX 
(Figure 1). Patient with BAP1mut UMs generally develop metastasis within five years 
after diagnosis whereas the majority of patients with SF3B1mut UMs develop metastasis 
at a mean of 8 years.4 This corresponds to the bimodal mortality patterns described by 
Demicheli and colleagues who show the peaks in mortality are at three years and nine 
years after treatment.5 Moreover, although the majority of metastasized SF3B1mut UMs 
manifest after five years, a substantial proportion (36%) is diagnosed within 5 years 
after diagnosis. Thus, patients with SF3B1mut UMs, do require an intensive follow-up 
even though SF3B1mut are not as frequent as BAP1mut, and early metastasis does not 
occur as often as with BAP1neg UMs.
Figure 1. A simplistic schematic overview of the tumorigenesis of UM.  GNAQ, GNA11, PLCB4 and 
CYSLTR2 mutation are considered the first driver mutation in UM. Following, UM develop almost 
mutual-exclusive mutation in the genes EIF1AX, SF3B1 and BAP1. These tumors also harbor specific 
chromosomal aberrations with either copy number variations of entire chromosomes and chromo-
some arms or only the terminal ends of the chromosomes. BAP1, SF3B1 and EIF1AX have different 
metastatic risk resulting in metastases.
Another perspective in looking at the prognostic value of an SF3B1mut, is the fact that 
patients with SF3B1mut UMs are diagnosed at an earlier median age of 54.5, whereas 
patients with BAP1neg UMs are diagnosed at a median age of 66.9 years. So, these 
patients are diagnosed more than ten years earlier than patients with BAP1neg UMs. 
In Figure 2 we can clearly see that the life-time metastasis-free survival is not different 
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for patients who develop metastasis with BAP1neg and SF3B1mut UMs, respectively. 
Although not significant, we can even observe that patients with SF3B1mut UMs have 
an earlier life-time onset of metastases. This data shows that SF3B1 mutations are not 
to be underestimated as a prognostic value.
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Figure 2. Survival analyses showing that the life-time risk for metastasis occurs at an younger age in 
patients who develop SF3B1-mutated UMs, compared to patients who develop BAP1 negative UMs. 
However this difference is limited to the first ten years and does not reach significance (P = 0.220).
Contrary to BAP1 and EIF1AX, much controversy exists concerning the prognostic 
values of GNAQ and GNA11 mutations. In concordance with most of the literature, 
our data shows that mutations in these genes do not correlate to the survival. How-
ever, there have been some reports stating that GNA11 mutations are associated with 
a worse outcome than patients with GNAQ mutations. For example, GNA11 mutations 
were found in 57% of the UM metastases, whereas GNAQ was mutated in only 22% of 
the UM metastases, suggesting that GNA11 mutations are possibly more aggressive. 
By analyzing specific point mutations in the mutational signatures as shown in Chap-
ter 2.2, we can clearly see different peaks of specific somatic nucleotide variants. When 
analyzed in more detail we observed that BAP1mut UMs are enriched with GNA11 
p.Q209L mutations. For SF3B1mut UMs on the other hand, GNAQ p.Q209P mutations 
are enriched. This difference in co-mutations would explain why GNA11 mutations 
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are present more often in UM metastases, since most UMs metastases harbor BAP1mut. 
Interestingly, when we stratify for BAP1 and SF3B1 (dataset obtained from Chapter 
2.1), we observe that patients with GNA11-SF3B1 mutations have a worse prognosis 
than patients with GNAQ-SF3B1 mutations (P = 0.011). We also observe a shorter 
metastasis-free survival for patients with GNA11-BAP1 compared to GNAQ-BAP1 
mutations, although this difference does not reach significance (P = 0.690).
Although GNAQ and GNA11 mutations are proposed as the first events in UM tum-
origenesis, the difference in co-mutated genes does suggest a different susceptibility 
to a second mutated gene. Moreover, patients with GNAQmut in the UM are diagnosed 
at a mean age of 58.9 years whereas patients with GNA11mut are diagnosed at a mean 
age of 66.5 years, which is similar to the age at diagnosis of patients with SF3B1mut 
or BAP1mut UMs respectively. GNAQ mutations are also found more of in pre-ma-
lignant melanocytic lesions, such as blue naevi than GNA11 mutations (55% versus 
7% respectively).6 It is possible that GNAQ hotspot mutations have a slower growth 
and are less aggressive. It might be that GNAQ mutations occur earlier than GNA11 
mutations in the melanocyte and perhaps give rise to choroidal naevi more often. This 
early occurrence of GNAQ mutation would explain the younger age of diagnosis in 
patients with SF3B1mut UMs, and also the slow growing rate of metastases. To date, 
choroidal nevi have not yet been investigated for GNAQ and GNA11 mutations. It 
would be interesting to investigate UMs that grow out of precursor lesions, a concept 
that has been performed for cutaneous melanoma.7 This would provide more insight 
in the tumorigenesis and the prognostic value of GNAQ and GNA11 mutations. 
A challenge in prognostication based on the mutation status is the interpretation 
of mutations in two or more of the prognostic predicting genes (BAP1, SF3B1 and 
EIF1AX). Although rare, these co-mutations are not absent. In Chapter 2.1 we describe 
a handful of SF3B1 and EIF1AX-mutated UMs. Do these patients have an intermediate 
risk (SF3B1 mutation) for metastases or the favorable effect of an EIF1AX mutation? 
The same applies to patients with BAP1neg UMs that harbor EIF1AX mutations. We 
would expect that co-mutations would make a tumor more aggressive. If the tumor 
would not have an advantage with the co-mutated gene the rest of the tumor that 
doesn’t harbor co-mutations would outgrow this subpopulation. However, our data 
does not support this assumption. For SF3B1 and EIF1AX co-mutated UMs none of 
the patients developed metastases (range follow-up, 36-167 months). For patients with 
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BAP1neg with EIF1AXmut UMs, one patient did develop metastasis within five year after 
diagnosis whereas the other two were metastasis-free after five years. This shows that 
large numbers of such cases are needed to draw conclusions about co-mutations.
Despite these limitations, mutation analyses provide robust results for prognostifica-
tion.  In Chapter 3.1 we describe an easy method to sequence all UM related genes with 
one panel using the ION torrent sequencer. Especially compared to gene expression 
profiling (GEP), that uses a 15-gene panel to classify patients with UMs in only two 
risk classes (high risk versus low risk). However for both methods the major limitation 
is prognosticating patients for which no tumor material is available for genetic testing. 
I will discuss this subject later on in this Chapter.


Chapter 4.2
Difficulties in using the 
mutations status for prognosis
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In Chapters 2.1 and 3.1 BAP1 is shown to be the most accurate prognostic marker 
for patients with UMs. In our cohort, BAP1 is determined using immunohistochem-
istry in almost all cases. Although this technique is a quick and cheap method for 
prognostication, it also has its limitations.8 BAP1 is located on chromosome 3p, and 
is inactivated by a double hit.8,9 Loss of BAP1 expression is almost congruent with 
monosomy 3, however this is not always the case. In some cases, we observe a BAP1 
negative expression whereas there are still two copies of chromosome 3. This is either 
by isodisomy 3 formation or local deletion of the BAP1 gene. Furthermore, we also 
observe a proportion of monosomy 3 UMs that do express BAP1. For these cases we 
also did not observe SF3B1 and EIF1AX mutations, and thus classified them as ‘No 
Recurrent Mutation’ (NRM) UMs as described in Chapter 2.2. Secondary mutation 
analyses of BAP1, revealed somatic non-truncating mutations in most cases, which 
would explain why BAP1 is still expressed. Moreover, these tumors display the same 
chromosomal patterns as BAP1neg UMs and also develop metastases at the same rate 
as BAP1neg UMs. This indicates that in these BAP1pos UMs with BAP1 mutations, BAP1 
is very likely impaired resulting in the same pathogenicity as in BAP1neg UMs. Since 
BAP1 is a tumor suppressor gene, infinite amount of mutations are possible to inac-
tive BAP1. Thus when mutated, BAP1 can contain large and complex deletions and 
insertions that are hard or even impossible to detect with conventional Sanger or 
Targeted-exome sequencing.10 Moreover, exon 1 of BAP1 is hardly covered with our 
next-generation sequencing techniques (ION torrent and WES) and is also hardly 
covered in the WES samples of UMs in The Cancer Genome Atlas (TCGA) database. 
Even with conventional Sanger sequencing exon 1 requires a different protocol than 
all other exons. Thus for BAP1 no method is perfect and cases that do not fit the profile 
(e.g. monosomy 3 with BAP1 expression) should be investigated in more thorougly.10 
So, some of the NRM UMs can be explained by a non-truncating mutation in BAP1, 
however many NRM UMs do not harbor a BAP1 mutation. Thus for these cases the 
novel gene discovery phase is not over yet. For this, publicly available genomic data 
such as The Cancer Genome Atlas (TCGA) and data-sharing initiatives by several pub-
lishers may play a huge role. Since several independent groups published WES and 
WGS data online, larger datasets could be made to investigate UMs for rare recurring 
mutated genes. In this way, mutations in CYSLTR2 and PLCB4 were found UMs that 
are wildtype for GNAQ and GNA11.11,12 Collectively, these four genes explain the early 
proliferative event (first mutated gene) in almost all UM.
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However, for the second mutated gene in UM more genes are yet to be discovered. 
In our cohort of 133 UMs (Chapter 2.1) we show that 17% of the UMs are wildtype 
for BAP1, SF3B1 and EIF1AX. For this a selections of UMs can be made for sequenc-
ing. A method would be to analyze UMs with BAP1-like, SF3B1-like or EIF1AX-like 
chromosomal patterns. In breast cancer it has already been shown that based on chro-
mosomal patterns the tumors can be divided into BRCA-like and non BRCA-like breast 
cancers.13 Interestingly, a large proportion of these BRCA-like breast cancers do not 
harbor BRCA mutations or methylation, but do display similar molecular character-
istics and also benefit from the same therapies as the tumors with BRCA mutations.14 
In the case of UMs, tumors which harbor SF3B1-like chromosome patterns should 
be analyzed for other splicing factors, especially since mutations in splicing factors 
such as SRSF2, U2AF1 and ZRSR2 are common in other malignancies.15 We also show 
that isochromosome formation is a characteristic of BAP1neg UMs. However, some 
UMs with isochromosomes are BAP1pos and lack BAP1 mutations. For these UMs it 
would be interesting to analyze other genes that are known to be involved in DNA 
integrity, chromosome segregation or isochromosome formation. For example, BAP1 
mutations are also found in a considerable proportion (5%) of hepatocellular carci-
nomas (HCCs).16 These BAP1mut HCCs also harbor isochromosomes (n = 15 of the 
24), in particular isochromosome 8q. Moreover, HCCs without BAP1mut also harbor 
isochromosomes.16 Recurrent mutated genes in these BAP1-like HCCs might also be 
mutated in BAP1-like UM.
Concluding, the novel gene discovery phase in UM research has made great advances, 
however there are still UMs that cannot be explained by the currently known genes. 
These cases pose a challenge in patient prognostication and might be a challenge in 
future targeted therapies. Therefore, sequencing selected UMs that harbor similar 
chromosomal patterns should lead to the discovery of de novo mutated genes involved 
in UM tumorigenesis.


Chapter 4.3
Uveal melanoma: genetically one 
tumor type or different tumor types?
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We clearly show that the chromosomal patterns for BAP1mut, SF3B1mut and EIF1AXmut 
UMs differ based on the different types of chromosomal aberrations.17 This observa-
tion, together with the mutual exclusivity of mutated genes, shows that UMs with 
different mutated genes are genetically distinct and are not part of one evolutionary 
process. For example, if one would expect that intermediate risk UMs (SF3B1mut) are 
predecessors of high risk UMs (BAP1mut), the latter group should harbor co-mutations. 
However we and others only rarely describe co-mutations.4,18-20 
BAP1mut UMs are characterized by numerical and whole chromosome arm aberrations 
such as isochromosomes and SF3B1mut UMs are characterized by structural CNVs 
(Figure 1). Singh and colleagues state that, evolutionary, the gain of the terminal end 
of 8q is the first event that is then followed by the gain of the centromeric part of 8q 
resulting in a gain of the entire chromosome 8q arm.21 According to our results in 
Chapter 2.2, gain of the entire arm of chromosome 8q is one event, resulting from 
isochromosome formation.17 This observation is confirmed by karyograms of UMs 
by looking at individual cells. This highlights that these conventional techniques are 
still useful and informative in research, since these observations contradicted purely 
mathematical analyses. Another hypothesis in UM research is that chromosome 8q 
gain precedes monosomy 3.22 This is based on calculation of the load of chromosome 
8q and chromosome 3 in the tumor samples. By assuming that chromosome 8q gain 
in UMs is based on three copies, and monosomy 3 is based on one copy, it is shown 
that most UMs have more tumor cells containing three copies of chromosome 8q 
than cells containing monosomy 3. Concluding that chromosome 8q gain precedes 
monosomy 3. However, this assumption is false since it has been described that UMs 
do not contain just three copies of chromosome 8q but usually more than three copies 
in most UM cells.23 Not taking this into count overestimates the amount of cells with 
chromosome 8q gain. Besides, we clearly show that BAP1 mutations are associated 
with isochromosome formation. Therefore it is much more likely that BAP1 deficiency 
(caused by loss of chromosome 3) causes isochromosome formation and thus chro-
mosome 8q gain. UMs with different mutated genes have other pathways involved 
in generating chromosomal aberrations and also give different risks for metastasis. 
Therefore, UMs can be divided in at least three subtypes based on the mutations status 
of BAP1, SF3B1 and EIF1AX. 
How about polyploidy? Are UMs with polyploidy a subtype, or is polyploidy part of 
an already defined evolutionary pathway? Polyploidy is a state of the cell in which 
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genome doubling has occurred.24 Polyploidy in other malignancies is shown to be 
associated with worse outcome and these polyploid malignancies also tend to be more 
therapy resistant due to their genomic instability.24,25 In UM patients we did observe 
a slight worse survival in polyploid BAP1neg UMs compared to diploid BAP1neg UMs. 
This would suggest that polyploid UMs are more aggressive, however we believe that 
this is a bias. No single sample harbored heterozygous BAP1 mutations even though 
some UMs contained two copies of chromosome 3, indicating that BAP1 mutations 
and the loss of chromosome 3 precedes the genome doubling (polyploidization). We 
hypothesize polyploidization is a late event in the tumorigenesis. This hypothesis is 
supported by the fact that polyploid BAP1neg UMs are larger than diploid BAP1neg UM 
at time of diagnosis. We believe that polyploidy is a late event in UM tumorigenesis, 
and thus does not represent a separate subtype. However, polyploidy can cause false 
results if prognostification is based on chromosome analyses. Therefore, the genome 
should be checked for polyploidy. Also, polyploidy might cause therapy resistance 
as in other malignancies. Unfortunately, no successful treatment of UM metastases is 
yet available.


Chapter 4.4
Clinical implications and 
therapeutic options
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BAP1 and SF3B1 are described in many cellular mechanisms. BAP1 is a deubiquinitase 
of Histone A2 (H2A). BAP1 deficiency is shown to increase the ubiquitinase of H2A, 
that might lead to anti-apoptotic features.26 In silico screens of therapeutic compounds 
in UM cell lines showed that Histone deacytelase (HDAC) inhibitors might be poten-
tial candidates for BAP1 deficient UM.27 In vivo experiments show that these HDAC 
inhibitors indeed cause cell cycle arrest and also induce melanocytic cell differentia-
tion.27 Malignant pleural mesothelioma also harbor BAP1 mutations resulting in loss 
of BAP1 expression.28 A clinical phase III trial, using the HDAC inhibitor vorinostat 
showed that this compound is unfortunately ineffective in patients with malignant 
pleural melanoma.29 Another consequence of loss of BAP1 is the increase of enhancer 
of zeste 2 polycomb repressive complex 2 subunit (EZH2) in the tumors of patients 
with malignant pleural mesothelioma.30 Although mesothelioma with BAP1 deficiency 
showed sensitivity to EZH2 inhibitors, this effect was not found in BAP1 deficient UM 
cells.31,32 These findings show that BAP1 deficiency between different malignancies do 
not need to results in the same molecular effects.
Most well-known function of SF3B1 is the role in splicing.33  SF3B1 mutations in uveal 
melanoma almost always target hotspot codon p.R625.4,20,33,34 For this mutation, and for 
the less occurring hotspot mutation p.K666, it is shown that mutant SF3B1 does not 
function as an oncogene or tumor suppressor gene, but rather as a change-of-function 
mutant gene.35 SF3B1mut results in an alternative use of 3’ splice site recognition sites 
and use of an alternative branch point, resulting in alternative spliced products, which 
may give rise to tumorigenesis. 35,36 Also, there are also reports on how cancer cells 
harboring mutation in genes encoding for splicing factors are dependent on the wild-
type allele of the gene to prevent apoptosis.37,38 This does not only provide possibilities 
by targeting alternative splicing in cancer but also targeting the normal functioning 
splicing factors.39,40 Similar to the DNA damage repair pathway targeted therapies, this 
might also push the cell ‘over the edge’, making it too unstable to survive.
Targeting the downstream pathways of GNAQ and GNA11 have also been investigated 
extensively. GNAQ and GNA11 hotspot mutations result in a continuous activation of 
Gα and its downstream pathways. A major downstream effector is the MEK-ERK1/2 
pathway, which is shown to be targetable in UM cell lines by MEK1/2 inhibitors such 
as selumetinib or trametinib.41,42 Unfortunately, in clinical trials, these inhibitors were 
not successful in treating metastatic disease in UM patients.43-45 Hepatocyte growth 
factor (HGF) is highly expressed in liver microenvironment, and is shown to cause 
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MEK-inhibitor resistance in UM cell lines.41 Ex vivo experiment showed that co-tar-
geting HGF with MEK inhibitors might be successful in treating metastatic disease.46 
Another downstream activated protein is Yes-associated protein (YAP). YAP is an 
effector protein of the Hippo pathway, a pathway involved in organ growth. In UM 
cell lines GNAQ and GNA11 mutations stimulate YAP through a Hippo-independent 
manner.47,48 YAP inhibition with verteporfin causes growth arrest in GNAQmut and 
GNA11mut UM cell lines.49 YAP is also identified as a cause for resistance in several 
malignancies and targeting YAP is shown to sensitize malignancies to MEK inhib-
itors.50 This emphasizes that co-targeting several pathways simultaneous might 
potentially provide success in treating metastatic disease.
Many potential pathways are targetable in patients with UM. Yet, no treatment is 
successful. Recent years, progress has been made in the field of oncology targeting 
DNA damage repair (DDR) impaired malignancies.51 Malignancies with impaired 
DNA damage pathways are more error-prone to genetic alterations. By targeting these 
pathways, cancer cells accumulate mutations and chromosomal aberrations, that make 
the already unstable cancer cells highly unstable for chromosomal aberrations, causing 
apoptosis.51,52 
BAP1 encodes for a deubiquitinase involved in chromatin remodeling and SF3B1 
encodes for a splicing factor as described earlier. However besides these functions, 
both genes are also involved in DDR.35,53-56 It is shown that BAP1 is involved in homol-
ogous recombination (HR), an error-free DNA repair mechanism.56 BAP1 deficient 
cells that become HR deficient might make use of the error-prone non-homologous 
end-joining (NHEJ) repair mechanism, resulting in chromosomal aberrations and 
mutational insertions and deletions (InDels).56 Also mutated SF3B1 in chronic lym-
phocytic leukemia is known to be involved in DDR.54 One might thus expect impaired 
DDR in UMs with mutations in BAP1 or SF3B1. Is this the case?
In several malignancies, DDR deficiencies lead to an accumulation of mutations and 
promote genome instability.57,58 WGS of UM samples show that the mutational burden 
per cell is less than one mutation per Mb of genome. On average only 20 coding 
single-nucleotide variations (SNVs) are found, placing UMs between pediatric malig-
nancies which also have a very low mutational load.33,59 Second argument in spite of 
DDR deficiency in UMs, is the chromosomal aberrations and the tumor heterogeneity. 
DDR deficiencies cause tumor heterogeneity due to the genomic instability and rapidly 
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changing genome.57,60 We show in Chapter 2.2 that BAP1mut UMs are characterized 
by the lack of structural variants making it very unlikely that these cells make use of 
NHEJ. Moreover, monosomy 3 UMs are shown to be quite homogenous.61 As SF3B1mut 
harbor more structural chromosomal aberrations, it might be that these tumors make 
use of NHEJ. Mutational signatures analysis is a recently developed method to gain 
more insight in the mutational spectrum of malignancies by analyzing somatic SNVs 
and the flanking nucleotides.62 In UM research this has also been performed in several 
studies. Although, signatures associated with DDR pathways are present in UMs, all 
three publications on this topic display a discrepancy in the found signatures.11,33,59
Summarizing, the mutational load and the lack of chromosomal instability suggest that 
DDR is not impaired or only slightly impaired, whereas the mutational signatures and 
functional experiments on non-UM cells do suggests impaired DDR in UM. 

Chapter 4.5
Future prospect and experimental 
considerations 
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In this Chapter I describe and discuss several insights in the genetics of UM. Using 
genetic data we draw conclusions regarding the prognosis and molecular processes. 
However, this also means that there is a bias towards larger tumors that are investi-
gated in this thesis. In our cohort, material from the primary tumors is almost always 
obtained by enucleation and hardly by biopsies. Medium-sized and small-sized UMs 
are generally treated using eye-saving irradiation techniques such as protonbeam, 
stereotactic radiotherapy and brachytherapy. In these patients, no material of the pri-
mary tumor is available unless a biopsy is taken. Currently, no other method than the 
AJCC classification is available to prognosticate these patients.
Luckily, many advances are made in the field of liquid biopsies.63 These techniques are 
already clinical used for analyzing fetal circulating free DNA (cfDNA) in the mothers’ 
plasma.64 Also for patients with solid malignancies it is shown that the load of cfDNA 
is higher compared to healthy subjects.65 Targeting specific somatic mutations of the 
primary tumor, the mutational load in the circulation can be calculated and used for 
monitoring.63
Taking advantage of the fact that roughly 95% of the UMs harbor a hotspot mutation 
(GNAQ p.Q209 and p.R184, GNA11 p.Q209 and p.R184, CYSLTR2 p.L129 and PLCB4 
p.D630), these mutations may be picked up using a handful of allele-specific PCRs on 
patient’ blood sample for whom the mutation status is unknown. This can also be used 
for SF3B1 since in UMs with SF3B1mut amino acid p.R625 is targeted in the majority of 
cases.  However, for BAP1 and EIF1AX this cannot be applied. Since BAP1 is a tumor 
suppressor gene, infinite possible mutations can cause a loss of BAP1. For these UMs 
is would be perhaps be more useful to detect the monosomy 3 of the primary tumor. 
For fetal DNA it is possible to detect e.g. trisomy 21 in the maternal plasma.64 This 
would be more challenging for circulating tumor DNA, since a loss of a chromosome 
would require different algorithms and also UMs contain more chromosomal aber-
rations which would make the analyses more difficult.66 Other methods using liquid 
biopsies are also possible and investigated in UM research. Achberger and colleagues 
describe the detection of circulating immune cells and microRNA as biomarkers for 
metastatic disease.67
Another development in the field of oncology is the use of exosomes obtained from 
patients’ plasma. Exosomes are small vesicles secreted by cells, which carry messenger 
RNA (mRNA), microRNA (miRNA) and also DNA.68,69 This provides novel transla-
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tional possibilities for surveillance of UM patients by harvesting exosomes secreted 
by primary or the metastatic tumor. Recent research also showed that exosomes play a 
part in the metastatic process. For gastric cancer it is shown that the membrane protein 
epidermal growth factor receptor (EGFR) of the exosomes can be transferred to liver 
stromal cells and activate HGF.70 Besides the role of HGF in MEK-inhibitor resistance 
in UM cell lines, HGF also plays a role in providing a suitable microenvironment for 
cancer cells.46,70 Yet again, this highlights that the metastatic process of UMs is compli-
cated and that more research is required for a better understanding.
Considering future treatment options for UM metastases we have touched upon the 
topic of using splicing inhibitors, targeting DNA-damage pathways, downstream 
pathways of GNAQ/11 and others. A more recent developed technique on gene level 
is using the clustered regularly interspaced short palindromic repeats (CRISPR) and 
CRISPR-associated System (cas); CRISPR-cas. Chen and colleagues used this technique 
in liver cancer and prostate cancer cells by exploiting cancer-specific genetic abnormal-
ities.71 They used a method that implemented ‘suicide’ genes in the fusion gene, and 
thus replacing the cancer gene that is responsible for tumor invasion and rapid growth 
by a suicide gene that causes cell death. This method proved to be effective in mice.
For UM this would be an applicable technique as almost all UM harbor a cancer-spe-
cific hotspot mutation in GNAQ or GNA11. By targeting this hotspot location replacing 
the oncogene by a suicide gene would result in apoptosis rather than proliferation. 
Unfortunately, this highly exciting new technique still has its limitations. In theory 
only cancer cells would be targeted since only these cell harbor the mutation. However, 
non-specific targets (non-cancer cells) and off-target binding are serious challenges 
that still need to be overcome.72 Another described problem is resistance/immunity 
against the (viral) vector that carry the CRISPR system.73 The CRISPR technique is 
promising, but needs to be investigated in more detail.
Concluding, although uveal melanoma have limited number of mutations the tum-
origenesis has not been completely unraveled, and additional research is needed to 
move forward for an efficient approach to treat metastatic disease in UM patients. 
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Summary
Uveal melanoma (UM) is a rare malignancy derived from the melanocytes in the 
choroid, ciliary body and iris. Although treatment of the primary tumor has a high 
(>90%) local tumor control, up to 50% of the patients still develop metastasis within 
15 years after diagnosis. The liver is affected typically, with two different metastasis 
patterns; nodular metastases and a miliary (innumerable small) metastases pattern. 
Metastases are lethal within a year in almost all patients. Several markers are known 
to predict patient prognosis. Besides the AJCC TNM classification, these markers clas-
sically divide patients in UM with high-risk and low-risk for metastasis.
Historically, the chromosomal aberrations in UM were the best predictors of meta-
static disease. Monosomy 3 (loss of chromosome 3) occurs in the UM of half of the 
patients, and has the strongest chromosomal association with an unfavorable prog-
nosis. Besides monosomy 3 also chromosome 8q gain is correlated with unfavorable 
outcome, whereas chromosome 6p gain predicts a favorable outcome. In the recent 
years, with the development of massive sequencing, many genes involved in UM 
tumorigenesis were discovered. Of these genes, the three genes correlating to survival 
were BAP1, SF3B1 and EIF1AX.
Patients with monosomy 3 and BAP1 mutations in the remaining allele (BAP1 is 
located on chromosome 3), predispose to a high risk for metastasis. The majority of 
the patients develop metastases within five years after diagnosis. A second group are 
the patients with SF3B1 mutations in combination with disomy 3 (no chromosome 3 
loss). These patients seem to have a favorable prognosis within the first years after 
diagnosis, however these patients typically develop metastases after five years. The 
third group is comprised of patients with EIF1AX mutations, also in combination with 
disomy 3. These patients have a very low risk of developing metastases.
Besides the differences in prognosis these almost-mutually exclusive mutated genes 
are also characterized by typical chromosomal patterns. BAP1-mutated UM contain 
copy number variations (CNVs) that affect entire chromosomes or chromosome arms. 
Also isochromosomes (two short or long arms of the same chromosome attached to 
each other) are almost only observed in BAP1-mutated UM. SF3B1-mutated UM on 
the other hand have more CNVs, however these CNV are smaller in size since they 
only affect the chromosome telomere. And finally, EIF1AX-mutated UM only harbor 
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very few CNVs, most typically only entire chromosome 6 gain or gain of a small ter-
minal part of chromosome 6p. This highlights that UM with mutations in these genes 
reflect different UM subtypes that differ in prognosis and chromosomal patterns. An 
association of the mutated genes and the metastases patterns (nodular versus miliary) 
could not be made.
Besides these genetic aberrations, patients with UM can also harbor rare chromosomal 
phenotypes such as polyploidy (genome doubling) and chromothripsis (shattered and 
randomly rearranged chromosomes). When analyzed in a dichotomous way (present 
versus absent), these chromosomal aberrations both correlate to worse patient survival. 
However, when corrected for the mutation status, this difference does not remain 
significant. These chromosomal aberrations occur more often in the BAP1-mutated 
patients, perhaps due to chromosomal imbalance, and therefor skew the prognosis 
towards an unfavorable outcome.
In conclusion, survival of UM patients is strongly correlated to mutations in the genes 
BAP1, SF3B1 and EIF1AX. These UM represent molecular distinct subclasses. These 
differences may provide patient and gene specific targets for future therapies.
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Uvea melanomen (UM) zijn zeldzame maligniteiten die ontstaan vanuit de mela-
nocyten in het choroid (vaatvlies), corpus ciliare (straalvormig lichaam) en iris 
(regenboogvlies). De behandeling van de primaire tumor leidt tot een goede lokale 
tumorcontrole (>90%). Desondanks ontwikkelt de helft van de patiënten leverme-
tastasen binnen 15 jaar na diagnose. Bij deze groep patiënten is de overlevingsduur 
gemiddeld  korter dan één jaar. Echter, ook binnen deze groep zijn de verschillen 
wat betreft overleving aanzienlijk. Om de prognose nader te bepalen wordt gebruik 
gemaakt van diverse markers. Naast de AJCC ‘Tumor Node Metastases’ (TNM) clas-
sificatie, verdelen de markers patiënten met UM in twee groepen; hoog risico en laag 
risico voor het ontwikkelen van metastasen.
Eén van de tumorkenmerken die helpen bij het voorspellen van metastasen zijn 
chromosoomafwijkingen. Chromosomen komen normaal gesproken altijd in paren 
(disomie). Wanneer één heel chromosoom verloren gaat spreekt men van een monoso-
mie. Monosomie van chromosoom 3 heeft de sterkste associatie met een korte survival 
en wordt gezien in de helft van de tumoren. Naast verlies van een chromosoom kan het 
ook  zijn dat er juist een (deel van) een chromosoom bij komt. Hierbij zien we dat winst 
van de lange arm van chromosoom 8 is gecorreleerd met een ongunstige uitkomst, 
terwijl winst van de korte arm van chromosoom 6 juist is geassocieerd met een gun-
stige overleving. Met behulp van nieuwe DNA sequentietechnieken zijn er ook genen 
ontdekt die betrokken zijn in het ontstaan (tumorgenese) van UM. Mutaties in drie 
van deze genen , BAP1, SF3B1 en EIF1AX correleren met de overleving van de patiënt.
Van deze genen geeft de BAP1 mutatie in de tumor het hoogste risico op metastasen. 
Het merendeel van deze patiënten ontwikkelt metastasen binnen 5 jaar na diagnose. 
Een gunstiger profiel wordt gezien bij patiënten met een SF3B1 mutatie in de tumor. 
Bij hen ontwikkelen metastasen zich na 7-10 jaar. De EIF1AX mutaties tenslotte, geven 
een zeer laag risico op het ontwikkelen van metastasen.
Naast het feit dat deze mutaties effect hebben op de overleving, zien we ook dat 
mutaties in deze genen gepaard gaan met een karakteristiek chromosomenpatroon. 
BAP1 gemuteerde UM bevatten chromosoomafwijkingen waarbij hele chromosomen 
of chromosoomarmen veranderd zijn . In UM met deze BAP1 mutatie worden ook 
isochromosomen gevonden, waarbij twee dezelfde chromosoomarmen aan elkaar vast 
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zitten. De tumoren met een SF3B1 mutatie hebben juist meer en kleinere chromo-
soom afwijkingen, waarbij alleen de uiteinden (telomeren) van de chromosomen zijn 
aangedaan. De tumoren met een EIF1AX mutatie hebben weinig chromosoom afwi-
jkingen, hoewel winst van heel chromosoom 6 of alleen winst van een kleine terminale 
einde van chromosoom 6p relatief vaak voorkomt.
Tenslotte hebben we gekeken naar twee bijzondere vormen van chromosoomafwijkin-
gen: polyploidie (verdubbeling van het genoom) en chromothripsis (herschikking van 
een [deel van] een chromosoom). Beide genetische veranderingen zien we vaak in com-
binatie met een BAP1 mutatie hetgeen geassocieerd is met een ongunstige prognose.
Concluderend: De overleving van patiënten met een uvea melanoom is sterk 
gecorreleerd met mutaties in BAP1, SF3B1 en EIF1AX genen. Daarnaast leiden de 
verschillende mutaties tot een verschillend chromosoom patroon. Met behulp van het 
genetisch profiel van een uvea melanoom kan zodoende een goede inschatting van de 
prognose gemaakt worden.
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List of abbreviations
AJCC  American Joint Committee on Cancer
ANOVA Analysis of Variance
BAP1  BRCA1-associated Protein 1
CAS  CRISPR-associated System
CBI  Ciliary Body Involvement
cfDNA  Circulating free DNA
CLL  Chronic Lymphocytic Leukemia
CN  Copy Number
CNV  Copy Number Variation
COMS  Collaborative Ocular Melanoma Study
CRISPR  Clustered Regulatory Interspaced Short Palindromic Repeats
CSV  Chromosomal Structural Variants
CT  Computed Tomography
CYSLTR2 Cysteinyl Leukotriene Receptor 2
DDR  DNA Damage Repair
DFS  Disease-Free Survival
DI  DNA Index
EIF1AX  Eukaryotic Translation Initiation Factor 1A, X-linked
EMT  Epithelial-to-Mesenchymal Transition
EXE  Extraocular Extension
EZHZ  Enhancer of Zester 2 Polycomb Repressive Complex 2, subunit
FAG  Fluorescence Angiography
FFPE  Formalin-Fixed Paraffin-Embedded
FISH  Fluorescence in-situ Hybridization 
FNAB  Fine-Needle Aspiration Biopsy
GEP  Gene Expression Profiling
GNA11  Guanine Nucleotide Binding Protein, subunit 11
GNAQ   Guanine Nucleotide Binding Protein, subunit q
H2A  Histone 2A
HC  Hierarchical Clustering
HDAC  Histone Deacytelase
HGF  Hepatocyte Growth Factor
HR  Homologous Recombination
ICG  Indocyanine Green Chorioangiography
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IHC  Immunohistochemistry
InDel  Insertion and/or Deletion
LOH  Loss of Heterozygosity
LUMPO Liverpool Uveal elanoma Prognosticator Online
MDS  Myelodysplastic Syndrome
MLPA  Multiplex Ligation Dependent Probe Amplification
MRI  Magnetic Resonance Imaging
miRNA  Micro RNA
mRNA  Messenger RNA
NHEJ  Non-Homologous End Joining
NRM  No Recurrent Mutation
OCT  Optical Coherence Tomography
PCC  Premature Chromosome Compaction
PLCB4  Phospholipase C Beta 4 
PRAME  Preferentially Expressed Antigen in Melanoma
RASSF1A Ras-associated Domain Family Member 1
ROMS  Rotterdam Ocular Melanoma Studygroup
SF3B1  Splicing Factor 3b, subunit 1
SKY  Spectral Karyotyping
SNP  Single NucleotidePpolymorphism
SNV  Single Nucleotide Variation
SRT  Stereotactic Radiation Therapy
TCGA  The Cancer Genome Atlas
TNM  Tumor Node Metastasis
UM  Uveal Melanoma
US  Ultrasonography
WES  Whole-Exome Sequencing
WGS  Whole-Genome Sequencing
YAP  Yes-associated Protein
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